Compositions and methods for diagnosing and treating diseases by targeting phospholipids
Phospholipids with two polyunsaturated fatty acyl tails (PL-PUFA2S) are used to target and induce ferroptosis in cancer cells, addressing the need for effective lipid markers and therapeutic approaches for ferroptosis modulation in disease treatment and diagnosis.
Patent Information
- Application Number
- PCT/US2024/027732
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-02-02
- Filing Date
- 2024-05-03
- Publication Date
- 2024-11-14
AI Technical Summary
Current methods lack effective strategies for identifying and targeting lipid markers and drivers of ferroptosis, a form of cell death linked to lipid peroxidation, which is crucial for diagnosing and treating diseases such as cancer.
The use of phospholipids with two polyunsaturated fatty acyl tails (PL-PUFA2S) that specifically interact with the mitochondrial electron transport chain, inducing ROS production and lipid peroxidation, and their application in compositions and methods for inhibiting mitochondrial complex I to modulate ferroptosis.
PL-PUFA2S are identified as key drivers of ferroptosis, effectively inducing cell death in cancer cells and providing a biomarker and therapeutic target for modulating ferroptosis, thereby aiding in disease treatment and diagnosis.
Smart Images

Figure US2024027732_14112024_PF_FP_ABST
Abstract
Description
COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DISEASES BY TARGETING PHOSPHOLIPIDSCROSS REFERENCE TO RELATED APPLICATIONS
[0001] The present application claims benefit of U.S. Provisional Patent Application Serial No. 63 / 549,305, filed on February 2, 2024, U.S. Provisional Patent Application Serial No. 63 / 602,850, filed on November 27, 2023, and U.S. Provisional Patent Application Serial No. 63 / 500,522, filed on May 5, 2023, which applications are incorporated by reference herein in their entireties.FIELD OF DISCLOSURE
[0002] The present disclosure provides, inter alia, compositions that inhibit mithochondrial complex I in a cell, methods for treating diseases such as a cancer using said compositions, and methods for diagnosing diseases such as a cancer in a subject by targeting certain lipid biomarkers, and treating with agents that induce ferroptosis. Also provided are dietary supplement comprising diPUFA lipids for a subject having a cancer.GOVERNMENT FUNDING
[0003] This disclosure was made with government support under grant no. CA209896, awarded by National Institutes of Health. The government has certain rights in the disclosure.INCORPORATION BY REFERENCE OF SEQUENCE LISTING
[0004] This application contains references to amino acids and / or nucleic acid sequences that have been filed concurrently herewith as sequence listing XML file “CU23302-24174-PCT-seq.xml”, file size of 16,944 bytes, created on April 26, 2024. The aforementioned sequence listing is hereby incorporated by reference in its entirety pursuant to 37 C.F.R. § 1.52(e)(5).BACKGROUND
[0005] Phospholipids Phospholipids are the basic building blocks of lipid bilayers that constitute cellular membranes. Membrane phospholipids are classified by their head groups, and include phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI), and phosphatidic acid (PA), among which PC is the most abundant species in mammalian cell membranes (Dai et al. 2021 ; Wang and Tontonoz, 2019). For most phospholipids, the sn1 position of glycerol backbone often contains a saturated fatty acyl tail, such as palmitic acid (C16:0) or stearic acid (C18:0), while the sn2 position has greater diversity, containing either a saturated fatty acyl (SPA), a monounsaturated fatty acyl (MLIFA), or a polyunsaturated fatty acyl (PLIFA) tail. Phospholipids with PLIFA tails in both sn1 and sn2 positions (PL-PUFA2S; diacyl- PUFA phospholipids) are uncommon lipid species (Chilton et al. 1996). While little is known about the functions of PL-PUFA2S, a few studies found them to be physiologically relevant. Diacyl-PUFA diglyceride containing arachidonoyl tails (C20:4) was first discovered by Siegel et al. in 1981 from rat neutrophils treated with arachidonic acid (Siegel et al. 1982). PC(20:4, 20:4) was then identified to be a unique species that rapidly increased after treatment with arachidonic acid (Blank et al. 1985; Chilton and Murphy, 1987). Diacyl-PUFA phosphatidylcholine was found to be most potent in reducing mammalian cell proliferation in comparison with other mixed-acyl phosphatidylcholine species (Werlein et al. 2015). The predominant model of PL-PUFA2 function is as a transiently increased carrier of PUFAs that serve as a mobile source of PUFAs for transfer to the sn2 position of other phospholipids (Blank et al. 1985).
[0006] Ferroptosis is an iron-dependent non-apoptotic form of cell death resulting from extensive lipid peroxidation that overwhelms lipid protection mechanisms. Phospholipids containing PUFA tails are particularly susceptible to peroxidation at bis-allylic carbons. Long-chain ® -6 and ®-3 PUFAs, such as arachidonic acid (ARA; C20:4) and docosahexaenoic acid (DHA; C22:6), which contain multiple double bonds, are particularly able to facilitate ferroptosis (Yuan et al. 2016; Shan et al. 2022).
[0007] Since mammalian cells are not able to synthesize long-chain PLIFAs, dietary PUFAs serve as important sources of intracellular PUFA-containing lipids (Liang et al. 2022). Dietary supplementation with free PUFAs sensitizes cells to ferroptosis, while supplementation with MUFAs inhibited ferroptosis through an unknown mechanism (Magtanong et al. 2019). PUFAs needs to be activated by acylcoenzyme A synthetase long-chain family member 4 (ACSL4) and incorporated into phospholipids by lysophospholipid acyltransferases (e.g., LPCAT3) to drive ferroptosis (Dixon et al. 2015; Doll et al. 2017). PL-PUFAs undergo peroxidation by labile iron and iron-containing enzymes to produce phospholipid hydroperoxides (PL- PUFA-OOHs) that spread quickly in membrane through oxidative chain reaction (Kagan et al. 2017). Lipid repair mechanisms suppressing ferroptosis include the glutathione-GPX4 pathway that reduces PL-PUFA-OOH to PL-PUFA-OH and the phospholipase A2 pathway that cleaves oxidized PUFA tails from PL-PUFA-OOHs to generate lysophospholipids (Stockwell, 2022). In addition, monounsaturated fatty acids (MUFAs) are potent inhibitors of ferroptosis, but the mechanism by which they protect from ferroptosis is unknown.
[0008] Due to the higher abundance of mixed-acyl phospholipids in mammalian cells, PL-PUFAis have long been considered the general reactant of lipid peroxidation and driver of ferroptosis. However, we found that the ability of the GTP cyclohydrolase-1 (GCH1) / BH4 axis to protect cells from ferroptosis was correlated with peroxidation and cleavage of specific PL-PUFA2 species (Kraft et al. 2020). GCH1 overexpression did not prevent the oxidation of most PL-PUFAis, and yet exerted an overall protective effect against ferroptosis. This suggested that PL- PUFA2S rather than PL-PUFAis play a key role in executing ferroptosis. However, the general role of phospholipids with two PUFA tails in cell death, and the specific mechanism by which they might function in ferroptosis is enigmatic.
[0009] Different subcellular organelles play distinct roles in the execution of ferroptosis. The endoplasmic reticulum (ER) has been shown to be a key site of lipid peroxidation in response to treatment with three classes of ferroptosis inducers, RSL3, FIN56, and FINO2 (von Krusenstiern et al. 2023). Upon cysteine starvation or treatment with system xc’ inhibitors, such as erastin or IKE, however, mitochondria play a role in initiating and amplifying ferroptosis, although they are not strictly required for cell death (Li et al. 2021 ; Li et al. 2021 ). The radical trapping lipidperoxidation and ferroptosis inhibitor, ferrostatin-1 , accumulates in mitochondria, lysosomes, and ER to suppress lipid peroxidation; localization in mitochondria protects against ferroptosis induced by cysteine starvation or system Xc' inhibitors, while ER localization protects against all classes of small molecule ferroptosis inducers (Gaschler et al. 2018). Mitochondria thus play an important role in promoting ferroptosis through the generation of mitochondrial reactive oxygen species (ROS), labile iron, and perhaps more generally through the disruption of mitochondrial-driven metabolic homeostasis (Chen et al. 2021 ; Gao et al. 2019). The mitochondrial electron transport chain (ETC) is a key part of cellular energyproducing machinery and the major site of ROS production that drives oxidative stress in cells (Mbah and Lyssiotis, 2022). In addition, mitochondria-targeted antioxidants prevent ferroptosis induced by system xc' inhibition or GPX4 inhibition (Oh et al. 2022). ROS produced by ETC complex I, but not complex III, has been shown to induce lipid peroxidation in mitochondria that leads to ferroptosis (Lyamzaev et al. 2023). Hence, mitochondria are key players in ferroptosis in response to cysteine withdrawal, but the mechanism by which ferroptosis is triggered in mitochondria is not known.
[0010] Accordingly, there is a need for developing methods for identifying lipid markers and drivers of ferroptosis and treating diseases by targeting such biomarkers for modulating ferroptosis in a subject in need thereof. This disclosure is directed to meeting these and other needs.SUMMARY
[0011] The present disclosure identified PL-PUFA2S as a specific lipid class that drives ferroptosis through the initiation of ROS production in mitochondria and lipid peroxidation in ER. It was found that PC-PUFA2 rapidly accumulated upon free PUFA treatment, supporting their role in regulating membrane PLIFA content and ferroptosis sensitivity. MLIFA selectively reduced PC-PUFA2 synthesis that reversed the effect of free PUFA. It was also found that PC-PUFA2S specifically interact with the mitochondrial ETC, where they induce production of ROS that further induce massive lipid peroxidation in the ER. Mitochondria-targeted antioxidants were sufficient to block ferroptosis in response to PC-PUFA2 treatment. Hence, theseresults illuminate a critical and unstudied lipid class that acts as a key driver of ferroptosis, and help shed light on four longstanding aspects of ferroptosis — how mitochondria promote ferroptosis, how free PUFAs promote ferroptosis, why MLIFAs suppress ferroptosis, and how ACSL4 is involved in fatty acid metabolism.
[0012] Accordingly, one embodiment fo the present disclosure is directed to a composition for inhibiting mitochondrial complex I in a cell. The composition comprises an effective amount of a phospholipid with two polyunsaturated fatty acyl tails (PL-PUFA2).
[0013] Another embodiment of the present disclosure is a method for inhibiting mitochondrial complex I in a cell. This method comprises contacting the cell with an effective amount of the composition disclosed herein.
[0014] Another embodiment of the present disclosure is a method for treating or ameliorating the effects of a disease in a subject in need thereof. This method comprises administering to the subject an effective amount of the composition disclosed herein.
[0015] Still another embodiment of the present disclosure is a method for inducing ferroptosis in a cell. The method comprises contacting the cell with an effective amount of a phospholipid with two polyunsaturated fatty acyl tails (PL- PIIFA2).
[0016] A further embodiment of the present disclosure is directed to a method for treating or ameliorating the effects of a disease in a subject in need thereof. This method comprises: (a) obtaining a biological sample from the subject; (b) measuring the level of a phospholipid with two polyunsaturated fatty acyl tails (PL-PUFA2) in the sample and comparing it to a predetermined reference; (c) identifying the subject as sensitive to an agent that induces ferroptosis, if the level of the PL-PUFA2 measured in step (b) is higher than the predetermined reference; and (d) administering to the sensitive subject an effective amount of the agent.
[0017] Yet another embodiment of the present disclosure is a method for treating or ameliorating the effects of a cancer in a subject in need thereof. This method comprises: (a) obtaining a biological sample from the subject; (b) measuring the level of a phosphatidylcholine with two polyunsaturated fatty acyl tails (PC- PIIFA2) in the sample and comparing it to a predetermined reference; (c) identifyingthe subject as sensitive to an agent that induces ferroptosis, if the level of the PC- PIIFA2 measured in step (b) is higher than the predetermined reference; and (d) administering to the sensitive subject an effective amount of the agent.
[0018] The present disclosure also provides a dietary supplement for a subject having a cancer. The dietary supplement comprises an effective amount of a composition disclosed herein, such as, e.g., a phospholipid with two polyunsaturated fatty acyl tails (PL-PUFA2).BRIEF DESCRIPTION OF THE DRAWINGS
[0019] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
[0020] Figs. 1A-1I show that PC-PUFA2S induce ferroptosis. (A) Viability of A549 cells (left) and IGROV-1 cells (right) treated with 50 pM phospholipids with different head groups and fatty acyl tails with or without 10 pM ferrostatin-1 (Fer-1) for 24 hr. (B) Viability of IGROV-1 cells co-treated with 50 pM PC(22:6, 22:6) and 10 pM Fer-1 , 100 pM deferoxamine (DFO), 20 pM Z-VAD-FMK, 20 pM necrostatin-1s (Nec-1s), or 100 nM bafilomycin A1 (Baf-A1) for 24 hr. (C) IC50 of PC-PUFA2 with two C22:6 or C20:4 tails versus PC-PUFA1 with one C18:0 tail and one of the C22:6 or C20:4 PUFA tail in multiple cancer cell lines. Each color represents a cell line. (D) IGROV-1 cells treated with vehicle, 10 pM Fer-1 alone, or 100 pM PC(22:6, 22:6) with or without 10 pM Fer-1 for 4 hr were stained with TfR1 antibody. Immunofluorescent images showing nucleus DAPI and TfR1 stain. Scale bar is shown as 20 pm. The relative mean fluorescence intensity of TfR1 membrane staining compared to vehicle is plotted as mean ± SD. Each dot represents a cell. n=50-164 for all groups. (E) Lipid peroxidation measured by C11-BODIPY581 / 591in IGROV-1 cells treated with 100 pM PC(22:6, 22:6) with or without 20 pM ferrostatin- 1 for 4 hr. The relative mean fluorescence intensity of oxidized C11-BODIPY581 / 591compared to vehicle is plotted as mean ± SD of n=3 biological replicates. (F) HT- 1080 cells were co-treated with 12.5 pM PC(22:6, 22:6) and ferroptosis inducers (RSL3 15.6 nM, IKE 0.63 pM, FIN56 10 pM, media cystine concentration 6.25 pM, C0Q10 complete depletion) for 24 hr. Data plotted as mean ± SD of n=2 technicalreplicates. (G) RSL3 IC50 in 20 cancer cell lines. Data plotted as mean ± SD of n=2 biological replicates. (H) The signal intensity of PCs normalized to protein concentration of each cell sample is plotted as mean ± SD of n=3 biological replicates. (I) Statistical analysis of PC abundances between ferroptosis-sensitive and resistant cells. Data plotted as mean ± SD of n=10 for each group. One-way and two-way ANOVA: p<0.03 (*), p<0.002 (**), p<0.0002 (***), p<0.0001 (****). See also Figs. 7A-7J and Table 1 .
[0021] Figs. 2A-2D show that dietary PC-PUFA2S are remodeled into the cell lipidome. (A) A498 cells were treated with 25 pM PC(18:0, 20:4) or PC(20:4, 20:4) for 6 hr. The relative abundance of PCs and lysoPCs compared to untreated group is plotted as mean ± SD of n=3 biological replicates. (B) Viability of IGROV-1 cells cotreated with 6.25 pM PC(22:6, 22:6) and 30 pM PLA2 inhibitor, ONO-RS-082 for 24 hr. Data plotted as mean ± SD of n=2 technical replicates. (C) Structures of deuterated PCs. (D) IGROV-1 cells were treated with 25 pM [d11 ]-PC(18:0, 20:4) or [d22]-PC(20:4, 20:4) for 6 hr. The relative abundance of original and remodeled deuterated lipid species compared to [d11]-PC(18:0, 20:4)-treated group is plotted as mean ± SD of n=4 biological replicates. Two-way ANOVA: p<0.03 (*), p<0.002 (**), p<0.0002 (***), p<0.0001 (****). See also Figs. 8A-8D.
[0022] Figs. 3A-3G show that PC-PUFA2 is involved in dietary fatty acid remodeling. (A) Viability of IGROV-1 cells treated with 50 pM DHA or PC(22:6, 22:6) with or without 10 pM Fer-1 for 24 hr. Data plotted as mean ± SD of n=2 technical replicates. (B) Viability of IGROV-1 cells pre-treated with 25 pM DHA, or 50 pM oleic acid, or both DHA and oleic acid for 24 hr and then treated with 31.3 nM RSL3 for 24 hr. Data plotted as mean ± SD of n=4 technical replicates. (C) Viability of Calu-1 cells pre-treated with 25 pM DHA, or 50 pM oleic acid for 24 hr and then treated with 25 pM PC for 24 hr. Data plotted as mean ± SD of n=2 technical replicates. (D) IGROV- 1 cells were treated with 25 pM DHA for 6 hr. The relative abundance of lipids compared to untreated group is plotted as mean ± SD of n=3 biological replicates. (E) IGROV-1 cells were treated with 25 pM DHA, or 50 pM oleic acid, or both DHA and oleic acid for 6 hr. The relative abundance of lipids compared to untreated group is plotted as mean ± SD of n=3 biological replicates. (F) Calu-1 cells were knockdown using pooled siRNA containing 4 different sequences targeting ACSL4 and then treated with 50 pM PCs for 24 hr. Viability is compared to vehicle-treatedgroup and is plotted as mean ± SD of n=4 technical replicates. The knockdown efficiency was confirmed by qPCR and western blot. (G) IGROV-1 cells were treated with PCs or vehicle for 5 hr and whole-cell lysate was analyzed for western blot detection of GPX4 and ACSL4. Two-way ANOVA: p<0.03 (*), p<0.002 (**), p<0.0002 (***), p<0.0001 (****). See also Figs. 9A-9B.
[0023] Figs. 4A-4E show that PL-PUFA2S exhibit interaction with mitochondrial electron transport chain. (A) Structures of biotinylated phospholipids. (B) HT-1080 whole-cell lysate was incubated with biotinylated phospholipids, vehicle, or biotin, and phospholipid-bound proteins were identified by MS-based proteomics. 2-D plot of principle component analysis (PCA) of proteomic data of all groups. (C) Volcano plot of genes differentially enriched in PL(22:6, 22:6) vs PL(18:0, 22:6) groups. Data cutoff at fold change >4 and FDR adjusted p <0.05. Significantly enriched mitochondrial complex I genes are labeled. (D) Western blot analysis of mitochondrial complex proteins in pull-down samples. Empty lanes are cut and shown by the dotted line. (E) HT-1080 cells were treated with 50 M biotinylated PL(22:6, 22:6) or PL(18:0, 22:6) for 6 hr and immunostained with anti-COX IV, anti- Calnexin, anti-Giantin, and anti-LAMP1 antibodies. Composite fluorescent images are shown as PL in red and each antibody in pseudo-cyan. Scale bar is shown as 20 pm. Colocalization between PL and each subcellular organelle is represented by Pearson’s coefficient plotted as mean ± SD of n=6-8 images for all groups. One-way ANOVA: p<0.03 (*), p<0.002 (“), p<0.0002 (***), p<0.0001 (““). See also Figs. 10A-10E.
[0024] Figs. 5A-5F show that PC-PUFA2S induces mitochondrial stress. (A) Mitochondrial superoxide accumulation measured by MitoSOX red in IGROV-1 cells treated with 100 pM PC or 5 pM antimycin A for 4 hr. The relative mean fluorescence intensity of MitoSOX compared to vehicle is plotted as mean ± SD of 2 biological replicates. (B) Mitochondrial membrane potential measured by rhodamine123 in IGROV-1 cells treated with 100 pM PC or 10 pM antimycin A for 4 hr. Scale bar is shown as 20 pm. The relative ratio of rhodamine123 to MitoTracker compared to vehicle is plotted as mean ± SD of n=9-10 images. (C) Oxygen consumption rate was measured kinetically for 4 hr in HT-1080 pre-treated with 100 pM PC(22:6, 22:6) with or without 20 pM Fer-1 , or 1 pM RSL3 for 2 hr. (D) Viability of IGROV-1 cells cotreated with 100 pM PC(22:6, 22:6) and 0.5 pM mitoquinone (MitoQ) or 0.5 pMdecylubiquinone (DecylQ) for 24 hr. (E) Mitochondrial superoxide accumulation measured by MitoSOX green in IGROV-1 cells treated with 100 pM PC(22:6, 22:6) with or without 10 pM Fer-1 or 0.2 pM mitoQ for 4 hr. Relative ratio of MitoSOX to MitoTracker compared to vehicle is plotted as mean ± SD. Each dot represents a cell. n=67-124 for all groups. (F) Lipid peroxidation measured by C11-BODIPY581 / 591in IGROV-1 cells co-treated with 100 pM PC(22:6, 22:6) and 0.5 pM mitoQ for 4 hr. One-way and two-way ANOVA: p<0.03 (*), p<0.002 (**), p<0.0002 (***), p<0.0001 (****).See a|S0 Fjgs 11 A.11 F
[0025] Figs. 6A-6D show that PC-PUFA2S induce lipid peroxidation, but not an unfolded protein response in ER. (A) Lipid peroxidation measured by Liperfluo in IGROV-1 cells treated with 100 pM PC(22:6, 22:6) for 4 hr. Cells were co-stained with ER-Tracker and MitoTracker. Composite fluorescent images are shown as Liperfluo in green and ER-Tracker or MitoTracker in pseudo-magenta. Scale bar is shown as 20 pm. Colocalization between Liperfluo and mitochondria or ER is represented by Pearson’s coefficient plotted as mean ± SD of n=9-11 images. (B) Relative mean intensity of Liperfluo compared to vehicle is plotted as mean ± SD of n=10-14 images. (C) Western blot analysis of UPR mediators, XBP1 s and GADD in IGROV-1 cells treated with 100 pM PC, 10 pM CCCP, or 1 pM Brefeldin A for 4 hr. The transcript levels of XBP1 s and CHOP were measured in same cells used for western blot. Data plotted as mean ± SD of n=3 technical triplicates. (D) Schematics of the mechanism of PC-PUFA2-induced ferroptosis. See also Figs. 12A-12C.
[0026] Figs. 7A-7J show that PC-PUFA2S induce ferroptosis. (A) Viability of HT-1080 cells treated with 100 pM phospholipids with different head groups with or without 10 pM ferrostatin-1 (Fer-1 ) for 24 hr. (B) Viability of IGROV-1 cells co-treated with 50 pM PC(22:6, 22:6) or PC(20:4, 20:4) and 10 pM Fer-1 , 100 pM DFO, 20 pM Z-VAD-FMK, 20 pM Nec-1 s, or 100 nM Baf-A1 for 24 hr. (C) IGROV-1 cells treated with 100 pM PC for 4 hr were immunostained with TfR1 antibody. Representative images showing TfR1 staining. Scale bar is shown as 20 pm. (D) Lipid peroxidation measured by C11-BODIPY581 / 591in HT-1080 cells treated with 100 pM PC and PE with or without 10 pM ferrostatin-1 , or 1 pM RSL3 for 4 hr. (E) IGROV-1 cells were treated with PC or vehicle for 5 hr and whole-cell lysate was analyzed for western blot detection of phospho-MLKL, pro and cleaved Caspase-3. (F) Dose response of FINO2 in HT-1080 cells pre-treated with 15 pM PC(22:6, 22:6) for 8 hr. (G) Thesignal intensity of monoacyl-PUFA-PLs normalized to protein concentration of each cell sample is plotted as mean ± SD of n=3 biological replicates. Statistical analysis of PC abundance between ferroptosis-sensitive and resistant cells. Data plotted as mean ± SD of n=10 for each group. (H) Volcano plot of PLs and lysoPLs differentially enriched in the hippocampus of 59-week-old vs. 3-week-old mice. Data cutoff at fold change >1.5 and FDR adjusted p <0.05. Significantly depleted diacyl-PUFA-PLs and enriched lysoPLs are labeled. (I) Heat maps (one-way ANOVA; FDR-corrected p- value <0.05) of diacyl-PUFA-PLs and monoacyl-PUFA-PLs in 59-week-old and 3- week-old mice. Top 14 differentially expressed lipids are shown. (J) Lipids from brain tissue of Huntington’s disease (HD, n=21) and normal cases (control, n=25) were extracted and analyzed by LC-MS-based lipidomics. The relative signal intensity of annotated diacyl-PUFA-PLs compared to control samples is plotted as mean ± SD. Two-way ANOVA: p<0.03 (*), p<0.002 (**), p<0.0002 (***), p<0.0001 (““).
[0027] Figs. 8A-8D show that dietary PC-PUFA2S are remodeled into the cell lipidome. (A) A549 cells were treated with 25 pM PC(18:0, 20:4) or PC(20:4, 20:4) for 6 hr. The relative signal intensity compared to untreated-samples of PEs detected is plotted as mean ± SD of n=3 biological replicates. (B) A549 cells were treated with 25 pM PS(20:4, 20:4) or PG(20:4, 20:4) for 6 hr. The relative signal intensity of PS(20:4, 20:4) and PG(20:4, 20:4) compared to vehicle are plotted as mean ± SD of n=3 biological replicates. (C) Dose response of deuterated lipids with or without 10 pM Fer-1 in HT-1080 at 24 hr. (D) IGROV-1 cells were treated with 25 pM [d11]- PC(18:0, 20:4) or [d22]-PC(20:4, 20:4) for 6 hr. The relative signal intensity of nondeuterated lipids compared to untreated-samples are plotted as mean ± SD of n=4 biological replicates. Unpaired t-test and two-way ANOVA: p<0.03 (*), p<0.002 (**), p<0.0002 (***), p<0.0001 (****).
[0028] Figs. 9A-9B show that PC-PUFA2 is involved in dietary fatty acid remodeling. (A) IGROV-1 cells were treated with 25 pM DHA or ARA with or without co-treatment of 30 pM phospholipase A2 inhibitor (PLA2i) ONO-RS-082 for 6 hr. The relative signal intensity of PC and PE compared to untreated samples are plotted as mean ± SD of n=3 biological replicates. (B) Cas9 overexpressing HT-1080 were transiently transfected with non-targeting or ACSL4-targeting sgRNA to achieve CRISPR knockdown. Viability is shown for knockdown cells treated with 1 pM RSL3 or 100 pM PC for 24 hr. The knockdown efficiency was confirmed by qPCR andwestern blot. Empty lanes are cut and indicated by the dotted line. One-way and two- way ANOVA: p<0.03 (*), p<0.002 (**), p<0.0002 (***), p<0.0001 (****).
[0029] Figs. 10A-10E show that PL-PUFA2S exhibit interaction with mitochondrial electron transport chain. (A) HT-1080 whole-cell lysate was incubated with biotinylated phospholipids, vehicle, or biotin, and phospholipid-bound proteins were identified by MS-based proteomics. Heat map (one-way ANOVA; FDR- corrected p-value <0.05) showing the top 25 hits of differentially enriched genes among all groups. n=3 technical replicates are shown for each group. (B) Dose response of PC(22:6, 22:6) in IGROV-1 cells transfected with pooled siRNAs targeting 11 proteins identified in the heat map. Relative viability is compared to vehicle-treated group and is plotted as mean ± SD of n=4 technical replicates. (C) Gene set enrichment analysis of genes enriched and depleted in PL(22:6, 22:6) compared to PL(18:0, 22:6). Top pathways and related genes are shown with p. adjusted <0.1 . A part of the detailed view of the chemical carcinogenesis — reactive oxygen species is shown. (D) HT-1080 cells were treated with 50 pM biotinylated PL(22:6, 22:6) for 6 hr and immunostained with streptavidin-cy5. Representative images showing PL stain. Scale bar is shown as 20 pm. (E) HT-1080 cells were treated with 25 pM PC(22:6, 22:6) for 6 hr. Mitochondria were isolated and lipids from mitochondria and the rest cell compartments were extracted. The signal intensity of PC(22:6, 22:6) is normalized to protein concentration of each sample and presented as fold change to untreated samples. Data are plotted as mean ± SD of n=3 biological replicates. Two-way ANOVA: p<0.03 (*), p<0.002 (**), p<0.0002 (***), p<0.0001 (““).
[0030] Figs. 11A-11 F show that PC-PUFA2S induces mitochondrial stress. (A) Representative images of rhodamine123 and MitoTracker deep red staining in IGROV-1 cells treated with 100 pM PC, vehicle, or 10 pM Antimycin A for 4 hr. Scale bar is shown as 20 pm. (B) Bright field images of HT-1080 cells treated with 100 pM PC(22:6, 22:6) or 1 pM RSL3 after the course of OCR assay for 6 hr. Scale bar is shown as 200 pm. (C) Representative images showing MitoSOX green and MitoTracker deep red staining in IGROV-1 cells treated with 100 pM PC(22:6, 22:6) with or without 10 pM Fer-1 and 0.2 pM mitoQ for 4 hr. (D) Lipid peroxidation measured by C1 1-BODIPY581 / 591in IGROV-1 cells treated with 10 pM Antimycin A or 5 pM rotenone for 4 hr. (E) Viability of IGROV-1 cells co-treated with PC(22:6, 22:6)and VDAC1 inhibitor, DI DS for 24 hr (left). IGROV-1 cells were knockdown with pooled siRNA targeting VDAC1 , VDAC2, or VDAC3 and then co-treated with PC(22:6, 22:6) for 24 hr (right). (F) HT-1080 cells overexpressing mcherry-Parkin were treated with 12.5 pM CCCP for 48 hr to induce mitophagy. Fluorescent images of MitoTracker deep red are shown. Relative fluorescent intensity compared to control is plotted as mean ± SD of n=9-10 images. MT-DNA transcript was measure by qPCR. Dose response curve of PC(22:6, 22:6) in CCCP-treated cells. Un-paired t-test and two-way ANOVA: p<0.03 (*), p<0.002 (**), p<0.0002 (***), p<0.0001 (****), not significant (ns).
[0031] Figs. 12A-12C show that PC-PUFA2S induce lipid peroxidation, but not an unfolded protein response in ER. (A) IGROV-1 cells were treated with 100 pM PCs for 4 hr. Representative images of cells co-stained with Liperfluo and MitoTracker and ER-Tracker. (B) The transcript level measured by qPCR and protein level measured by western blot of UPR mediators, XBP1s, ATF4, and GADD in IGROV-1 cells treated with 25 pM PC, 1 pM Brefeldin A, or 1 pM thapsigargin (Tg) for 24 hr. (C) Mitochondrial lipid peroxidation measured by mitoCLox in IGROV-1 cells treated with 100 pM PC(22:6, 22:6) for 4 hr. Cells were co-stained with ER- Tracker or MitoTracker. Fluorescent images are shown as composite of Liperfluo in green and ER-Tracker or MitoTracker in pseudo-magenta. Relative fluorescent intensity compared to control is plotted as mean ± SD of n=135-145 cells. Un-paired t-test and two-way ANOVA: p<0.03 (*), p<0.002 (**), p<0.0002 (***), p<0.0001 (****), not significant (ns).
[0032] Figs. 13A-13C show that bead-stimulated Tregs isolated from healthy PBMCs exhibit strong FoxP3 phenotype and suppression of responder T cells. (A) Experimental scheme detailing the isolation of PBMCs from human buffy coat, staining of PBMCs with immune cell markers to collect Treg population via FACS, and subsequent activation and expansion of Tregs in vitro via bead-mediated stimulation. (B) Representative suppression assay with readout as proliferation of Tresps, Tconv and CD8+T cells. Tregs were co-cultured with CFSE-labeled Tresps at appropriate Tresp: Treg ratios. 72 hours later, cells were analyzed by flow cytometry to determine the effect of Tregs on Tresp proliferation. Tresp= responder T cells. Tconv= conventional T cells. (C) Representative FoxP3 expression of Tregsfollowing stimulation in culture. FMO= fluorescence minus one. (B-C) Data are representative of at least 3 independent experiments.
[0033] Figs. 14A-14B show that Tregs are sensitive to ferroptosis. (A) Tregs were seeded at a density of 2,000 cells / well in 384-well plates. Tregs were treated with RSL3 ± 2 pM Fer-1. Cell viability was assessed 24 hours later. Data are normalized to vehicle-treated cells. Mean ± SEM (n=3). **p < 0.01 and ***p < 0.001 by Student’s t test, ns = non-significant. DMSO = dimethyl sulfoxide. Fer-1 = ferrostatin-1. (B) Tregs were seeded at a density of 200,000 cells / well in a 24-well plate. Tregs were treated with DMSO or 1 pM of RSL3 ± 10 pM Fer-1 . After 1 hour, lipid ROS was evaluated using C11-BODIPY via flow cytometry. Quantitative analysis was performed using FlowJo software to determine MFI and SD. -10,000 events were recorded. Data are plotted as Mean ± SEM. Data are representative of 3 independent experiments. ****p < 0.0001 by one-way ANOVA. MFI = median fluorescence intensity, ns = non-significant.
[0034] Figs. 15A-15D show that single-cell RNA sequencing (scRNA-seq) and gene set enrichment analysis (GSEA) of combined PBMCs and expanded Tregs reveal OXPHOS as a top metabolic pathway enriched in Tregs. (A) 2D UMAP of scRNA-seq data; each dot represents a cell colored by specific immune cell clusters annotated by DGE. DGE= differential gene expression. (B) 2D UMAP of scRNA-seq data in (A) with cells colored by condition, as either originating from PBMCs or Tregs in the initial sample. (C) GSEA analysis on ranked list of all -6,000 genes from DGE analysis highlighting OXPHOS as a metabolic pathway enriched in the Treg cluster. NES is ± in PBMCs relative to Tregs. NES= normalized enrichment score. (D) Table of OXPHOS genes in ETC complexes enriched in Tregs, based on results from GSEA.
[0035] Figs. 16A-16B show that targeting complex 1 induces ferroptosis in Tregs. (A) Tregs were seeded at a density of 2,000 cells / well in 384-well plates. Tregs were treated with rotenone or antimycin from 100 pM to 3.125 pM ± 2 pM Fer- 1 , and diethyl butylmalonate (DBM) or NaNs from 20 mM to 0.625 mM ± 2 pM Fer-1. Cell viability was assessed 24 hours later. Data are normalized to vehicle-treated cells. Mean ± SEM (n=3). *p < 0.05 and ***p < 0.001 by Student’s t test, ns = nonsignificant. (B) Tregs were seeded at a density of 200,000 cells / well in a 24-well plate and treated with DMSO or 50 pM of rotenone ± 10 pM Fer-1. After 12 hours,lipid ROS was evaluated using C11-BODIPY via flow cytometry. Quantitative analysis was performed using FlowJo software to determine MFI and SD. -10,000 events were recorded. Data are plotted as Mean ± SEM. Data are representative of 3 independent experiments. ****p < 0.0001 by one-way ANOVA. MFI = median fluorescence intensity.
[0036] Figs. 17A-17E show that PC(22:6; 22:6) induces ferroptosis in Tregs and inhibits Treg-mediated suppression. (A) Tregs were seeded at a density of 2,000 cells / well in 384-well plates. Tregs were treated with PC(22:6; 22:6), PC(20:4; 20:4), and PC(18:3; 18:3) ± 10 pM Fer-1. Cell viability was assessed 24 hours later. Data are normalized to vehicle-treated cells. Mean ± SEM (n=3). *p < 0.05, **p < 0.01 , and ***p < 0.001 by Student’s t test, ns = non-significant. (B) Tregs were seeded at a density of 200,000 cells / well in a 24-well plate. Tregs were treated with 100 pM of PC(22:6; 22:6) ± 10 pM Fer-1. After 4 hours, lipid ROS was evaluated using C11- BODIPY via flow cytometry. Quantitative analysis was performed using FlowJo software to determine MFI and SD. -10,000 events were recorded. Data are plotted as Mean ± SEM. Data are representative of 3 independent experiments. ****p < 0.0001 by one-way ANOVA. MFI = median fluorescence intensity. (C) Tregs were seeded at a density of 500,000 cells / well in a 24-well plate. Tregs were treated with 40 pM of PC(22:6; 22:6) or vehicle. After 24 hours, Tregs were stained with 500 nM calcein-AM for 20 minutes, followed by 1 mM DFO for 1 hour. Effect on labile iron pool (LIP) was evaluated via flow cytometry. Quantitative analysis was performed using FlowJo software to determine MFI and SD. Data are plotted as Mean ± SEM. -10,000 events were recorded. Data are representative of 3 independent experiments. ****p < 0.0001 by Student’s / test. MFI = median fluorescence intensity. (D) Tregs were treated with 100 pM of PC (22:6; 22:6) or vehicle. After 4 hours, a minimum of 4 million cells were harvested per condition, mRNA was extracted, and qPCR was performed. Mean ± SEM (n=3). *p < 0.05 and **p < 0.01 by Student’s t test. (E) Tregs were pre-treated with vehicle or 20 pM PC(22:6; 22:6) ± 10 pM Fer-1 . After 24 hours, Tregs were harvested per condition and co-cultured with CFSE- labeled Tresps at appropriate Tresp: Treg ratios. 72 hours later, cells were analyzed by flow cytometry to determine the effect of pre-treated Tregs on the proliferation of Tresps. Data are representative of 3 independent experiments.
[0037] Figs. 18A-18C show that OXPHOS expression in Tregs from the tumor microenvironment and peripheral blood in breast cancer. (A-B) Spatial analysis of OXPHOS signature expressions in tumor microenvironments of primary estrogen receptor (ER)-positive breast cancer replicate 1 (A) and 2 (B). Left: coordinates of tumor regions and Treg-enriched spots; Middle: spatial distribution of OXPHOS signatures in Treg-enriched spots; Right: correlations of OXPHOS signature expressions in Treg-enriched spots and distance to tumor regions. A one-sided / test was performed in both replicates, p-value = 1.26x 10-21(A), p-value = 8.93 x 10'12(B). (C) Volcano plot of gene expressions from tumor-resident Treg versus Tregs from the peripheral blood in primary breast cancer. Highlighted genes in green represent significant DGEs in tumor-Tregs against PBMC-Tregs (p < 0.05, absolute log-fold change > 1). Annotated genes in red are significant if OXPHOS signatures belong to DGEs.
[0038] Fig. 19 shows immunophenotyping of PBMCs via flow cytometry. Representative flow cytometry data of PBMCs stained with panel of antibodies used to identify Tregs. The Treg population collected via FACS is CD4+CD25+CD127|OW. Data is representative of at least 3 independent experiments.
[0039] Figs. 20A-20F show probing ferroptosis signatures in Tregs and in additional donors. (A)Tregs were seeded at a density of 2,000 cells / well in 384-well plates. Tregs were pre-treated with 20 pM ARA or vehicle. After 24 hours, Tregs were treated with RSL3 from 100 nM to 0 nM ± 2 pM Fer-1. Cell viability was assessed 24 hours later. Data are normalized to vehicle-treated cells. Mean ± SEM (n=3). **p < 0.01 and ****p < 0.0001 by Student’s t test, ns = non-significant. ARA = arachidonic acid. (B-C) Tregs were seeded at a density of 200,000 cells / well in a 24- well plate. Tregs were treated with DMSO or 1 pM of RSL3 ± 10 pM Fer-1. After 1 hour, lipid ROS was evaluated using C11-BODIPY via flow cytometry. Quantitative analysis was performed using FlowJo software to determine MFI and SD. -10,000 events were recorded. Data are plotted as Mean ± SEM. ****p < 0.0001 by one-way ANOVA. MFI = median fluorescence intensity. (B) and (C) represent different donor Tregs, respectively. (D) Identified PLIFAs, diPUFA-PCs, and mono-PUFA-PLs from untargeted lipidomics of Tregs. Lipidomics were performed on 5 independent Treg cell pellets of 5,000,000 cells each. PUFA= polyunsaturated fatty acid. diPUFA-PC= phosphatidylcholine with two polyunsaturated fatty acyl tails. mono-PUFA-PL=phospholipid with one polyunsaturated fatty acyl tail. (E-F) Tregs were seeded at a density of 200,000 cells / well in a 24-well plate and treated with DMSO or 50 pM of rotenone ± 10 pM Fer-1. After 12 hours, lipid ROS was evaluated using C11- BODIPY via flow cytometry. Quantitative analysis was performed using FlowJo software to determine MFI and SD. Data are plotted as Mean ± SEM. -10,000 events were recorded. Data are representative of 3 independent experiments. ****p < 0.0001 by one-way ANOVA. MFI = median fluorescence intensity. (E) and (F) represent different donor Tregs, respectively.
[0040] Figs. 21A-21E show probing the effect of PC(22:6; 22:6) on Tregs from additional donors. (A)Tregs were seeded at a density of 200,000 cells / well in a 24- well plate. Tregs were treated with 100 pM PC(22:6; 22:6) ± 10 pM Fer-1. After 4 hours, lipid ROS was evaluated using C11-BODIPY via flow cytometry. Quantitative analysis was performed using FlowJo software to determine MFI and SD. -10,000 events were recorded. Data are plotted as Mean ± SEM. ****p < 0.0001 by one-way ANOVA. MFI = median fluorescence intensity. D1 and D2 represent different donor Tregs, respectively. (B-C) Tregs were seeded at a density of 500,000 cells / well in a 24-well plate. Tregs were treated with 40 pM PC(22:6; 22:6), 8 mM FAC, or vehicle. After 24 hours, Tregs were stained with 500 nM calcein-AM for 20 minutes, followed by 1mM DFO for 1 hour. Effects on the labile iron pool (LIP) were evaluated via flow cytometry. Quantitative analysis was performed using FlowJo software to determine MFI and SD. Data are plotted as Mean ± SEM. -10,000 events were recorded. Data are representative of 3 independent experiments. ****p < 0.0001 by Student’s / test. MFI = median fluorescence intensity. FAC= ferric ammonium citrate. D3 and D4 represent different donor Tregs, respectively. (D) IP-Western blot analysis. Eluted samples were analyzed by western blot and stained with NDUFS1 and NDUFAB1 , markers for complex 1. IP= immunoprecipitation. (E) Tregs were pretreated with vehicle or 20 pM PC(22:6; 22:6) ± 10 pM Fer-1. After 24 hours, Tregs were harvested per condition and co-cultured with CFSE-labeled Tresps at appropriate Tresp: Treg ratios. 72 hours later, cells were analyzed by flow cytometry to determine the effect of pre-treated Tregs on proliferation of Tresps. D5 and D6 represent different donor T cells, respectively.
[0041] Figs. 22A-22F show the ferroptosis sensitivities of Tregs vs. PBMCs, unstimulated Tregs, stimulated CD4+Tconv and CD8+T cells. (A-B) Cells wereseeded at a density of 2,000 cells / well in 384-well plates. PBMCs, stimulated Tregs, and unstimulated Tregs were treated with rotenone from 100 pM to 3.125 pM. Cell viability was assessed 24 hours later. (C-F) Stimulated Tregs, CD4+Tconv, and CD8+T cells were seeded at a density of 2,000 cells / well in 384-well plates. T cells were treated with rotenone or PC(22:6; 22:6) from 100 pM to 3.125 pM, or RSL3 from 100 nM to 3.125 nM. Cell viability was assessed 24 hours later. (E) and (F) represent different donors, respectively. (A-F) Data are normalized to vehicle-treated cells. Mean ± SEM (n=3). *p < 0.05, **p < 0.01 , ***p < 0.001 , and ****p < 0.0001 by Student’s t test, ns = non-significant.
[0042] Figs. 23A-23F show the hallmarks of PC9 / PSPsystem. (A) PC9 and PSPC9cells stained for CD24, CD133, and sorted by FACS. Representative of 3 independent experiments, 1x105total events per cell type. (B) 48hr CellTiter-Glo (CTG) viability assay of PSPC9and (C) PSPC9vs PC9 treated with RSL3 1 / zM, with and without ferrostatin-1 (Fer-1) 2 / zM and Z-VAD-FMK (ZVAD) 10 / zM. Technical triplicate (B) or quadruplicate (C) per experiment, n = 8 independently cultured biological replicates pooled, counted, and set up as technical replicates per experiment. Representative of 4 (B) or 10+ (C) independent experiments. (D) Giemsa stain and corresponding 4x light microscopy images of PSPC9cells grown in 10 pM erlotinib (left), with subsequent removal of erlotinib and regrowth (center), and re-introduction of 10 pM erlotinib (right). (E) Cell count of rederived PC9 growth upon erlotinib removal by trypan blue exclusion dye; erlotinib removed day 11, cells counted day 21. (D) and (E) representative of 3 independent regrowth experiments. (F) 48hr CTG viability assay of PC9ps -> PC9cells treated with erlotinib 11 [iM or RSL3 1 M. Technical quadruplicate per experiment, n = 2 independently cultured biological replicates, pooled and counted, per experiment. Representative of 2 independent experiments. For (B), (C) and (F) data are presented as % of DMSO control, mean ± s.d., * P < 0.05, ** P < 0.01 , *** P < 0.001 , and **** P < 0.0001 by two-way or one-way ANOVA followed by Tukey's multiple comparisons test or unpaired two-tail t-test. ns = non-significant.
[0043] Figs. 24A-24B show transcriptional analysis of PC9 vs PSPC9. (A) Top 20 differentially expressed genes for PC9 vs PSPC9batch effect corrected joint Stockwell-Green lab data set. Colored by scaled reads per base and generated using Sleuth “plot_transcript_heatmap” function with transcripts clustered (Jensen-Shannon distance, hierarchical clustering of rows and columns). Benjamini- Hochberger (BH) corrected significance (all displayed have corrected p < 10-6). n = 9 independently cultured biological replicates per cell type, pooled into 3 replicates for PS and n = 3 independently cultured biologically replicates of PC9 for Stockwell samples. (B) GSEA on ranked list of all -17,000 genes from DGE analysis, red arrows highlight sugar or lipid metabolic pathways. NES is ± in PSPC9relative to PC9. BH corrected p < .15 displayed.
[0044] Figs. 25A-25B show untargeted lipidomics analysis of PC9 vs PSPC9. (A) Abundance of 79 identified PUFA-PLs and (B) 26 identified FFA changed significantly (FDR < .05) in PC9 vs PSPC9. Red arrows highlight PL-PUFA2S. 4 x106cells per sample for all cell types. Independently cultured biological replicates cultured in sufficient quantity and pooled into 5 replicates of PS, n = 5 independently cultured biological replicates of PC9. One-way ANOVA of normalized peak intensity with Euclidean distance and Ward clustering, rows and columns.
[0045] Figs. 26A-26F show multi time point untargeted and pseudo-targeted lipidomics analysis of NSCLC, prostate carcinoma, and fibrosarcoma models persister models. (A) 53 of the 79 previously identified mono and PUFA-PLs and (B) 21 of the 26 previously identified FFA again identified among significantly (FDR < .05) changed abundance across all NSCLC cell types. Red arrows highlight diPUFA PLs. One-way ANOVA of normalized peak intensity with Euclidean distance and Ward clustering, rows and columns. (C) 48hr CTG viability assay of PC9, PSPC9, and 34-day PC9PS PC9treated with RSL3 1 jtzM. Viability experiment is of same set of samples used for lipidomics. (D) Targeted diPUFa PL abundance in prostate carcinoma and fibrosarcoma persister models; retention time and m / z validated by standard run in tandem. Independently cultured biological replicates cultured in sufficient quantity and pooled into 5 (A) or 3 (D) replicates for PS, n = 5 (A) or 3 (D) independently cultured biological replicates of PC9, LNCaP, and HT1080, respectively. 4 x106(A) or 3 x106(D) cells per sample for all cell types. (E) 48hr CTG viability assay of PC9, PSPC9, and 15-day PC9PS _> PC9RSL3 1 / zM or erlotinib 1 / zM. Technical quadruplicate (C) or triplicate (E) per experiment, n = 2 independently cultured biological replicates, pooled and counted per experiment. Representative of 2 independent experiments. (F) Bar chart of PUFA-PLs abundant and deplete in ferroptosis resistant (PC9, 34-day PC9PS -> PC9) vs sensitive (PSPC9, 15-day PC9ps ->PC9) cells, respectively. For (D) and (F), * P < 0.05, “ P < 0.01 , *** P < 0.001 , and **** p < 0.0001 by two-way or one-way ANOVA followed by Tukey's multiple comparisons test, ns = non-significant. For (C) and (E), data are presented as % of DMSO control, mean ± s.d., * P < 0.05, ** P < 0.01 , and *** P < 0.001 by two-way ANOVA followed by Sidak's multiple comparisons test, ns = non-significant.
[0046] Figs. 27A-27D show the effect of mitochondrial elimination on ferroptosis sensitivity in HT1080 vs psHT108°. (A) Western blot of Cytochrome C and (B) ATF4, with B actin as control of HT1080 vs PSHT108° vs HT1080 + CCCP vs PSHT 1080 + CCCP. (C) 56hr CTG viability assay of RSL3 25 nM or doxorubicin 150 nM treated cells. (D) Repeat of (c) but for 48hr using 2.5% FBS media. Technical quadruplicate per experiment, n = 8 independently cultured biological replicates, pooled, counted, and set up as technical replicates per experiment. Representative of 3 independent experiments. (A), (B), and (C) were drawn from the same counted samples per each independent experiment. Data are presented as % of DMSO control, mean ± s.d., * P < 0.05, ** P < 0.01 , *** P < 0.001 , and **** P < 0.001 by two- way ANOVA followed by Sidak's multiple comparisons test, ns = non-significant.
[0047] Figs. 28A-28E show the PSPC9and PC9 persister and ferroptosis relevant protein signature. Western blot of PSPC9and PC9 cells stained for (A) ATF4 (~50kDa), (B) GPX4 (~20kDa), and (C) GCH1 (~25 kDa) with p actin (~40 kDa) as control for all. (D) Western blot of proteins from (A-C) in direct comparison of PC9, PSPC9, cycling PSPC9, and PC9PS _> PC9. Representative of 3 (A-C) and 2 (D) independant experiments, e, ATF4, GPX4, and GCH1 actin control stain in direct comparison of PSPC9, PC9, cycling PSPC9, and PC9PS -> PC9cells.n= g independently cultured biological replicates, pooled, counted, and set up as technical replicates per experiment for PS for (A-E), n = 2 biological replicates, pooled and counted, each of PC9, cycling PSPC9, and PC9ps -> PC9for (A-E).
[0048] Figs. 29A-29F show LNCaP and psLNCaPpersister and ferroptosis relevant viability and protein signature. (A) 48hr CTG viability assay of LNCaP, pgLNCaPand CyC|ing psLNCaPtreated with RSL3 1 fiM, with and without Fer-1 2 fiM and ZVAD 2 / zM. Technical quadruplicate per experiment, n = 8 independently cultured biological replicates pooled, counted, and set up as technical replicates per experiment. Representative of 3 independent experiments. (B) Flow cytometry histogram of LNCaP and psLNCaPcells stained with C11 -BODIPY treated withDMSO, RSL3, and Fer-1. 1 or 10 pM RS L3 treatment for 1 hour with or without 2 pM Fer-1. Representative of 2 independent experiments, 2x104total events per condition. (C) Western blot of LNCaP and PSLNCaPfor ATF4 and GPX4, with p actin as control. Representative of 3 biologically independent experiments, n = 8 independently cultured biological replicates, pooled, counted, and set up as technical replicates per experiment for psLNCaP, n - 2 independently cultured biological replicates for LNCaP per experiment. (D) Cell count of rederived LNCaP (LNCaPps ->LNCaP) growth upon enzalutamide removal and (E) enzalutamide re-addition by trypan blue exclusion dye. For (D), enzalutamide removed day 3, cells counted day 9; for (E), 48 hrs treatment. x4 Light microscopy of plates prior to counting, n = 2 (D) and n = 3 (E) independently cultured biological replicates per experiment. Data is average of 2 independent regrowth experiments (D) or 3 independent cultured replicates per condition (E). Microscopy images from same independent experiments for (D) and (E). (F) 48hr CTG viability assay of LNCaPps->LNCaPsubject to 2 day, 20 pM enzalutamide treatment, after which media removed and cells treated with RSL3 1 AtM, with and without Fer-1 2.5 jtM. Technical quadruplicate per experiment, n = 2 independently cultured biological replicates pooled, counted, and set up as technical replicates per experiment. For (A) and (F), data are presented as % of DMSO control, mean ± s.d., * P < 0.05, “ P < 0.01 , *** P < 0.001 and **** P < .0001 by oneway ANOVA followed by Tukey's multiple comparisons test or unpaired two-tail t- test. ns = non-significant.
[0049] Figs. 30A-30C show the identification and removal of batch effect and analysis of bulk RNAseq data. (A) PC 1 vs 2 (top), PC 2 vs 3 (middle) and % variance accounted for by each PC (bottom) of Green (DS1 ) and Stockwell (DS2) lab samples prior to batch correction. (B) Intersection of significant (FDR < .01 ) DEG genes by data set (DS1 , DS2, and DS1 + DS2) and (C) clustering (same method as Figs. 24A-24B) on -1400 significant genes post batch correction. Sample statistics same as Figs. 24A-24B.
[0050] Figs. 31A-31C show global lipidomics profile of multi time point untargeted and pseudo-targeted lipidomics analysis of NSCLC, prostate carcinoma, and fibrosarcoma models persister models. Normalized peak intensity with Euclidean distance and Ward clustering, rows and column, of all detected m / z RT values for (A) PC9 vs PSPC9, (B) PC9 vs PS vs 15- and 34-dayPSLNCaP, HT1080, and PSHT108°. Statistics same as Figs. 25A-25B and Figs. 26A- 26F.
[0051] Figs. 32A-32D show short term ATF4 KD and long term ATF4 KO in PSPC9. Western blot for ATF4 with actin control in (A) PC9 vs PSPC9vs PSPC9nontargeting siRNA (NT KD) vs PSPC9ATF4 targeting siRNA (ATF4 KD) and (B) PC9 vs PSPC9vs PSPC9with sgRNA to non-existent PC9 protein green fluorescent protein as control (GFP KO) vs PSP ATF4 targeting sgRNA (ATF4 KO). 48hr CTG viability of (C) 2-day ATF4 KD and (D) 1 -month ATF4 KO, treated with RSL3 1 fiM and erlotinib 10 ftM. n = 8 independently cultured biological replicates, pooled, counted, and set up as technical replicates per experiment for all cell types for both siRNA and CRISPR / Cas9 KD and KO for both western blot and viability assay (the viability assays and western blots are performed from the same sets of samples for each independent experiment). For viability assays, technical quadruplicate. Representative of 2 independent experiments. Data are presented as % of DMSO control, mean ± s.d., * P < 0.05, “ P < 0.01 , by two-way ANOVA followed by Tukey’s multiple comparisons test.
[0052] Figs. 33A-33E show the establishment of HT1080 / PSHT1O8° mitochondrial ablation system. 48hr CTG viability assay of (A) HT1080 treated with RSL3 1 ftM with and without Fer-1 2 fiM and (B) HT1080 vs psHT108° treated with RSL3 25 nM or doxorubicin 200 nM. (C) HT1080 vs psHT108° previously treated with 12.5 juM CCCP, treated with RSL3 25 nM or doxorubicin 200 nM. Technical quadruplicate for (A-C). Representative of 2 independent experiments. Data are presented as % of DMSO control, mean ± s.d., * P < 0.05, “ P < 0.01 , *** P < 0.001 , and **** P < 0.001 by two-way ANOVA followed by Tukey’s multiple comparisons test. Western blot of HT1080 and psHT108°, with and without 12.5CCCP, for Cytochrome c (~15 kDa) (D) and Tom20 (~15 kDa) (E), with p actin as control. Representative of 2 independent experiments, n = 8 independently cultured biological replicates, pooled, counted, and set up as technical replicates per experiment for psHT108°, n = 2 independently cultured biological replicates for HT1080 per experiment. For (C-E), the viability assays and western blots are performed from the same sets of samples per experiment.
[0053] Figs. 34A-34B show the effect of reduced serum media (2.5% FBS) on HT1080 / PSHT1O8° mitochondrial ablation system. 48hr CTG viability assay of (A)HT1080 and (B) PSHT1080, treated with RSL3 25 nM or doxorubicin 150 nM, with and without 12.5 M CCCP, in 10% or 2.5% FBS containing media. Technical quadruplicate per condition. Representative of 2 independent experiments. Data are presented as % of DMSO control, mean ± s.d., * P < 0.05, ** P < 0.01 , *** P < 0.001 , and **** P < 0.001 by two-way ANOVA followed by Tukey’s multiple comparisons test.DETAILED DESCRIPTION OF THE DISCLOSURE
[0054] Phospholipids containing polyunsaturated fatty acyl tails (PL-PUFAs) are susceptible to lipid peroxidation by reactive oxygen species, lipoxygenases, and radical species. The accumulation of peroxidized lipids in cell membranes overwhelms endogenous lipid repair processes and triggers ferroptosis. The present disclsoure discovered that phospholipids with both PUFA tails (PL-PUFA2S) acted as key drivers of ferroptosis in numerous cancer cell lines, compared with phospholipids with a single PUFA tail (PL-PUFAis), which were substantially less capable of inducing ferroptosis. It was found that exogenously supplied phosphatidylcholine with two PUFA tails (PC-PUFA2) was rapidly incorporated into and remodeled membranes in cell lipids. Moreover, PC-PUFA2S were enriched upon free PUFA treatment, suggesting a key role in driving free-PUFA-initiated ferroptosis. We examined the protein-binding profile of PC-PUFA2 and found a specific interaction with the mitochondrial electron transport chain complex I. It was confirmed that PC- PUFA2S accumulate in mitochondria and induce production of mitochondrial ROS, which then spread to the endoplasmic reticulum. Depletion of mitochondria through mitophagy eliminated the enhanced potency of PC-PUFA2S over PC-PUFAis in driving ferroptosis, consistent with mitochondria being the key target of PC-PUFA2S. PC-PUFA2S are thus important lipid markers and drivers of ferroptosis and may serve as future biomarkers and therapeutic targets for modulating ferroptosis in pathological contexts.
[0055] Accordingly, one embodiment fo the present disclosure is directed to a composition for inhibiting mitochondrial complex I in a cell. The composition comprises an effective amount of a phospholipid with two polyunsaturated fatty acyl tails (PL-PUFA2).
[0056] As used herein, a “complex I”, “mitochondrial complex I”, “respiratory complex I”, “NADH:ubiquinone oxidoreductase”, or “Type I NADH dehydrogenase” refers to the first large protein complex of the respiratory chains of various organismas, e.g., from bacteria to humans. It catalyzed the transfer of electrons from NADH to coenzyme Q10 (CoQ10) and translocates protons across the inner mitochondrial membrane in eukaryotes or the plasma membrane of bacteria, which contributes to the formation of cross-membrane proton gradient that drives the ATP synthase to produce ATP.
[0057] In some embodiments, the cell is selected from a neural cell, a cancer cell, a persister state cancer cell, a pro-tumorigenic regulatory T cell (Treg), and combinations thereof.
[0058] With respect to a cancer cell, in some embodiments, the cancer is selected from the group consisting of hepatocellular carcinoma, sarcoma, glioma, fibrosarcoma, renal cell carcinoma, ovarian cancer, prostate cancer, breast cancer, pancreatic cancer, melanoma, colon cancer, diffuse large B cell lymphoma, leukemia, multiple myeloma, lung cancer, clear-cell carcinoma, and non-small cell lung carcinoma.
[0059] As used herein, a “phospholipid” is a class of lipid whose molecule has a hydrophilic “head” containing a phosphate group and two hydrophobic “tails” derived from fatty acides, joined by an alcohol residue (usually, e.g., a glycerol molecule). The phosphate group can be modified with simple organic molecules such as, e.g., choline, ethanolamine, or serine. In some embodiments, the phospholipid is selected from a phosphatidylethanolamine (PE), a phosphatidylcholine (PC), a phosphatidylserine (PS), a phosphatidylinositol (PI), a phosphatidic acid (PA), or combinations thereof.
[0060] In some embodiments, the PL-PUFA2 is a phosphatidylcholine with two polyunsaturated fatty acyl tails (PC-PUFA2). For example, in some embodiments, the PC-PUFA2 is PC(22:6; 22:6), which is a phosphatidylcholine containing two docosahexaenoic acid (DHA) tails.
[0061] Another embodiment of the present disclosure is a method for inhibiting mitochondrial complex I in a cell. This method comprises contacting the cell with an effective amount of the composition disclosed herein.
[0062] Another embodiment of the present disclosure is a method for treating or ameliorating the effects of a disease in a subject in need thereof. This method comprises administering to the subject an effective amount of the composition disclosed herein.
[0063] In some embodiments, the disease is a glutathione peroxidase 4 (GPX4)-associated disease. In some embodiments, the disease is selected from the group consisting of a cancer, a neurotic disorder, a neurodegenerative disorder, spondylometaphyseal dysplasia, mixed cerebral palsy, pontocerebellar hypoplasia, and male infertility. In some embodiments, the disease is a cancer. Non-limiting examples of cancers in the context of the present disclosure include hepatocellular carcinoma, sarcoma, glioma, fibrosarcoma, renal cell carcinoma, ovarian cancer, prostate cancer, breast cancer, pancreatic cancer, melanoma, colon cancer, diffuse large B cell lymphoma, leukemia, multiple myeloma, lung cancer, clear-cell carcinoma, and non-small cell lung carcinoma.
[0064] In some embodiments, the cancer is hypersensitive to ferroptosis. In some embodiments, the cancer is refractory to standard cancer treatment. Nonlimiting examples of a standard cancer treatment include chemotherapy, radiation therapy, targeted therapy, immunotherapy, and combinations thereof.
[0065] In some embodiments, the neurodegenerative disorder is associated with retromer complex dysfunction, altered p-amyloid metabolism, tau hyperphosphorylation, or combinations thereof. Non-limiting examples of neurodegenerative disorders in the context of the present disclosure include Alzheimer’s Disease, Parkinson’s Disease, Frontotemporal Lobar Degeneration, Down’s Syndrome, Hereditary Spastic Paraplegia, Neuronal Ceroid Lipofuscinoses, Amyotrophic lateral sclerosis, Friedreich’s ataxia, Multiple sclerosis, Huntington’s Disease, Transmissible spongiform encephalopathy, Charcot-Marie-Tooth disease, Dementia with Lewy bodies, Corticobasal degeneration, and Progressive supranuclear palsy.
[0066] In some embodiments, the disease is a minimal residual disease (MRD). As used herein, a “minimal residual disease” or “MRD”, also called measurable residual disease, is a term given to small numbers of cancer cells that remain in a person either during or after treatment when the patient is in remission(no symptoms or signs of disease). An MRD positive test result means that disease was still detected after treatment.
[0067] In some embodiments, the subject has persister state cancer cells. As used herein, “persister state cancer cells” or “persister cells” refer to a subpopulation of cancer cells present in tumors that strongly correlate to the development of acquired resistance to cancer therapy and cause relapse.
[0068] In some embodiments, the subject has pro-tumorigenic regulatory T cells (Tregs) in the tumor microenvironment (TME). As used herein, “turner microenvironment” or “TME” is a complex ecosystem surrounding a tumor, composed of cancer cells, stromal tissue (including blood vessels, immune cells, fibroblasts and signaling molecules) and the extracellular matrix. Mutual interaction between cancer cells and the different components of the tumor microenvironment support its growth and invasion in healthy tissues which correlates with tumor resistance to current treatments and poor prognosis.
[0069] In some embodiments, the method disclose herein further comprises administering to the subject an effective amount of a second agent that induces ferroptosis. Non-limiting examples of an agent that induces ferroptosis include erastin, imidazole ketone erastin (IKE), piperazine erastin (PE), sulfasalazine, sorafenib, RSL3, ferroptosis inducer 56 (FIN56), caspase-independent lethal 56 (CIL56), deplete GPX4 protein, mevalonate-derived coenzyme Q10, ferroptosis inducer endoperoxide (FINO2), and combinations thereof.
[0070] Still another embodiment of the present disclosure is a method for inducing ferroptosis in a cell. The method comprises contacting the cell with an effective amount of a phospholipid with two polyunsaturated fatty acyl tails (PL- PIIFA2).
[0071] In some embodiments, the cell is a persister state cancer cell. In some embodiments, the cell is a pro-tumorigenic regulatory T cell (Treg).
[0072] In some embodiments, the PL-PUFA2 is PC(22:6; 22:6), which is a phosphatidylcholine containing two docosahexaenoic acid (DHA) tails.
[0073] In some embodiments, the method disclosed herein further comprises contacting the cell with an effective amount of a second agent that induces ferroptosis. In some embodiments, the second agent is selected from the groupconsisting of erastin, imidazole ketone erastin (IKE), piperazine erastin (PE), sulfasalazine, sorafenib, RSL3, ferroptosis inducer 56 (FIN56), caspase-independent lethal 56 (CIL56), deplete GPX4 protein, mevalonate-derived coenzyme Q10, ferroptosis inducer endoperoxide (FINO2), and combinations thereof.
[0074] The compositions disclosed in the present disclosure includes pharmaceutical compositions, comprising one or more phospholipids with both PLIFA tails (PL-PUFA2S) disclosed herein and a pharmaceutically acceptable carrier, adjuvant or vehicle. In some embodiments, the PL-PUFA2 is a phosphatidylcholine with two polyunsaturated fatty acyl tails (PC-PUFA2). In some embodiments, the PC- PIIFA2 is PC(22:6; 22:6), which is a phosphatidylcholine containing two docosahexaenoic acid (DHA) tails.
[0075] A further embodiment of the present disclosure is directed to a method for treating or ameliorating the effects of a disease in a subject in need thereof. This method comprises: (a) obtaining a biological sample from the subject; (b) measuring the level of a phospholipid with two polyunsaturated fatty acyl tails (PL-PUFA2) in the sample and comparing it to a predetermined reference; (c) identifying the subject as sensitive to an agent that induces ferroptosis, if the level of the PL-PUFA2 measured in step (b) is higher than the predetermined reference; and (d) administering to the sensitive subject an effective amount of the agent.
[0076] In some embodiments, the disease is a glutathione peroxidase 4 (GPX4)-associated disease. GPX4 is a selenoprotein that helps eliminate PL-PUFA peroxides in cells. When GPX4 activity is compromised, lipid peroxidation can cause ferroptosis.
[0077] As used herein, “ferroptosis” means regulated cell death that is irondependent. Ferroptosis is characterized by the overwhelming, iron-dependent accumulation of lethal lipid reactive oxygen species. Ferroptosis is distinct from apoptosis, necrosis, and autophagy. In the context of this disclosure, a therapy based on other non-ferroptosis cell death such as apoptosis can be co-administered to the subject.
[0078] In some embodiments, the disease is selected from the group consisting of a cancer, a neurotic disorder, a neurodegenerative disorder,spondylometaphyseal dysplasia, mixed cerebral palsy, pontocerebellar hypoplasia, and male infertility.
[0079] In some embodiments, the disease is a cancer. In some embodiments, the cancer is selected from the group consisting of hepatocellular carcinoma, sarcoma, glioma, renal cell carcinoma, ovarian cancer, prostate cancer, breast cancer, pancreatic cancer, melanoma, colon cancer, diffuse large B cell lymphoma, leukemia, lung cancer, clear-cell carcinoma, and non-small cell lung carcinoma.
[0080] In some embodiments, the cancer is hypersensitive to ferroptosis. In some embodiments, the cancer is refractory to standard cancer treatment. Nonlimiting examples of a standard cancer treatment include chemotherapy, radiation therapy, targeted therapy, immunotherapy, and combinations thereof.
[0081] As defined above, in the context of the present disclosure, a “subject” is a mammal, preferably, a human. In addition to humans, categories of mammals within the scope of the present disclosure include, for example, agricultural animals, veterinary animals, laboratory animals, etc. Some examples of agricultural animals include cows, pigs, horses, goats, etc. Some examples of veterinary animals include dogs, cats, etc. Some examples of laboratory animals include primates, rats, mice, rabbits, guinea pigs, etc. In some embodiments of the present disclosure, the phrase “a subject” means a subject having a disease such as a cancer.
[0082] As used herein, a "biological sample" means a biological specimen, which may be a bodily fluid or a tissue. Biological samples include, for example, whole blood, serum, plasma, cerebro-spinal fluid, leukocytes or leukocyte subtype cells (e.g. neutrophils, basophils, and eosinophils, lymphocytes, monocytes, macrophages), fibroblast sample, olfactory neuron sample, and tissues from the central nervous system, such as the cortex (e.g., dorsolateral PFC) and hippocampus, and cells previously exposed to the CNS environment, such as dendritic cells trafficked from the brain, or other immune or other cell types. Examples of preferred biological samples include, e.g., a blood sample, a biopsy sample, a plasma sample, a saliva sample, a tissue sample, a serum sample, a tear sample, a sweat sample, a skin sample, a cell sample, a hair sample, an excretion sample, a waste sample, a bodily fluid sample, a nail sample, a cheek swab, a cheek cell sample, or a mucous sample. In the context of this disclosure, the biologicalsample can be a tissue section, a biopsy sample, a blood sample, or other appropriate bodily fluid. In some embodiments, the biological sample is a biopsy sample. In some embodiments, the biological sample is a blood smaple that contains circulating cancer cells.
[0083] In some embodiments, the phospholipid is selected from a phosphatidylethanolamine (PE), a phosphatidylcholine (PC), a phosphatidylserine (PS), a phosphatidylinositol (PI), a phosphatidic acid (PA), or combinations thereof. In some embodiments, the PL-PUFA2 is a phosphatidylcholine with two polyunsaturated fatty acyl tails (PC-PUFA2).
[0084] The level of the PL-PUFA2 can be determined by any appropriate methods that are available or feasible in the art. For example, in some embodiments, the level of the PL-PUFA2 is measured by mass spectrum. In some embodiments, the level of the PL-PUFA2 is measured by antibodies or other binding agents, using ELISA.
[0085] In some embodiments, the agent that induces ferroptosis is selected from the group consisting of erastin, imidazole ketone erastin (IKE), piperazine erastin (PE), sulfasalazine, sorafenib, RSL3, ferroptosis inducer 56 (FIN56), caspase-independent lethal 56 (CIL56), deplete GPX4 protein, mevalonate-derived coenzyme Q10, ferroptosis inducer endoperoxide (FINO2), and combinations thereof.
[0086] Yet another embodiment of the present disclosure is a method for treating or ameliorating the effects of a cancer in a subject in need thereof. This method comprises: (a) obtaining a biological sample from the subject; (b) measuring the level of a phosphatidylcholine with two polyunsaturated fatty acyl tails (PC- PIIFA2) in the sample and comparing it to a predetermined reference; (c) identifying the subject as sensitive to an agent that induces ferroptosis, if the level of the PC- PIIFA2 measured in step (b) is higher than the predetermined reference; and (d) administering to the sensitive subject an effective amount of the agent.
[0087] As used herein, the terms "treat," "treating," "treatment" and grammatical variations thereof mean subjecting an individual subject to a protocol, regimen, process or remedy, in which it is desired to obtain a physiologic response or outcome in that subject, e.g., a patient. In particular, the methods and compositions of the present disclosure may be used to slow the development ofdisease symptoms or delay the onset of the disease or condition, or halt the progression of disease development. However, because not every treated subject may respond to a particular treatment protocol, regimen, process or remedy, treating does not require that the desired physiologic response or outcome be achieved in each and every subject or subject population, e.g., patient population. Accordingly, a given subject or subject population, e.g., patient population, may fail to respond or respond inadequately to treatment.
[0088] As used herein, the terms “ameliorate”, "ameliorating" and grammatical variations thereof mean to decrease the severity of the symptoms of a disease in a subject.
[0089] In the present disclosure, an "effective amount" of a therapeutic is an amount of such therapeutic that is sufficient to effect beneficial or desired results as described herein when administered to a subject. Effective dosage forms, modes of administration, and dosage amounts may be determined empirically, and making such determinations is within the skill of the art. It is understood by those skilled in the art that the dosage amount will vary with the route of administration, the rate of excretion, the duration of the treatment, the identity of any other drugs being administered, the age, size, and species of the subject, and like factors well known in the arts of, e.g., medicine and veterinary medicine. In general, a suitable dose of a therapeutic according to the disclosure will be that amount of the agent, which is the lowest dose effective to produce the desired effect with no or minimal side effects. The effective dose of a therapeutic according to the present disclosure may be administered as a single dose, or two, three, four, five, six or more sub-doses, administered separately at appropriate intervals throughout the treatment course (e.g., not necessarily on the same day).
[0090] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. As used in the specification and the appended claims, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise.
[0091] The present disclosure also provides a dietary supplement for a subject having a cancer. The dietary supplement comprises an effective amount of a composition disclosed herein, such as, e.g., a phospholipid with two polyunsaturatedfatty acyl tails (PL-PUFA2). In some embodiments, the dietary supplement comprises an effective amount of PL-PUFA2 that is PC(22:6; 22:6), which is a phosphatidylcholine containing two docosahexaenoic acid (DHA) tails.
[0092] The following examples are provided to further illustrate the methods of the present disclosure. These examples are illustrative only and are not intended to limit the scope of the disclosure in any way.EXAMPLESExample 1Phospholipids with two polyunsaturated fatty acyl tails promote ferroptosis STAR MethodsData and code availability
[0093] Proteomics data are available via ProteomeXchange with identifier PXD041993. Lipidomics data including raw mass spectrometry data files, processed data, and annotated lipid features are available in the public repository, MetaboLights, under accession number MTBLS7772. All other data generated or analyzed during this study are included in this article (and its supplementary information files).Experimental modelCell lines
[0094] All mammalian cells were cultured following ATCC recommended protocols and in medium supplemented with 10% fetal bovine serum (FBS, Thermo Fisher Scientific 26400044) and 1 % Penicillin-Streptomycin (Thermo Fisher Scientific 15140122). IGROV-1 , CAL-85-1 , MCF-7, CAL-120, CAL-51 , A549, C-33A, and Huh7 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with high glucose (Corning-FISHER 10-013). HT-1080 cells were maintained in DMEM supplemented with additional 1 % non-essential amino acids (Thermo Fisher Scientific 1140076). SU-DHL-5, SU-DHL-6, AU565, HCC2218, 786-0, LS513, NCI- H358, NCI-H2087, NCI-H1299 cells were cultured in RPMI-1640 medium (Cytiva SH30096). Calu-1 , SK-BR-3, HCT116 cells were cultured in McCoy's 5A medium (Thermo Fisher Scientific 16600108). 143B cells were cultured in Eagle’s minimumessential medium (VWR 10128). Mycoplasma tests were routinely performed to ensure cell culture quality and cells were passaged no more than 20 passages. Mcherry-Parkin overexpressing HT-1080 cells were prepared following the previous protocol and cultured in normal medium supplemented with 400 pg / mL zeocin (Gaschler et al. 2018). Mitophagy was induced by treatment of 12.5 pM CCCP for 48 hr before switching to original media for cell assays. Cas9 overexpressing HT-1080 cells were prepared following the previous protocol and cultured in normal medium supplemented with 1 pg / mL puromycin (Kraft et al. 2020).Human subject
[0095] Analysis on human brain samples were performed under theInstitutional Review Board of Columbia University (AAAQ8027, approved 04 / 07 / 2016). The caudate nucleus region of the brain autopsy samples from Huntington’s disease and control patients were collected. All control patients were age-matched with HD patients obtained from the same tissue bank.Method detailsAntibodies and chemicals
[0096] (1S,3R)-RSL3, IKE, FINO2 were synthesized as previously described(Gaschler et al. 2018; Yang et al. 2014; Zhang et al. 2019). All commercially available phospholipids were purchased from Avanti Polar Lipids. Biotinylated phospholipids were synthesized by Avanti Polar Lipids and deuterated phospholipids were synthesized by Cayman Chemical. Fatty acids including arachidonic acid, docosahexaenoic acid, and oleic acid were purchased from Cayman Chemical. Other chemicals were purchased from certified vendors: ferrostatin-1 (Sigma-Aldrich SML0583), deferoxamine mesylate (Sigma-Aldrich D9533), Z-VAD-FMK (Selleck Chemicals S7023), necrostatin-1s (Cell Signaling Technology 17802S), bafilomycin A1 (Cayman Chemical 11038), FIN56 (Selleckchem S8254), ONO-RS-082 (Cayman Chemical 20243), CCCP (Cayman Chemical 25458), brefeldin A (Cayman Chemical 11861), thapsigargin (Cayman Chemical 10522), mitoquinone mesylate (Cayman Chemical 29317), decylubiquinone (Cayman Chemical 21027), DIDS sodium salt (Cayman Chemical 16125), rotenone (EMD Millipore 557368), antimycin A (Sigma- Aldrich A8674), zeocin (Thermo Fisher Scientific R25001 ), puromycin (Santa Cruz Biotechnology SC-108071A), biotin-PEG-SH (Polypure 41156-1095), 2-Hydroxypropyl-p-cyclodextrin (Cayman Chemical 16169), 4-chlorobenzoic acid (Sigma-Aldrich 135585). The following antibodies were used: anti-GPX4 (ab125066), anti-ACSL4 (clone F-4, Santa Cruz Biotechnology sc-365230), anti-phospho-MLKL Ser345 (clone D6E3G, Cell Signaling Technology 37333S), anti-Caspase-3 (Cell Signaling Technology 9662S), anti-cleaved Caspase-3 Asp175 (Cell Signaling Technology 9661S), anti-XBP1s (clone 143F, BioLegend 647501), anti-GADD (clone B-3, Santa Cruz Biotechnology sc-7351), anti-GAPDH (Abeam ab9485), anti-pan- Actin (clone D18C11 , Cell Signaling Technology 8456S), anti-alpha-Tubulin (clone DM1 A, Santa Cruz Biotechnology sc-32293), anti-Calnexin (Abeam ab22595), anti- COX IV (Abeam ab33985), anti-Giantin (clone 9B6, Abeam ab37266), anti-LAMP1 (clone D2D11 , Cell Signaling Technology 9091 T), anti-TfR1 (clone 3F3-FMA) (Feng et al. 2020), anti-ETC complex sampler (anti-NDUFS1 , anti-NDUFAB1 , anti- UQCRFS1 , anti-COX IV, Cell Signaling Technology 42642), anti-mouse IgG (H+L) Alexa Fluor 488 (Thermo Fisher Scientific A32723), anti-mouse IgG (H+L) Alexa Fluor 594 (Thermo Fisher Scientific A-11032), anti-rabbit IgG (H+L) Alexa Fluor 405 (Thermo Fisher Scientific A48254), anti-mouse IgG (H+L) IRDye 800CW (Biosciences 926-32210), anti-rabbit IgG (H+L) IRDye 680RD (Biosciences 926- 68071).Cell viability assay and phospholipid treatment
[0097] Cells were seeded in 384-well format culture plate (Thermo Fisher Scientific 164610) at 400 cells per well for adherent cells and 5,000 cells per well for suspension cells and incubated overnight. Before treatment, phospholipid stock solution in chloroform was dried under nitrogen flow, re-dissolved in vehicle containing 20% ethanol and 16% 2-Hydroxypropyl-P-cyclodextrin in phosphate buffered saline (PBS), and sonicated to get a clear solution. Phospholipids were further diluted in media to reach desired concentration and added to cell plates. The final vehicle concentration in cells was less than 0.02%. Cells were treated with phospholipids for 24 hr and cell viability was measured by CellTiter-Glo (Promega G7573) using a luminescent plate reader according to the manufacturer’s instructions. CoQw-depleted media was prepared by filtering FBS through 15 kD protein filters before adding to culture media along with additional 1 mM 4- chlorobenzoic acid. Cells were cultured in CoQw-depleted media for 48 hr and then treated with phospholipids and 10 pg / mL human holo-Transferrin (Sigma-AldrichT0665). For cystine depletion, cells were cultured in DMEM without methionine and cystine (Thermo Fisher Scientific 21013024). Glutamate (Thermo Fisher Scientific 35050061 ), sodium pyruvate (Cytiva SH30239.01 ), and methionine (Sigma-Aldrich M9625) were added back to DMEM and cystine (Sigma-Aldrich C8755) was titrated in culture plates. Cell viability was measured after cystine depletion for 24 hr.Cytosolic and mitochondrial ROS measurement
[0098] For lipid ROS determination, cells were seeded in 10 cm dishes at 2 million cells per plate and incubated overnight. Cells were treated with 100 pM phospholipids for 4 hr and washed once with HBSS (Thermo Fisher Scientific 14025092). Cells were then incubated with HBSS containing 2 pM C1 1- BODIPY581 / 591(Invitrogen D-3861) at 37 °C for 30 min in dark. Cells were trypsonized (Invitrogen 25200-114), washed once with HBSS, and resuspended in fresh HBSS for flow cytometry analysis. For mitochondrial superoxide detection using flow cytometry, cells were incubating with 5 pM MitoSOX red (Thermo Fisher Scientific M36008) at 37 °C for 30 min in dark. Samples were detected with excitation at 488 nm and emission at FITC channel with 525 / 40 nm bandpass filter for oxidized C11- BODIPY and PE channel with 585 / 42 nm bandpass filter for MitoSOX red and reduced C11 -BODIPY. 10,000 events after gating were collected for each sample. Flow cytometry data were processed in FlowJo (version 10.8). Cells were gated for live cells in SSC-A vs FSC-A plot and for singlet cells in FSC-H vs FSC-A plot. The FITC-A and PE-A histogram of singlet cells were plotted, and the mean intensity of each peak was quantified.Transfection
[0099] Cells were transfected with Lipofectamine RNAiMAX Transfection Reagent (Thermo Fisher Scientific 13778075) by reverse transfection according to the manufacturer’s protocol. In brief, 20 pmol of siRNA SMARTpool (Dharmacon) and 2.5 pL Lipofectamine RNAiMAX was mixed in 500 pL Opti-MEM reduced serum medium (Life Technologies 31985) at room temperature for 30 min. Then 0.5 million cells in 1.5 mL media were mixed with transfection reagent and added to each well in 6-well plate. After 48 hr, cells were harvested for cell assay. For CRISPR knockdown, cas9-overexpressing HT-1080 cells were transfected with sgRNA targeting ACSL4 or non-targeted sgRNA using Lipofectamine for 48 hr.Protein quantification
[0100] Protein amount in cell lysate was quantified using Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific 23225) following the manufacturer’s protocol. In brief, the standard curve was generated by serial dilutions of BSA standards. Both standards and samples were added in 96-well format clear assay plate (Greiner Bio-One 655101) in duplicates and incubated with the colorimetric working solution at 37 °C for 30 min at dark. The plate was measured using the plate reader and detected by absorbance at 562 nm. The concentration of sample is interpolated from the standard curve.Targeted lipidomicsSample preparation
[0101] Cells were seeded in 10 cm dishes at 2 million cells per plate overnight. Culture media was swapped with fresh media containing 25 pM deuterated, non-deuterated phospholipids, PUFAs or vehicle and cells were incubated for 6 hr. Cells were harvested for lipid extraction. For basal lipid measurement, 5 million cells were collected for each triplicate of each cell line and lipids were extracted from all cell pellet at the same time. Protein concentration was measure for each cell line and used to normalize lipid signal. For mitochondrial lipid measurement, mitochondria were isolated using the Mitochondria Isolation Kit (Thermo Fisher Scientific 89874) following manufacturer’s instructions. 20 million cells were collected for mitochondrial isolation for each triplicate. Oleic acid-d17 was added to both mitochondrial fraction and the rest cell fraction as internal standard to normalize extraction efficiency. Lipids were extracted as previously described (Kraft et al. 2020; von Krusenstiern et al. 2023). In brief, cells were homogenized in methanol, and cell lysates were transferred into glass vials containing methyl tertbutyl ether. Mixture was vortexed and incubated in ice for 2 hr for lipid extraction, followed by phase separation by adding water. Top organic layer was dried and redissolved in isopropanol: acetonitrile: water 4:3:1 for LC-MS sample loading. The aqueous layer was dried and redissolved in RIPA buffer for protein concentration measurement. Lipid extraction from brain tissue followed the same method as cell extraction with additional step of tissue homogenization.Data analysis
[0102] Lipids were analyzed using LC-MS as previously described (Kraft et al. 2020; von Krusenstiern et al. 2023). All raw files acquired via MassLynx software (version 4.1 , waters) were imported to Progenesis QI software (Waters, Non-linear Dynamics) and aligned against the QC reference, followed by peak extraction and retention time alignment. Identification of detected lipid features was initially obtained by searching monoisotopic masses against the available online databases such as METLIN, LipidMAPS, and HMDB with a mass tolerance of 5 ppm. Moreover, isotopic patterns and retention time of each lipid precursor ion were assessed. Structural elucidation of lipids was confirmed by inspecting the diagnostic fragment ions and corresponding acyl chain fragment information obtained by UPLC-HDMSE. The extracted lipid features were normalized by total protein concentrations, median normalization, and log-transformed within each sample before statistical analysis.
[0103] For public lipidomics dataset (Metabolomics Benchwork ST001637), all annotated diacyl-PUFA phospholipids, mono-acyl-PUFA phospholipids, and lysophospholipids with structural elucidation of acyl tails were selected and analyzed in MetaboAnalyst (version 5.0).Quantitative proteomics
[0104] Affinity pull-down assay was conducted using the Pierce MS- Compatible Magnetic IP Kits (Thermo Fisher Scientific 90408), following manufacturer’s instructions. In brief, HT-1080 cells were seeded in 15 cm round culture plates and cultured until confluent. Cells were washed once with cold PBS and scraped off the plate using 2 mL IP-MS Cell Lysis Buffer containing protease inhibitor cocktail (ApexBio K1007). Cells were incubated on ice for 10 min and spun at 17,000 xg for 15 min at 4 °C. Supernatant containing soluble proteins was collected and quantified for protein amount. Meanwhile, 0.5 mg biotinylated phospholipid in chloroform was dried under nitrogen stream and redissolved in 20 pL MeOH and 480 pL PBS. In each reaction sample, 500 ug protein was mixed with 10 ug lipid or an equal amount of vehicle or biotin-PEG-SH in 500 pL Cell Lysis Buffer. Mixture was incubated overnight at 4 °C. 0.25 mg of Pierce Streptavidin Magnetic Beads was washed and added to each reaction tube and mixed at 4 °C for 2 hr. Magnetic beads were collected on a magnetic stand and washed three times with wash buffer A and B. Protein was eluted from beads and analyzed by proteomics as previously described (Feng et al. 2020).Proteomics data processing
[0105] Statistical analysis was performed in MetaboAnalyst (version 5.0) including heatmaps, principal component analysis, and volcano plot. Log2 transformed abundance for each protein were used for heat map generation. Clustering method was set using the “Ward” method with distance measurement using “Euclidean distance” setting. Group differences were calculated using one-way ANOVA (Fisher’s LSD, p< 0.05) and a false discovery rate of 5% to control for multiple comparisons. GSEA was performed using DAVID (version 6.8) and clusterprofiler (version 4.6.2) on the output of the global proteomics data (Huang et al. 2009; Sherman et al. 2022; Wu et al. 2021 ; Yu et al. 2012). Briefly, gene IDs from each protein were converted to Entrez IDs and ranked by incorporating p-value and fold change using formula: -logio(p.value)*log2(FC). GSEA was performed on the ranked list utilizing KEGG database in FGSEA method (Kanehisa and Goto, 2000; Korotkevich et al. 2021). Bar and cnet plots were generated using enrichplot package in R Studio (version 1.4).Western blot
[0106] Approximately 3 million cells were collected and washed twice with PBS. Cell pellet was lysed in 40 pL RIPA buffer (Thermo Fisher Scientific 89901) containing protease inhibitor cocktail (Sigma-Aldrich 11697498001) and incubated on ice for 10 min. Lysate was centrifuged at 17,000 xg for 15 min 4 °C. The supernatant was collected, quantified, and diluted with 3x blue loading buffer containing 125 pM DTT (Cell Signaling Technology 7722S) and incubated at 80 °C for 10 min. An equal amount of protein in the range of 25-40 pg was loaded in each lane of the NuPAGE 4-12% Bis-tris gel (Fisher Scientific WG1401) and transferred onto nitrocellulose membranes (Thermo Fisher Scientific IB23002) using electrophoretic semi-dry western blot transfer system. Membranes were blocked with TBS blocking buffer (Thermo Fisher Scientific 37535) for 1 hr at room temperature and incubated with primary antibody diluted in TBS-T (TBS with 0.1 % Tween20): blocking buffer 1 :1 overnight at 4 °C. Membranes were washed three times in TBS-T and then incubated with secondary antibodies diluted at 1 :10,000 in 1 :1 TBS-T: blocking buffer for 1 hr at room temperature. Membrane was washed three times in TBS-T and imaged on LI-COR Odyssey infrared imaging system. Images were collected and optimized contrast settings using the Image Studio software. Foraffinity pull-down assay followed by western blot, 1 mg protein was mixed with 1 mg lipid or an equal amount of vehicle or biotin-PEG-SH in 1 mL Cell Lysis Buffer. After pull-down, proteins were eluted from beads in SDS buffer with DTT and all elution samples were loaded in NuPAGE gel.Quantitative PCR
[0107] RNA from cells was isolated using RNeasy Mini Kit (Qiagen 74136) according to the manufacturer's instructions. Extracted RNA was reverse transcribed to cDNA and qPCR reactions were performed using Power SYBR Green PGR Master Mix (Thermo Fisher Scientific 4368577) and analyzed on the ViiA 7 Real- Time PCR System (Thermo Fisher Scientific) according to the manufacturer's instructions. TBP transcript was used as the housekeeping gene for the normalization of other target genes. Following forward and reverse qPCR primers were used (TBP: F 5’- GCGGTTTGCTGCGGTAATC -3’ (SEQ ID NO: 1) and R 5’-CTTCACTCTTGGCTCCTGTGC -3’ (SEQ ID NO: 2); XBP1s: F 5’-GCGGTTTGCTGCGGTAATC -3’ (SEQ ID NO: 1) and R 5’-CTTCACTCTTGGCTCCTGTGC -3’ (SEQ ID NO: 2); GADD: F 5’-GAATCTGCACCAAGCATGAAC -3’ (SEQ ID NO: 3) and R 5’-CACTAGTGAGAGGGTAGTCAGT -3’ (SEQ ID NO: 4); ACSL4: F 5’-GTAATTGTTGACCTCCTGCTTTG -3’ (SEQ ID NO: 5) and R 5’-TTCCCTGGCACCATCATTC -3’ (SEQ ID NO: 6); MT-ND1 : F 5’-CCACATCTACCATCACCCTC -3’ (SEQ ID NO: 7) and R 5’-TTCATAGTAGAAGAGCGATGGT -3’ (SEQ ID NO: 8); MT-ND2: F 5’-GACATCCGGCCTGCTTCTT -3’ (SEQ ID NO: 9) and R 5’-TACGTTTAGTGAGGGAGAGATTTGG -3’ (SEQ ID NO: 10); MT-ND5: F 5’-TTCAAACTAGACTACTTCTCCATAATA -3’ (SEQ ID NO: 11) and R 5’-TTGGGTCTGAGTTTATATATCACAGTGA -3’ (SEQ ID NO: 12); ATF4 predesigned primers ordered from IDT PrimeTime qPCR Primers Hs.PT.56a.744435.g).Immunofluorescence
[0108] Cells were seeded on 8-well chambered slides (Celltreat 229168) at 0.05 million cells per well and cultured overnight. Cells were treated with 50 pM biotinylated phospholipids for 6 hr. Cells were fixed and blocked as previously described (von Krusenstiern et al. 2023; Feng et al. 2020). Cells were co-stained with cy5 conjugated streptavidin (ApexBio K1080), anti-Calnexin antibody, anti-COXIV antibody, anti-Giantin antibody, and anti-LAMP1 antibody at 1 :250 dilution overnight at 4 °C and then stained with secondary antibodies at 1 :500 dilution at room temperature for 1 hour. Slides were finished by adding VECTASHIELD mounting medium (Vector Laboratories H-1900) and covered with clean cover glass. For immunofluorescent imaging of TfR1 , cells were treated with 100 pM phospholipids for 4 hr and then fixed and stained with anti-TfR1 antibody at 1 :250 dilution overnight.Live-cell imaging
[0109] Cells were seeded in 8-chamber coverglass (Thermo Fisher Scientific 155411 PK) at 0.05 million cells per well and cultured overnight. For measuring lipid ROS, cells were treated with serum-free culture medium containing 5 pM Liperfluo (Dojindo L248-10) for 30 min before treatment with 100 pM phospholipids for 4 hr. Cells were washed once with HBSS containing calcium and magnesium and then treated with HBSS containing 50 nM MitoTracker deep red (Invitrogen M22426) and 1 pM ER-Tracker blue-white (Invitrogen E12353) for 30 min at 37 °C. Cells were washed once with HBSS and imaged using confocal microscope. For measuring mitochondrial membrane potential, cells were treated with 100 pM phospholipids for 4 hr and stained with HBSS containing 250 nM rhodamine123 (Sigma-Aldrich 83702), 50 nM MitoTracker deep red, and NucBlue (Thermo Fisher Scientific R37605) for 30 min at 37 °C. For measuring mitochondrial superoxide, cells were stained with HBSS containing 5 pM MitoSOX green (Thermo Fisher Scientific M36006), 200 nM MitoTracker deep red, and NucBlue for 30 min at 37 °C. For measuring mitochondrial lipid ROS, cells were stained with HBSS containing 200 nM mitoCLox (Lumiprobe 3549), 50 nM MitoTracker deep red, and NucBlue for 30 min at 37 °C.Image collection and processing
[0110] All slides were imaged by Zeiss LSM800 confocal microscope with 63x71.40 Oil DIC objective. All imaging parameters including laser power, scanning speed, and scanning area remained constant for each experiment. Images were captured randomly across each well to ensure unbiased data collection. Quantification of the fluorescence intensity was performed using Cell Profiler-4.0.7 (CellProfiler Image Analysis Software, RRID:SCR_007358). The mean fluorescent intensity in each channel image was measured and exported. The colocalization ofchannels was performed using the implemented MeasureColocalization tool in CellProfiler. Two selected channels were corrected using ImageThreshold tool to reduce the background and analyzed using colocalization metrics for pixels above a certain threshold which was set as 20% of the maximum intensity of the image. Pearson’s coefficient was used to represent the correlation of pixel intensity between the two channels. For cell identification, the implemented object identification tool was used to first identify nucleus in the DAPI channel and then identify cell region by propagation around the nucleus. Membrane was defined as the outer 5-pixel region of the cell boarder as previously described (Feng et al. 2020).Oxygen consumption rate (OCR)
[0111] OCR was measured using Oxygen Consumption Rate Assay Kit (Cayman Chemical Company
[0112] 600800) following manufacturer’s instructions. IGROV-1 cells were seeded in 96-well black clear bottom plate at 0.5 million cells per well and pretreated with 100 pM phospholipids or 1 pM RSL3 in culture media for 2 hr. Media wad switched to HBSS containing each treatment and phosphorescent oxygen probe. Plate was immediately scanned using Tecan plate reader standard fluorescent measurement in kinetic mode for 4 hr.Statistical analysis
[0113] Statistical analysis including unpaired t-test and ANOVA was performed using GraphPad Prism 9 in most figures unless otherwise stated in the figure legend. All data shown are representative data of at least two independent experiments with similar outcomes. Data are plotted as mean ± SD.ResultsPC-PUFA2 induces ferroptosis
[0114] To investigate the mechanism of phospholipid-regulated ferroptosis, we supplemented multiple cancer cell lines in culture with different phospholipid species and measured the impact of each on cell viability. We observed a differential reduction in cell viability caused by phospholipid species that differ in head groups and fatty acyl tails (Figs. 1A and 7A). Phosphatidylcholines had the highest potency and specificity for inducing ferroptosis compared to PEs, PGs, and PSs, indicated bya complete rescue in the presence of the ferroptosis inhibitor, ferrostatin-1 . In comparison with PCs containing one PLIFA tail (PC-PUFAis), PCs with two PLIFA tails (PC-PUFA2S) exhibited much higher potency for ferroptosis that could not be simply explained by the presence of two equivalents of PUFA (Fig. 1C). Among the numerous cancer cell lines tested, the ovarian cancer cell line IGROV-1 , the nonsmall cell lung cancer cell line Calu-1 , and the fibrosarcoma cell line HT-1080 were particularly sensitive to PC-PUFA2S treatment and were selected for additional experiments.
[0115] To investigate whether other forms of cell death were involved in the lethal effects of phospholipids, we co-treated cells with PC-PUFA2S and different cell death inhibitors, including the apoptosis inhibitor Z-VAD-FMK, the necroptosis inhibitor necrostatin-1s, the autophagy inhibitor bafilomycin A1 , and the ferroptosis inhibitors ferrostatin-1 and deferoxamine; only the ferroptosis inhibitors prevented PC-PUFA2-induced cell death (Figs. 1 B and 7B). In addition, PC-PUFA2 treatment did not initiate caspase-3 cleavage or mixed lineage kinase domain-like protein (MLKL) phosphorylation, which are signatures of apoptosis and necroptosis, respectively (Fig. 7E). In contrast, IGROV-1 cells treated with PC-PUFA2S displayed a significant increase of the ferroptosis marker, transferrin receptor-1 translocation to the plasma membrane, which was reversible upon ferrostatin-1 co-treatment (Figs. 1D and 7C) (Feng et al. 2020). PC-PUFA2 treatment also increased lipid peroxide accumulation in cells, measured by the fluorescent probe C11-BODIPY, that exhibited a shifted emission spectrum upon oxidation by lipid peroxides (Figs. 1E and 7D). The lipid peroxidation induced by PC-PUFA2S was inhibited by co-treatment with ferrostatin-1. Moreover, co-treatment of PC-PUFA2S synergized with all ferroptosis inducers tested, including RSL3, IKE, FIN56, cysteine deprivation, and C0Q10 deprivation, except for FINO2 which may oxidize extracellular PC-PUFA2 before cellular uptake (Figs. 1F and 7F) (Gaschler et al. 2018). Together, these data support the notion that PL-PUFA2S, specifically PC-PUFA2S, act as potent ferroptosis-inducing phospholipids.
[0116] To further understand the physiological role of PC-PUFA2 in ferroptosis, we investigated the basal level of PC-PUFA2 in ferroptosis-sensitive and ferroptosis-resistant cancer cell lines. We collected 20 different cell lines and measured their sensitivity to RSL3. Ferroptosis-resistant cell lines showed a separation from ferroptosis-sensitive cell lines, reflected by > 100-fold increases inRSL3 ICso (Fig. 1G). We measured the basal levels of diacyl-PUFA and monoacyl- PLIFA phospholipids using LC-MS-based targeted lipidomics in these cell lines cultured in normal media. Without ferroptosis induction, we detected significantly higher abundance of PC-PUFA2S in sensitive cell lines compared with resistant cell lines (Figs. 1H and 11). The abundance of monoacyl-PUFA-PL abundance was not significantly different among these two groups (Fig. 7G). Despite the difference in tissue-dependent expression of other ferroptosis regulators, the abundance of PC- PIIFA2S strongly correlated with cell sensitivity to ferroptosis.
[0117] We further examined PC-PUFA2 as a diagnostic marker in aging and ferroptosis-related diseases. By reanalyzing published lipidomics dataset (Metabolomics Benchwork ST001637) from a study using aged mouse brain, we selected all annotated phospholipid species and compared the abundance of PC- PLIFAs between 3-week-old (n=16) and 59-week-old mice (n=16) (Ding et al. 2021 ). We found a strong depletion of diacyl-PUFA-PLs in the hippocampus of 59-week-old mice, while the changes in monoacyl-PUFA-PLs were not consistent (Fig. 7I). In addition, lysophospholipid species increased in 59-week-old mice compared to 3- week-old mice, suggesting oxidation of PL-PUFAs, followed by cleavage of PLIFA tails by phospholipases during ferroptosis (Fig. 7H) (Chen et al. 2021 ).
[0118] Ferroptosis has been implicated in aging-related neurodegenerative diseases (Stockwell et al. 2017). In particular, the hippocampus, a major brain structure involved in learning and memory, has been shown to selectively accumulate iron during aging that increases the risk of ferroptosis (Jakarta et al. 2021). Our analysis suggests that PC-PUFA2 are more sensitive to oxidation and may contribute to ferroptosis propagation and age-related diseases.
[0119] Furthermore, we performed targeted lipidomics on the caudate nucleus tissue from Huntington’s Disease (HD) patients (n=21 ) and age-matched control patients (n=25) (Table 1). The HD cases were selected based on the neuropathology of the brain during both gross and microscopic examinations. The brain tissues of control patients were unaffected. We detected a significant depletion of PL-PUFA2S in HD tissue compared to normal brain tissue, suggesting lipid dysregulation and oxidation associated with HD neuropathology (Fig. 7J). Overall, we found strong relevance of diacyl-PUFA phospholipids for ferroptosis during both physiological and pathological conditions, which suggests the potential of PL- PUFA2S as ferroptosis biomarkers.Table 1. Age and sex information of Huntington’s disease and control patients.Abbreviation: HD, Huntington’s disease; NYBB, New York Brain Bank at Columbia University; Miami, Brain Endowment Bank at University of Miami; HBSFRC, Human Brain and Spinal Fluid Resource Center; Harvard, Harvard Brain Tissue Resource Center at Harvard Medical School Teaching Hospital; Maryland, NIH NeuroBioBank’s Brain and Tissue repository at the University of Maryland; Mt Sinai, Mount Sinai NBTR NeuroBioBank.Dietary PC-PUFA2S are remodeled into the cell lipidome
[0120] To investigate whether exogenous PC-PUFA2S, such as when consumed as dietary phospholipids, were incorporated into cells, we extracted lipids from IGROV-1 cells treated with sublethal amount of PC-PUFA2 and utilized LC-MS- based lipidomics to detect the accumulation of lipids. Cells treated with PL-PUFA1 such as PC(18:0, 20:4) had increased lysoPC(18:0) which was likely produced by cleavage of the PUPA tail at the sn2 position, while no significant accumulation of the original PC(18:0, 20:4) was observed (Fig. 2A). In contrast, exogenous diacyl-PUFA phospholipids including PC, PS, and PG were maintained relatively intact in cells (Figs. 2A and 8B). We observed a less accumulation of lysoPC(20:4) results in PC(20:4, 20:4) treatment than PC(18:0, 20:4) treatment, which could be due to either lower susceptibility of PC(20:4, 20:4) to cleavage by phospholipase A2s or rapid recycling of some lysoPC(20:4) to other lipid species. Treatment with phospholipase A2 inhibitor sensitized IGROV-1 cells to PC-PUFA2S, highlighting the rapid remodeling of PC-PUFA2S, but not lower reactivity with phospholipase A2s that accounted for lysoPC depletion (Fig. 2B). We did not detect conversion to PE species after either PC-PUFA1 of PC-PUFA2 treatment (Fig. 8A).
[0121] To elucidate the remodeling of PC-PUFA2S, we designed phospholipids deuterated in the fatty acyl tails, but not at the bis-allylic positions: these deuterium labels were thus for tracking purposes, but not inhibiting lipid peroxidation (Fig. 2C) (von Krusenstiem et al. 2023). Cells treated with a deuterated PC-PUFA2, [d22]- PC(20:4, 20:4), exhibited significant accumulation of [d22]-PC(20:4, 20:4) species and greater incorporation of deuterium-labeled PUFAs in other lipid classes, including PEs and DAGs, in comparison with [d 11 ]-PC(18:0, 20:4)-treated cells (Fig. 2D). Of note, [d11]-PC(18:0, 20:4) treatment stimulated metabolism of non-labeled PC(18:0, 20:4) and lysoPC(18:0), which was, however, still not enough to competewith [d22]-PC(20:4, 20:4) potency (Figs. 8C and 8D). Indeed, these results suggest that PC-PUFA2S were incorporated into the cell and sculpted a pro-ferroptosis lipid profile.PC-PUFA2 is involved in dietary fatty acid remodeling
[0122] From the lipidomic analysis of phospholipid remodeling, we observed an increase in free PUFAs in PC-PUFA2-treated cells. We hypothesized that there might be an equilibrium between free PUFAs and PC-PUFA2S. Free PUFAs were less potent than PC-PUFA2S in inducing ferroptosis, but sensitized cells to RSL3- induced ferroptosis (Figs. 3A and 3B). Co-treatment with free PUFAs had a larger synergistic effect with PC-PUFAis than PC-PUFA2S in Calu-1 cells (Fig. 3C). These results suggest that free PUFA and PC-PUFA1 may serve as precursors to form PC- PUFA2 that initiates ferroptosis.
[0123] MUFA incorporation has been shown to protect cells from ferroptosis (Magtanong et al. 2019). Oleic acid (C18:1) treatment fully prevented cell death induced by PC-PUFA1 and RSL3, but only partially protected from cell death induced by PC-PUFA2 (Figs. 3B and 3C). When cells were co-treated with both DHA (022:6) and oleic acid, the ferroptosis-sensitizing effect of DHA was compromised by oleic acid (Fig. 3B).
[0124] To investigate the mechanism by which dietary free fatty acids, PUFA and MUFA, modulate ferroptosis, we conducted targeted lipidomic analysis on IGROV-1 cells treated with PUFA and MUFA. When cells were treated with PUFA alone, we observed a significant increase of PC-PUFA2S in both DHA-treated and ARA-treated cells (Figs. 3D and 9A). PC-PUFA2S containing ARA (C20:4) tails — PC(20:4, 20:4) and PC(20:4, 22:6) — experienced fast cleavage, reflected by the further accumulation when co-treated with phospholipase A2 inhibitor, ONO-RS-082. PC-PUFA2 containing DHA (22:6) tails — PC(22:6, 22:6) — was relatively stable in cells (Fig. 9A). This can be rationalized as exogenous PC(22:6, 22:6) being more potent for inducing ferroptosis than PC(20:4, 20:4). In contrast, PE-PUFA species were not significantly changed after PUFA treatment (Fig. 9A). These results confirmed the enrichment of PC-PUFA2S upon free PUFA supplementation and highlighted their relevance to ferroptosis triggered by free PUFAs.
[0125] Next, we analyzed cells co-treated with MUFA and PUFA. Oleic acid slightly reduces PC(22:6, 22:6) levels when treated alone but more significantlywhen co-treated with DHA. This is consistent with cell viability data showing that oleic acid can mitigate the ferroptosis-sensitizing effect of DHA. PC-PUFAi — PC(18:0, 22:6) — was not significantly changed by dietary fatty acids. Both dietary fatty acids were detected in treated cells, suggesting effective intracellular fatty acid uptake (Figs. 3D and 3E). In summary, we confirmed that PC-PUFA2 synthesis is required for the sensitizing effect of dietary PLIFAs, and selective blocking of PC- PUFA2 synthesis is likely part of the ferroptosis-inhibitory effect of MLIFAs such as oleic acid.
[0126] ACSL4 catalyzes the ligation of acyl-coenzyme A (acyl-CoA) to long- chain PLIFAs, especially arachidonic acid and adrenic acid, which facilitates their incorporation into phospholipids (Doll et al. 2017). Knockdown of ACSL4 by a pool of small interfering RNAs or by CRISPR partially protected cells from PC-PUFAis but did not affect the lethality of PC-PUFA2S (Figs. 3F and 9B). In addition, PC-PUFA2 treatment did not affect the protein levels of ferroptosis regulators, GPX4 and ACSL4 (Fig. 3G). These data further support that PC-PUFA2S readily induce ferroptosis, downstream of lipid metabolism by ACSL4. Thus, PC-PUFA2S are downstream of necessary PUFA incorporation, implicating PC-PUFA2S as proximal mediators of ferroptotic cell death.PL-PUFA2S exhibit interaction with mitochondrial electron transport chain
[0127] To decipher the effectors that mediate PL-PUFA2-induced ferroptosis, we conducted affinity pull-down assay combined with mass spectrometry (MS) to identify phospholipid-bound protein complexes. We designed phospholipids with biotinylated head groups that were subjected to pull-downs with streptavidin-coated beads to isolate specifically bound proteins (Fig. 4A). A whole-cell lysate from HT- 1080 cells was incubated with biotinylated PL-PUFA2, PL-PUFA1, or PL-SFA2, while negative control groups were incubated with vehicle and biotin. Target proteins were eluted and analyzed by MS-based proteomics for peptide identification. This workflow identified roughly 3,500 proteins from all samples and a principal components analysis revealed a clear separation of biotin-PL(22:6; 22:6) group from all other treatment groups and a tight clustering among biological triplicates (Fig. 4B). The differentiation between proteins associated with biotinylated PL(18:0; 22:6) and PL(16:0; 16:0) was small, while the negative control groups were well-separated from all phospholipid groups.
[0128] A heatmap analysis revealed a cluster of proteins enriched in the biotin-PL(22:6; 22:6) group (Figs. 10A and 10B). A volcano plot analysis comparing biotin-PL-PUFA2 and biotin-PL-PUFAi revealed that mitochondrial electron transport chain (ETC) complex I proteins were specifically enriched in pull-downs using biotin- PL(22:6; 22:6) (Fig. 4C). We detected ETC complex proteins in elution samples by western blotting and found that complex I proteins were present only in biotin- PL(22:6, 22:6)-treated samples, while complex III and IV were also present in biotin- PL(18:0, 22:6)-treated samples (Fig. 4D). These data suggests that mitochondrial complex I is particularly involved in the mechanism of action of PL-PUFA2.
[0129] To further evaluate the connections of the identified genes potentially involved in PL-PUFA2 mechanism of action, we performed gene set enrichment analysis (GSEA) between PL-PUFA2 and PL-PUFA1. GSEA evaluates genes in the context of KEGG pathways and highlights the ones with significant p value and fold change. Top pathways involved the key genes that were either most significantly enriched or depleted in the PL-PUFA2 group. We found two pathways, non-alcoholic fatty liver disease and chemical carcinogenesis — reactive oxygen species, enriched in the PL-PUFA2 group, while the peroxisome pathway was enriched in the PL- PIIFA1 group (Fig. 10C). A part of the detailed view of the chemical carcinogenesis- reactive oxygen species pathway shows that complex I is the most enriched protein complex in the PL-PUFA2 group. Mitochondrial oxidative phosphorylation is a major source of reactive oxygen species, particularly produced from complex I and III. The chemical carcinogenesis — reactive oxygen species pathway is also frequently identified along with other ferroptosis related pathways in pathological contexts (Dong et al. 2023). These data highlights that PL-PUFA2 involves in the function and assembly of mitochondrial ETC.
[0130] We further investigated the distribution of exogenous PL-PUFA2S in different subcellular organelles. We treated IGROV-1 cells with biotinylated PL(22:6, 22:6) or PL(18:0, 22:6) and stained cells with fluorophore-conjugated streptavidin for phospholipid detection. To determine the structures of subcellular organelles, cells were co-stained with an ER-marker anti-Calnexin antibody, a mitochondrial marker anti-COX IV antibody, a Golgi marker anti-Giantin antibody, and a lysosome marker anti-LAMP1 antibody. We observed a prominent accumulation of biotin-PL(22:6, 22:6) in the mitochondria and the ER, but no accumulation in the Golgi or lysosomes(Fig. 4E). Negative controls using vehicle or biotin-treated cells had no staining with streptavidin-cy5, confirming the specificity of phospholipid labeling (Fig. 10D).
[0131] In addition, we treated HT-1080 cells with sublethal amount of PC(22:6, 22:6) and isolated mitochondria from the rest of the cell compartments. Lipids in the mitochondria and other cellular structures were extracted and analyzed using LC- MS. We found PC(22:6, 22:6) in both mitochondria and the rest of cellular structures, while the increase of PC(22:6, 22:6) upon treatment was higher in the mitochondria (Fig. 10E). Mitochondria appear to be an important site for PC-PUFA2 accumulation.PC-PUFA2S induces mitochondrial stress
[0132] To investigate mitochondrial stress associated with PL-PUFA2 accumulation, we evaluated mitochondrial function from three different angles: mitochondrial reactive oxygen species, mitochondrial membrane potential, and mitochondrial oxidative phosphorylation. PC-PUFA2S induced an increase in mitochondrial superoxide production, measured by fluorescent probe, MitoSOX (Fig. 5A). ROS produced by the mitochondrial ETC complex I has been reported to promote ferroptosis (Gao et al. 2019; Lyamzaev et al. 2023). The accumulation of excess PC-PUFA2S may disrupt ETC complex I structure and affect electron flow, resulting in increased ROS production. Mitochondrial membrane potential was measured using a cationic fluorescent probe, rodamine123, which labeled normal polarized mitochondria. Treatment of PC-PUFA2S, including PC(22:6, 22:6) and PC(20:4, 20:4), significantly reduced mitochondrial membrane polarization compared with PC-PUFA1 or vehicle treatment, indicated by a reduction of rodamine123 labeling (Figs. 5B and 11 A). We then determined oxygen consumption rate to reflect mitochondrial respiration activity. PC(22:6, 22:6) treatment significantly halted oxygen consumption rate which is partially restored upon co-treatment with ferrostatin-1 (Fig. 5C). RSL3 did not affect oxygen consumption rate, consistent with previous reports suggesting mitochondria is dispensible in the mechanism of RSL3- induced ferroptosis (Gaschler et al. 2018). PC(22:6, 22:6)-treated cells did not change morphology during the assay, suggesting that the observed reduced oxygen consumption rate is due to inhibition on mitochondrial respiration rather than on cell viability (Fig. 11 B). Moreover, we evaluated other ETC complex inhibitors, including complex I inhibitor rotenone and complex III inhibitor antimycin A. These inhibitors induced mitochondrial stress but did not induce lipid peroxidation and ferroptosis(Fig. 11 D). Together, these data confirmed that mitochondria are essentially involved with PC-PUFA2-induced ferroptosis.Mitochondrial ROS is essential in PC-PUFA2-induced ferroptosis
[0133] To evaluate the role of mitochondria-induced ROS in PC-PUFA2 mechanism, we investigated the effect of mitochondria-targeted ROS scavengers on PC-PUFA2 treatment. Co-treatment with mitochondria-targeted antioxidant, mitoquinone (mitoQ), protected cells from PC-PUFA2 treatment (Fig. 5D). The nontargeted counterpart of mitoQ, decylubiquinone, had a smaller effect compared to mitoQ. In addition, mitoQ can effectively reduce mitochondrial superoxide accumulation upon PC-PUFA2 treatment, confirming the mechanism of these antioxidants in scavenging mitochondrial ROS (Figs. 5E and 11C). MitoQ can fully suppress lipid peroxidation induced by PC-PUFA2 (Fig. 5F). These data suggests that mitochondrial ROS is essential during the mechanism of PC-PUFA2-induced ferroptosis and may facilitate lipid peroxidation initiation and propagation to other cellular membranes. Voltage-dependent anion channel (VDAC) localizes to the mitochondrial outer membrane and has various functions in regulating mitochondrial membrane potential, lipid transport, crosstalk with ER, and cell death (Sassano et al. 2022; Niu et al. 2022). Co-treatment of VDAC inhibitor DIDS partially suppressed the lethal effect of PC-PUFA2, although may through a broader effect on all VDAC family proteins because single knockdown of VDAC1-3 did not achieve the same effect (Fig. 11 E).
[0134] We evaluated PC-PUFA2 potency in mitochondrial depleted cells generated by parkin-directed mitophagy (Gaschler et al. 2018; Gao et al. 2019). Parkin-overexpressing HT-1080 cells were induced mitophagy through treatment with the uncoupling agent carbonyl cyanide m-chlorophenyl hydrazone (CCCP), and we confirmed the depletion of mitochondrial content by staining with MitoTracker and quantification of mitochondrial DNA transcripts (Fig. 11 F). Compared to normal cells, mitochondrial-depleted cells were less sensitive to PC-PUFA2 treatment, suggesting that depletion of mitochondrial membrane and ROS reduces dietary PC-PUFA2 potency. The backup accumulation of PC-PUFA2 in other subcellular membranes such as ER when mitochondria are absent may still promote ferroptosis. Overall, our data support the notion that the potency of dietary PC-PUFA2 requires functionalmitochondrial ETC structure and ROS production, which may be particularly beneficial when targeting cancer cells with hyperactive mitochondrial function.PC-PUFA2S induce lipid peroxidation, but not an unfolded protein response in ER
[0135] We recently reported that ER is a key site of lipid peroxidation that drives ferroptosis17. Interestingly, by co-staining cells with the fluorescent lipid hydroperoxide probe, Liperfluo, with MitoTracker and ER-Tracker, we observed a significant increase in lipid peroxidation in cells treated with PC-PUFA2S but not PC- PUFAis (Figs. 6B and 12A). The co-localization of Liperfluo signal with ER-Tracker was significantly higher than MitoTracker, indicating extensive lipid peroxidation in the ER that was consistent with this previous report (Fig. 6A). In addition, we evaluated mitochondrial lipid peroxidation using a mitochondrial-targeting probe, mitoCLox. Although mitoCLox contains a mitochondrial-targeting structure, it showed major staining outside mitochondrial in cells treated with PC(22:6, 22:6), suggesting that mitochondria are not the major site for lipid peroxidation (Fig. 12C).
[0136] To evaluate ER stress upon PC-PUFA2 treatment, we measured the expression level of genes mediating the ER unfolded protein response (UPR). The protein level of GADD and XBP1s measured by western blot were increased in positive control cells treated with the UPR-inducing compounds, brefeldin A and thapsigargin, but neither was detected in cells treated with PC-PUFA2S for either 4 hours or 24 hours (Figs. 6C and 12B). The transcript levels of XBP1s and GADD measured by quantitative PCR were consistent with western blot results. Cells treated with CCCP, which disrupted oxidative phosphorylation in mitochondrial, also failed to induce UPR, suggesting independent pathways regulating mitochondrial and ER stress.DISCUSSION
[0137] In this study, we identified a minor phospholipid species, PC-PUFA2S containing arachidonoyl or docosahexaenoyl tails that initiate ferroptosis. Due to low basal abundance in cells, diacyl-PUFA phospholipids have been neglected in studies and little is known about their functions in physiological and pathological contexts. PL-PUFA2S are implicated in ferroptosis, based on the observation that selective protection of PL-PUFA2S peroxidation is essential during GCH1 -centered protectionfrom ferroptosis (Kraft et al. 2020). Our study validates that PC-PUFA2 is a pro- ferroptosis lipid marker and has a mechanism of action involving mitochondrial ROS generation.
[0138] In the past, oxidized PEs with arachidonoyl and adrenoyl tails have been reported as a unique feature of ferroptotic cells (Kagan et al. 2017; Wiernicki et al. 2020; Wenzel et al. 2017; Zhao et al. 2011). In our study, supplementation with PE-PUFAs-induced cell death with low potency and specificity to ferroptosis in comparison with PC-PUFAs (Figs. 1A, 7A and 7D) This may be due to the less efficient incorporation of PE-PUFAs into cells and more general PE-induced cytotoxicity. In contrast, PC-PUFA2 shows rapid incorporation into the cell lipidome, which is beneficial in dietary treatment. In addition, when we treated cells with non- lethal amount of PUFAs such as ARA and DHA, the abundance of PCs, particularly PC-PUFA2S, were significantly increased, while PE-PUFAs remained unchanged. The selective incorporation of PUFAs in the sn1 position of PC phospholipids was also reported in a previous study using ^-linoleic acid (Defries et al. 2022). This suggests that the PC-PUFA2 level is responsive to dietary PUFA supplementation and affects ferroptosis sensitivity. In addition, peroxisomes are reported to be involved with ether-phospholipid synthesis which contributes to ferroptosis (Cui et al. 2021 ; Lee et al. 2021). We found that the protein-binding profile of biotinylated PL- PUFA1 but not PL-PUFA2 showed enrichment in peroxisome-related proteins, implying a mechanism involving peroxisomes for dietary PL-PUFA1 that is distinct from PL-PUFA2.
[0139] Here, we found that diacyl-PUFA phospholipids are key drivers of ferroptosis that involves initial mitochondrial ROS production and subsequent ER lipid peroxidation (Fig. 6D). In this model, the intracellular level of diacyl-PUFA phospholipids, such as PC-PUFA2S, accumulate by either direct PC-PUFA2 uptake or free PUFA uptake followed by fatty acid remodeling to readily induce ferroptosis. A portion of dietary PC-PUFA2S were remodeled into other PUFA-containing lipid species. One phospholipid remodeling pathway, the Lands cycle, involves the phospholipase-A2-catalyzed cleavage of fatty acyl tails and the attachment of new fatty acyl chains by lysophospholipid acyltransferases. Phospholipase A2 facilitates the clearance of oxidized PL-PUFAs as a defense mechanism against ferroptosis (Sun et al. 2021 ; Lu et al. 2019). Inhibition of fatty acid synthase (FASN) thatregulates SFA and MLIFA synthesis disrupts the Lands cycle in lung cancer and leads to the accumulation of PC-PUFA2S and lysoPC-PUFAs (Bartolacci et al. 2022). Lipid remodeling was also reported upon exogenous PUFA perturbation to restore membrane lipid homeostasis (Levental et al. 2020). We observed that DHA- containing PC-PUFA2 experience less lipid remodeling compared with ARA- containing PC-PUFA2, which contributes to its higher potency to initiate ferroptosis. Therefore, the remodeling of exogenous PC-PUFA2S into other PUFA-containing lipid species may be a strategic mechanism to reduce the toxicity of PC-PUFA2S. Consistently, dietary MUFA and ACSL4 knockdown abolished cell-death induced by PC-PUFA1S but had less effect on PC-PUFA2S. This implies that PC-PUFA2s are the proximal lipid effector to execute ferroptosis and dietary MUFA and PUFA are affecting the synthesis of diacyl-PUFA phospholipids.
[0140] Critically, incorporation of PUFAs, at least arachidonic acid, into phospholipids via the Kennedy pathway or the Lands pathway has been shown to be a high-affinity but low-capacity pathway (Chilton et al. 1996). Thus, it is likely that the abundance of PL-PUFA1 species generated through CoA-PUFAs is limited and perhaps insufficient to support ferroptosis. Instead, formation of PL-PUFA2S as a mobile carrier of PUFAs that can support a transacylation mechanism such as that originally reported by Irvine and Dawson is likely essential to provide a sufficient capacity of PL-PUFA species to enable ferroptotic cell death (Irvine and Dawson, 1979). PL-PUFA2S is thus highly responsive to intracellular PUFA pool and governs cell sensitivity to ferroptosis.
[0141] Mitochondria have been shown to play a potentiating role in ferroptosis in recent studies identifying the protective effect of mitochondria antioxidants and mitochondria-localized GPX4 overexpression on ferroptosis (Oh et al. 2022; Lyamzaev et al. 2023). In our study, we found that PL-PUFA2S were transported to the mitochondria, implying that endogenous PL-PUFA2 trafficking systems are enriched in mitochondria. Mitochondria have been reported as the intracellular sink for short-chain di-unsaturated phospholipids in yeast, although the similar transport system has not been characterized in mammalian cells (Renne et al. 2022). Besides, dietary PUFA such as DHA and has been shown to affect mitochondrial structure, oxidative phosphorylation, and unsaturated lipid content (Sullivan et al. 2018; Herbst et al. 2014; Malis et al. 1990). These studies demonstrate that dietary PUFA are effectively incorporated into mitochondrial membrane phospholipid and accompaniedby mitochondrial stress including membrane depolarization and decreased activity of ETC complexes. This explains that when we supplemented cells with free PLIFA, accumulation of PC-PUFA2 may occur in the mitochondria due to high regional concentration of PUFA most likely in the inner mitochondrial membrane and intermembrane space.
[0142] It has been reported that mitochondrial ROS produced by ETC complex I is responsible for mitochondrial lipid peroxidation and ferroptosis (Lyamzaev et al. 2023; Basit et al. 2017). Based on our proteomic data, PL-PUFA2 had certain interactions with complex I protein that may directly or indirectly affect mitochondrial ROS (mtROS) homeostasis and induce mitochondrial membrane depolarization. We found that the lethal effect of PC-PUFA2 was protected by the mitochondria-targeted ROS-quencher such as mitoquinone, but not by ubiquitously localized decylubiquinone (Fig. 5D). Mitoquinone was also sufficient to block mitochondrial ROS accumulation and lipid peroxidation that is essential during PC- PUFA2-induced ferroptosis.
[0143] Due to accumulation of PC-PUFA2 and mtROS, mitochondria act as an initiation site of ferroptosis, while propagation of lipid hydroperoxides occur mainly in the ER. ER is a central organelle for lipid metabolism and contains abundant labile PUFA phospholipids. Lipid hydroperoxides from mitochondria can communicate with ER membrane through mitochondria-ER contact sites (Simoes et al. 2020; Vecellio Reane et al. 2020). We found that PC-PUFA2S induced lipid peroxide accumulation in the ER, consistent with the established model that ER is the primary site of lipid peroxidation (von Krusenstiern et al. 2023).
[0144] In summary, PC-PUFA2 is a critical pro-ferroptosis lipid class. We found that PC-PUFA2 is a potent downstream effector of dietary PUFA and modulates cellular oxidative stress by disruption of mitochondrial ROS homeostasis. The accumulation of PC-PUFA2S can rationalize the ferroptosis-promoting benefit of PUFA treatments during cancer therapy, the effects of MUFAs in suppressing ferroptosis, the role of mitochondria in contributing to ferroptosis, and impact our understanding of ACSL4 function during lipid remodeling. PC-PUFA2S therefore represent an important driver of ferroptosis, with implications for understanding the basic biology and chemistry of ferroptosis, as well as how ferroptosis can be detected and regulated in disease states. In this sense, the level of PC-PUFA2 may be a marker of ferroptosis-sensitivity, with implications for linking PUFA content ofdiet, aging, degenerative disease states, and cancer cell contexts to ferroptosis sensitivity.CONCLUSION
[0145] In conclusion, our findings indicate that PC-PUFA2 is an important ferroptosis-regulating lipids. We found interactions of PC-PUFA2 with mitochondrial ETC complex I that contribute to ROS production, essential for the initiation and propagation of lipid peroxidation that drives ferroptosis. Although these results suggest the involvement of the mitochondrial ETC in PC-PUFA2-induced ferroptosis, further structural analysis is needed to determine the exact binding site of PC-PUFA2 within the ETC complexes to fully understand the mechanism behind PC-PUFA2- induced ROS production.
[0146] Furthermore, our current data demonstrates that accumulation of PC- PUFA2 specifically drives ferroptosis, however a more comprehensive analysis of whether depletion of PC-PUFA2 blocks ferroptosis is limited by the current methods. Although we showed that MUFA treatment selectively reduced PC-PUFA2 concentration in cells in the presence of PLIFA, future study on PC-PUFA2 biosynthetic pathway is important to identify enzymes that account for the accumulation of PC-PUFA2 in cells, so that blockage of these pathways can achieve complete depletion of PC-PUFA2.Example 2Targeting mitochondrial complex I with PC(22:6; 22:6) induces ferroptosis in regulatory T cells
[0147] Pro-tumorigenic regulatory T cells (Tregs) in the tumor microenvironment adapt metabolism to survive harsh conditions; targeting Treg metabolism is a possible therapeutic strategy. In this Example, we investigated Treg metabolism via single-cell RNA sequencing and gene set enrichment analysis, and identified oxidative phosphorylation as a metabolic pathway enriched in Tregs. Tregs are dependent on intact complex I for protection against ferroptosis, a regulated cell death mechanism controlled by metabolism. We found that PC(22:6; 22:6), a phospholipid with two polyunsaturated fatty acyl docosahexaenoyl tails, induces ferroptosis in Tregs via targeting complex I, increasing lipid reactive oxygen species and the labile iron pool, and reducing immunosuppression. These results reveal akey role of complex I in regulating Treg metabolism and Treg ferroptosis, and highlight the potential of PC(22:6; 22:6) for driving ferroptosis in Tregs.
[0148] Regulatory T cells (Tregs) in the tumor microenvironment (TME) of aggressive and drug-resistant cancers contribute to tumor growth, diminished antitumor immunity, and reduced clinical efficacy of immunotherapies (Huang et al. 2021 ; Humphries et al. 2010; Saleh and Elkord, 2020; Tang et al. 2014; Togashi et al. 2019). Mounting evidence suggests that high Treg infiltration in the TME is correlated with poor clinical outcomes in cancer patients (Tang et al. 2014; Togashi et al. 2019; Dees et al. 2021 ; Sayour et al. 2015). Moreover, Tregs are particularly metabolically flexible, which enables them to meet their nutrient and energetic demands and survive harsh conditions of the TME (McRitchie and Akkaya, 2022; Miska et al. 2019; Rao et al. 2021 ; Sasidharan et al. 2021 ; Wang et al. 2020; Yan et al. 2022). Thus, specifically targeting metabolism in Tregs is a therapeutic approach to potentiate anti-cancer immune responses and tumor clearance.
[0149] Ferroptosis, an iron-dependent regulated cell death mechanism (Dixon et al. 2012) controlled by metabolism that results in the accumulation of toxic lipid reactive oxygen species (lipid ROS) (Stockwell, 2022), has been studied as an approach to induce cell death by targeting cancer cell metabolism (Badgley et al. 2020; Ferrada et al. 2023; Upadhyayula et al. 2023; Zhang et al. 2022). Recently, it was reported that phospholipids with two polyunsaturated fatty acyl tails (diPUFA- PLs) drive ferroptosis in cancer cells via targeting mitochondrial complex I in oxidative phosphorylation (OXPHOS) (see Example 1 ). While ferroptosis has been extensively studied in the context of cancer cells, ferroptosis in Tregs has been only minimally explored. Moreover, it is not known how to specifically perturb Treg metabolism as a therapeutic strategy to induce ferroptosis in this critical cell type.
[0150] Here, we confirmed OXPHOS as a top metabolic pathway in activated Tregs and found that mitochondrial complex I is particularly critical as a regulator of ferroptosis in Tregs. We validated the ferroptosis sensitivity of Tregs using ferroptosis-inducing compounds and elucidated previously unknown aspects of the Treg lipidome that support its pro-ferroptosis profile. We found that in Tregs, inhibition of mitochondrial complex I in OXHPOS via treatment with PC(22:6; 22:6), a diPUFA-PL containing two docosahexaenoic acid (DHA) tails, induces ferroptosis. We observed that PC(22:6; 22:6) treatment leads to an increase in lipid ROS as well as the labile iron pool (LIP). As OXPHOS is essential for the suppressive function ofTregs, we found that Tregs pre-treated with PC(22:6; 22:6) have weakened immunosuppressive capacities.
[0151] Collectively, these findings highlight the therapeutic potential of PC(22:6; 22:6) to inhibit Treg metabolism and induce ferroptosis. Because diPUFA- PLs may be enhanced through diet (see Example 1 ), these findings also illuminate opportunities for translational dietary approaches to use PC(22:6; 22:6) therapeutically.MATERIALS AND METHODSChemicals
[0152] The following chemicals were purchased from certified vendors: dimethyl sulfoxide (Sigma-Aldrich 276855), ferrostatin-1 (Sigma-Aldrich SML0583), rotenone (EMD-Millipore 557368), antimycin (Sigma-Aldrich A8674), deferoxamine mesylate (Sigma-Aldrich D9533), diethyl butylmalonate (Sigma-Aldrich 112038), sodium azide (Sigma-Aldrich S2002), PC (22:6; 22:6) (Avanti Polar Lipids 850400C), PC (20:4; 20:4) (Avanti Polar Lipids 850397C), PC (18:3; 18:3) (Avanti Polar Lipids 850395C), arachidonic acid (Cayman Chemical 90010). (1 S, 3R)-RSL3 was synthesized as previously reported (Yang et al. 2014). Biotinylated PL (22:6; 22:6) was synthesized by Avanti Polar Lipids.PBMC isolation
[0153] Human buffy coats were obtained from the New York Blood Center. Buffy coats were diluted 10-fold in PBS. For one 50 mL falcon tube, 25 mL of diluted blood was layered over 20 mL histopaque (Sigma-Aldrich 10771). Tubes were centrifuged at 500 g at room temperature with decreased acceleration (level 5) for 30 minutes. The layer of peripheral blood mononuclear cells (PBMCs) was collected, diluted 1 :1 with PBS, and centrifuged at 500 g for 7 minutes. After aspirating the supernatant, the PBMC pellet was resuspended in PBS. Cells were counted, centrifuged at 1 ,400 rpm for 5 minutes, and resuspended in cryopreservation medium of 90% fetal bovine serum (FBS. Thermo Fisher Scientific 16140071) and 10% DMSO for storage in LN2.Isolation of T cells
[0154] T cells were isolated from PBMCs via fluorescence-activated cell sorting (FACS). First, PBMCs were thawed and incubated overnight in 5% CO2 at 37°C as described previously (Wang et al. 2016) in RPMI-1640 (ATCC 30-2001 ) with10% FBS and 1 % Pen / Strep (Thermo Fisher Scientific 15140163). The following day, PBMCs were centrifuged at 1 ,400 rpm for 5 minutes, counted via VI-CELL, resuspended in 100 pL FACS Buffer (PBS with 10% FBS), and stained with antibodies in the FACS panel for 30 minutes on ice. Cells were quenched and washed with FACS buffer, and resuspended in FACS buffer in FACS tubes. The following antibodies were used in the sorting panel: anti-human CD4 (clone OKT4, Tonbo Biosciences 80-0048-T100), anti-human CD8 (clone SK1 , Biolegend 344714), anti-human CD3 (clone UCHT1 , BD Biosciences 563852), anti-human CD25 (clone BC96, Biolegend 302606), anti-human CD127 (clone A019D5, Biolegend 351342). DAPI (Thermo Fisher Scientific 62248) was used as the live / dead cell stain. The Treg population was collected as CD3+CD4+CD25+CD127|OW. The conventional CD4+T cell (Tconv) population was collected as CD3+CD4+CD25'CD127high. The CD8+T cell population was collected as CD3+CD8+. FACS was performed on a BD Influx cell sorter (BD Biosciences 646500) with four lasers (405, 488, 561 , and 638).T Cell Culture
[0155] T cells were cultured and stimulated in RPMI-1640 medium with 10% FBS and 1 % Pen / Strep with beads. Tregs were stimulated with Dynabeads Human Treg Expander (Thermo Fisher Scientific 1129D) and interleukin-2 (Sigma-Aldrich 11011456001) following vendor’s instructions, i.e., initially 500 U / mL rlL-2 and subsequently 100 U / mL rlL-2. TGF-beta 1 (R&D Systems 7754-BH-005) was also added to the Treg culture at 10 ng / mL. CD4+Tconv and CD8+T cells were cultured and stimulated with Dynabeads Human T-Activator CD3 / CD28 for T cell Expansion and Activation (Fisher Scientific 11-161-D) following vendor’s instructions. All cells were counted every few days via VI-CELL and split accordingly. Experiments were performed around day 4 to day 14 of culture, with restimulations as needed, following vendor’s instructions, and periodic QC checks to ensure integrity and purity of cell types. Cells were incubated in 5% CO2 at 37°C.FoxP3 Expression
[0156] Tregs were checked periodically throughout the culture period for maintenance of high FoxP3 expression. First, Tregs were centrifuged at 1 ,400 rpm for 5 minutes and resuspended in 100 pL of FACS buffer. Cells were then stained with the following antibodies for 30 minutes on ice: anti-human CD3 (clone UCHT1 , BD Biosciences 563852), anti-human CD4 (clone SK3, BD Biosciences 563550), anti-human CD8 (clone SK1 , Biolegend 344714), anti-human CD25 (clone 2A3, BDBiosciences 564467), and anti-human CD127 (clone A019D5, Biolegend 351342). After quenching and washing with FACS buffer, cells were washed 2x in PBS (protein-free). Cells were resuspended in 1 mL of PBS and stained with fixable viability dye (Thermo Fisher Scientific 65-0863-14) following vendor’s instructions. Fix / perm and perm buffers for FoxP3 transcription factor staining (Ebioscience 00- 5523-00) were prepared following vendor’s instructions. Cells were resuspended in 1 mL of fix / perm, incubated at RT in the dark for 30 minutes, and centrifuged at 1 ,250 rpm for 5 minutes at RT. Cells were washed once with perm buffer at 1 ,250 rpm for 5 minutes, resuspended in 100 pL of perm buffer, and stained with FoxP3 (clone 236A / E7, Thermo Fisher Scientific 12-4777-42) at RT for 30 minutes. Cells were washed with perm buffer at 1 ,250 rpm for 5 minutes and resuspended in FACS buffer for flow cytometry analysis. Data was acquired on a BD LSRII Flow Cytometer (BD Biosciences 340551 ) with six lasers (355, 405, 488, 532, 594, and 633). Data analysis was performed using FlowJo (version 10.9.0).Cell viability Assays
[0157] Cells were seeded in RPMI-1640 medium with 10% FBS and 1 % Pen / Strep at a concentration of 2,000 cells / well in 384-well plates (Thermo Fisher Scientific 164610). Cells were treated with corresponding compounds at concentrations described in the figures with the final volume per well as 40 uL. For phospholipid treatment, phospholipids were prepared as described in Example 1. After 24-hour incubation in 5% CO2 at 37°C, CellTiter-Glo (Promega G7573) was added, and cell viability was measured using a luminescent plate reader following vendor’s instructions. All cell viability data was normalized to vehicle and background subtracted with a media-only column (no cells).Suppression Assay
[0158] 5-10 million Tresps (combined CD4+Tconv and CD8+T cells) were collected into one collection tube via FACS using the methods described under Isolation of T cells. Tresps were centrifuged at 1 ,400 rpm for 5 minutes, resuspended in 1 mL of PBS (protein-free), and stained with Celltrace CFSE Cell Proliferation Kit (Thermo Fisher Scientific C34570) following vendor’s instructions. Cells were then washed with FACS and resuspended in RPMI-1640 medium with 10% FBS and 1 % Pen / Strep. Separately, 5-10 million Tregs were centrifuged at 1 ,400 rpm for 5 minutes and resuspended in 1 mL PBS (protein-free) and stained with violet dye (BD Biosciences 562158) following vendor’s instructions. Tregs were then resuspendedin RPMI-1640 medium with 10% FBS and 1 % Pen / Strep. In a round-bottom 96-well plate (Celltreat 229190), Tresps and Tregs were co-cultured at ratios described in the figures with Dynabeads Human T-Activator CD3 / CD28. For Tresps, 100,000 cells were seeded per well while the number of Tregs varied depending on the ratio of Tresp: Tregs. For pre-treatment experiments, the same number of live Tregs were added across all control and treatment conditions. Stimulated Tresps, without Tregs, were used as the positive control. Unstimulated Tresps, without Tregs and beads, were used as the negative control. The total volume per well was 200 pL. After incubating for 72 hours in 5% CO2 at 37°C, cells in each condition / well were harvested, beads were removed, and cells were washed in FACS buffer at 1 ,400 rpm for 5 minutes. Each group was stained in 100 pL of FACS buffer with the following antibodies for 30 minutes on ice: anti-human CD4 (clone OKT4, Tonbo Biosciences 80-0048-T100), anti-human CD8 (clone RPA-T8, Biolegend 301043), anti-human CD3 (clone UCHT1 , BD Biosciences 563852), anti-human CD25 (clone BC96, Biolegend 302606). After quenching and washing with FACS buffer, cells were washed 2x in PBS (protein-free). Cells were then stained with Zombie NIR Fixable Viability Dye (Biolegend 423105) following vendor’s instructions. Cells were resuspended in FACS buffer for flow cytometry analysis. Data was acquired on a BD LSRFortessa (BD Biosciences 649225) with three lasers (405, 488, and 633). Data analysis was performed using FlowJo (version 10.9.0).Lipid ROS
[0159] Tregs were seeded in 24-well plates at 200,000 cells / well and treated with corresponding compounds at concentrations described in the figure captions. After the treatment period, cells were harvested, per condition, and centrifuged at 1 ,400 rpm for 5 minutes. Cells were resuspended in D-PBS (Invitrogen 14190144) containing 5 pM C1 1-BODIPY581 / 591(Invitrogen D-3861 ). After 30 minutes at 37°C in the dark, cells were centrifuged at 1 ,400 rpm for 5 minutes and resuspended in D- PBS for flow cytometry analysis via Beckman CytoFLEX System B4-R0-V0 flow cytometer. Samples were detected with excitation at 488 nm and emission at FITC channel with 525 / 40 nm bandpass filter for oxidized C11-BODIPY581 / 591. Approximately 10,000 events after gating were collected for each sample. Cells were gated for live cells in SSC-A vs. FSC-A and gated for single cells in FSC-H vs FSC- A. Data analysis was performed using FlowJo (version 10.9.0)Labile Iron Pool
[0160] Tregs were seeded in 24-well plates at 500,000 cells / well. Cells were treated with corresponding compounds at concentrations described in the figures. After the treatment period, cells were harvested and centrifuged at 1 ,400 rpm for 5 minutes and washed with PBS 2x. Cells were resuspended in 500 nM of calcein-AM (AAT Bioquest 22002) and incubated at 37°C in the dark for 20 minutes. Cells were centrifuged at 1 ,400 rpm for 5 minutes and washed with PBS 2x. Cells were resuspended in PBS and treated with 1 mM DFO for 1 hour followed by flow cytometry analysis via Beckman CytoFLEX System B4-R0-V0 flow cytometer. Cells were gated for live cells in SSC-A vs. FSC-A and gated for single cells in FSC-H vs FSC-A. Data analysis was performed using FlowJo (version 10.9.0)Untargeted LipidomicsSample Preparation
[0161] Treg cultures were maintained as described above and 5 million Tregs per group were harvested. Cells were washed with PBS, flash-frozen, and stored at -80°C until lipid extraction was performed. For lipid extraction, the procedure was adapted from previously described methods (von Krusenstiern et al. 2023). Briefly, cell pellets were resuspended in ice-cold 300 pL LC-MS-grade methanol with 0.01 % butylated hydroxytoluene (Sigma-Aldrich W218405). Cells were further homogenized with a microtip sonicator. Homogenized samples were transferred to new glass vials with 1000 pL of ice-cold methyl tert-butyl ether and 1 pL of SPLASH lipidomics standard (Avanti Polar Lipids). Samples were left overnight at -80°C. The next day, 250 pL of ice-cold LC-MS-grade water was added to each sample. Samples were left on ice for 20 minutes and then centrifuged at 3,000 rpm for 20 minutes at 4°C. Approximately 600 pL of the organic layer was collected in a new glass vial and then dried under a stream of nitrogen gas. The dried samples were stored at -80°C until the LC-MS analysis. Immediately before LC-MS analysis, dried samples were reconstituted in 100 pL 2-propanol / acetonitrile / water (4:3:1 v / v / v). A quality control (QC) sample was also prepared by combining 20 pL from each sample.LC-MS Conditions
[0162] Samples were analyzed with a Synapt-XS mass spectrometer coupled to Acquity UPLC system (Waters Corp). The procedure was adapted from previously described methods (Tian et al. 2022). Chromatographic separation was performed over a 20-minute gradient elution profile on an Acquity Premier Peptide CSH C18 Column (1.7 pm, 2.1 x 100 mm) (Waters Corp) with column temperature set to 65°C.Samples were analyzed in both positive and negative electrospray ionization mode using a binary mobile phase of solvent A (60:40 v / v acetonitrile: water) and solvent B (85:10:5 vNNI isopropanol: acetonitrile: water). Both solvent A and B contained 10 mM ammonium acetate and 0.1 % acetic acid. The solvent gradient was as follows: 40% B at the start, linear gradient to 50% by 2 minutes followed by ramping up to 99% B by 18 minutes, and column equilibration for 2 minutes back to 40% B. The flow rate was 400 pL / min. The injection volume for positive mode was 4 pL and 8 pL for negative mode. For fragmentation, data was also acquired using high-definition data independent mode with ion mobility (HDMSE). The following parameters were used for data acquisition with and without ion mobility for both positive and negative mode: mass range of m / z 50 to 1200 Da, scan rate of 0.1 sec / scan, 2.0 kV capillary voltage, 40.0 kV sampling cone voltage, 120°C source temperature, 450°C desolvation temperature, and 800 L / hr for desolvation gas flow. MS data calibration, collision energy, and mass calibration was set to exact parameters as previously described (Tian et al. 2022).Identification of Lipids
[0163] First, the accurate mass values of free PUFAs, diPUFA-PLs, and monoPUFA-PLs were matched against the LIPID MAPSRLMSD database (70), with a mass tolerance of 5ppm. Lipidomics data acquired from Tregs in HDMSEmode from the pooled QC samples were then analyzed using MSEdata viewer (version 1.3, Waters Corp) to identify the precursor mass and their corresponding fragments. Fragmentation patterns in the QC spectra were carefully analyzed to identify signature fragments of phospholipid classes such as phospholipid head groups as well as specific fatty acid tails. The assignment was also based on their corresponding retention times. For quantification, QuantLynx Application Manager (Waters Corp) was used to compute the area-under-the-curve (AUC) values of the accurate mass of precursor ions with their corresponding retention times.Protein Quantification
[0164] The Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific 23225) was used to quantify protein in the supernatant following vendor’s instruction. Briefly, standards and samples in duplicate were added to a 96-well plate. After incubation for 30 minutes at 37°C with the working solution from the kit, a standard curve was generated and then used to quantify the unknown protein concentration of the samples of interest.Streptavidin-IP
[0165] Streptavidin-IP procedures were adapted from methods described in Example 1. First, 100 million Tregs were collected and washed with PBS. Cells were washed with 1 mL ice-cold IP-MS Cell Lysis Buffer from the Pierce MS-Compatible Magnetic IP Kit (Thermo Fisher Scientific 90408) containing protease inhibitor cocktail (Sigma-Aldrich 11697498001 ). After 10 minutes on ice with periodic mixing, the lysate was centrifuged at 17,000 g for 15 minutes at 4°C. Protein quantification in the supernatant was performed as mentioned above. The biotinylated phospholipid, dried under gentle nitrogen gas stream, and the biotin-PEG-thiol (Polypure 41156- 1095) were independently resuspended in mixture of methanol and PBS. Next, 1 mg of protein from the cell lysate was mixed with 2 mg of the biotinylated phospholipid or biotin-PEG-thiol to yield a total volume of 500 pL. Additional IP-MS-Cell Lysis Buffer was added as needed for the 500 pL total volume. The protein x lipid mixture was incubated for 2 hours at 4°C with continuous mixing. Next, 0.5 mg of Pierce Streptavidin Magnetic Beads and 175 pL of IP-MS Cell Lysis Buffer were mixed in a 1.5 mL low protein-binding microcentrifuge tube. After collecting the beads via a magnetic stand and repeating this wash step again, 500 pL of the sample mixture was then mixed with the beads and incubated for 2 hours at 4°C with continuous mixing. The beads were then collected again with the magnetic stand and washed with IP-MS Wash Buffer A and B. The eluted samples were then mixed with 3x blue loading buffer containing 125 pM DTT (Cell Signaling Technology 7722S) and heated for 10 minutes at 50°C. The samples were further heated for 5 minutes at 80°C. A small volume of the original lysate was also mixed with 3x blue loading buffer containing 125 pM DTT and heated for 5 minutes at 80°C. The samples were then analyzed by western blot as described below.Western Blot
[0166] Western blot was performed following methods described in Example 1. In brief, protein concentration was normalized across samples such that equal amounts of protein were loaded in NuPAGE 4-12% Bis-tris gel (Fisher Scientific WG1401) lanes. The gel was transferred to nitrocellulose membranes (Thermo Fisher Scientific 1 B23002) via iBlot2 (Invitrogen) electrophoretic semi-dry western blot transfer system. After blocking membranes for 1 hour in TBS blocking buffer (Thermo Fisher Scientific 37535), membranes were incubated with primary antibodies diluted 1 :1 in TBS-T (TBS with 0.1% Tween20): TBS blocking buffer atappropriate concentrations. The following primary antibodies were used: anti- NDUFS1 (clone E4K3E, Cell Signaling Technology 70264) at 1 :250, anti-NDUFAB1 (clone E2V9B, Cell Signaling Technology 71814) at 1 :250. Membranes were incubated overnight at 4°C with continuous shaking. The following day, membranes were washed with TBS-T and incubated with secondary antibodies diluted at 1 :10,000 in 1 :1 TBS-T: TBS blocking buffer for 1 hour at RT with continuous shaking. The following secondary antibody was used: anti-rabbit IgG (H+L) IRDye 680RD (926-68071). After washing membranes with TBS-T, membranes were imaged on Ll- COR Odyssey infrared imaging system.Quantitative PCR
[0167] Approximately 4 million cells, at conditions listed in the figures, were harvested and washed with PBS at 1 ,400 rpm for 5 minutes. RNA extraction was performed using RNeasy Mini Kit (Qiagen 74136) using vendor’s instructions followed by reverse transcription to cDNA. Quantitative PCR (qPCR) was carried out using Power SYBR Green PCR Master Mix (Thermo Fisher Scientific 4368577) on a ViiA 7 Real-Time PCR System (Thermo Fisher Scientific). All qPCR primers were purchased from Integrated DNA Technologies. The following qPCR primers were used: (TBP: F 5’- CTTCGGAGAGTTCTGGGATTG -3’ (SEQ ID NO: 13) and R 5’- AGCAAACCGCTTGGGATTA -3’ (SEQ ID NO: 14); SLC7A11 : F 5’- GGTTGCCCTTTCCCTCTATTC -3’ (SEQ ID NO: 15) and R 5’-CCTGGGTTTCTTGTCCCATATAA -3’ (SEQ ID NO: 16); CHAC1 : F 5’- TGGCATACCAAGTGCAAGG -3’ (SEQ ID NO: 17) and R 5’-CCAGACGCAGCAAGTATTCA -3’ (SEQ ID NO: 18)).Single-cell RNA Sequencing and Gene Set Enrichment Analysis
[0168] Single-cell RNA sequencing (scRNA-seq) on a combined Treg and PBMC sample was performed at the JP Sulzberger Columbia Genome Center Single Cell Analysis core. Libraries were prepared using the 10x Genomics Chromium Single Cell 3’ Reagent Kit following vendor’s instructions, with a target of 5,000 cells and 350 million reads. Samples were sequenced on an Illumina NovaSeq 6000 Sequencing System. All scRNA-seq data were processed and analyzed following Seurat (V4) (Butler et al. 2018; Hao et al. 2021 ; Hao et al. 2023; Satija et al. 2015; Stuart et al. 2019). The resulting list of genes from DGE analysis was then ranked by incorporating p-value and fold change using formula: -logio(p.value)*log2(FC). Gene set enrichment analysis (GSEA) was then carried out on the ranked list using theKEGG database in FGSEA method (Kanehisa et al. 2023; Kanehisa et al. 2000; Korotkevich et al. 2021) and clusterProfiler (versions 4.6.2) (Wu et al. 2021 ; Yu et al. 2012).Analysis of Treg-OXPHOS expressions in breast cancer
[0169] KEGG OXPHOS signatures were downloaded from the Molecular Signatures Database (MSigDB) (Liberzon et al. 2015). Spatial transcriptomics analysis was performed on publicly available 10X Visium data from two adjacent ER+breast cancer tissues (He et al. 2024). Treg-enriched spots were defined as the ones with >10% predicted Treg proportion through deconvolution with Starfysh, while intratumoral regions were reported from He et al. 2024. The spatial correlation between OXPHOS expressions in Treg-enriched spots and intratumoral regions was examined. Specifically, for each Treg-enriched spot * , we plotted the averageA[Oxphos] - ifoxnhosli ' ^G[Oxphos]OXPHOS expression11 1 J Sagainst itsEuclidean distance to the closest intratumoral spot where ^ represents the log- normalized gene expression counts with Scanpy functions “scanpy.pp.normalize_total” and “scanpy. pp.logl p” (version 1.9.3) . A one-tailed Student’s t test was performed on the linear regression coefficients j8i, with alternative hypothesis being / 3i > 0. In addition, a volcano plot was plotted to summarize the differential OXPHOS expressions reported in Tregs from the TME (TME-Tregs) against Tregs from the peripheral blood (PBMC-Tregs) in a publicly available RNA-seq breast cancer dataset (52). Differentially expressed OXPHOS markers are defined as p-value < 0.05 (two-tailed Student’s t test) and abs(LFC( TME-Tregs vs. PBMC-Tregs)) > 1. The spatial and bulk RNA-seq analysis along with statistical tests were performed with scikit-learn (version 1 .3.2).Visualization
[0170] Schematics were created using BioRender.com. Graphs and plots were created using Seurat (V4), FlowJo (10.9.0), and GraphPad Prism 9 where applicable.Statistics
[0171] For scRNA-seq and GSEA, statistical analyses were performed using Seurat (V4) (32-36) or clusterProfiler (version 4.6.2) (Wu et al. 2021 ; Yu et al. 2012), respectively. Student’s t test or one-way ANOVA was performed via GraphPad Prism9 where applicable, as detailed in the figure legends, with data plotted as Mean ± SEM. For all experiments, statistical analyses are described in the figure legends.ResultsCultured Tregs isolated from PBMCs exhibit Treg hallmarks
[0172] We designed a system to isolate, activate, and expand Tregs, adapting existing methods (Fig. 13A) (Hui et al. 2021 ; Maj et al. 2017; Zuo et al. 2021). First, we obtained human donor buffy coats and isolated PBMCs following density gradient cell separation. The PBMCs were stained with a panel of antibodies to identify the Treg population as CD3+CD4+CD25+CD127|OWcells (Fig. 19). Tregs were collected via fluorescence activated cell sorting (FACS) and cultured with superparamagnetic beads and cytokines to enable activation and expansion.
[0173] We validated that the Tregs in this system are suppressive, as indicated by the markedly diminished proliferation in responder T cells (Tresps) as the Tresp: Treg ratio decreased, and FoxP3+expression (Figs. 13B and 13C). These data demonstrate that Tregs in this experimental system exhibit expected phenotypes.Tregs are sensitive to ferroptosis
[0174] While many studies have investigated ferroptosis in cancer cells (Badgley et al. 2020; Ferrada et al. 2023; Upadhyayula et al. 2023; Zhang et al. 2022; Dos Santos et al. 2023; Zhang et al. 2019), ferroptosis in Tregs have been minimally explored. To that end, we treated Tregs with RSL3, a ferroptosis-inducing compound that inhibits glutathione peroxidase 4 (GPX4) activity (Yang and Stockwell, 2008). We observed that Tregs were sensitive to RSL3 in a dosedependent manner, and when co-treated with ferrostatin-1 (Fer-1), a ferroptosis inhibitor, Treg cell viability was maintained, confirming ferroptosis as the Treg cell death mechanism in response to RSL3 (Fig. 14A).
[0175] To identify additional ferroptosis hallmarks in human-donor-derived Tregs, we measured lipid ROS via C11-BODIPY, a fluorescent probe widely used in the study of ferroptosis (Badgley et al. 2020; Upadhyayula et al. 2023; Zhang et al. 2019), following treatment with RLS3 ± Fer-1. In all donors, we observed a rightward shift under RSL3 treatment, indicating the presence of lipid ROS, and a leftward shiftcompared to RSL3 only treatment when co-treated with Fer-1 , indicating reduction of lipid ROS production by Fer-1 (Figs. 14B, 20B and 20C).
[0176] Recent reports suggested that free polyunsaturated fatty acids (PUFAs) sensitize cells to ferroptosis (Badgley et al. 2020; Upadhyayula et al. 2023; Klasson et al. 2022; Magtanong et al. 2019). To that end, we tested whether arachidonic acid (ARA), a PLIFA, could synergize with RSL3 to potentiate ferroptosis in Tregs. We indeed observed that ARA potentiated ferroptosis in Tregs, as cell viability was further decreased under ARA+RSL3 treatment in a dose-dependent manner (Fig. 20A).
[0177] We evaluated the Treg lipidome via untargeted lipidomics to identify ferroptosis sensitivity lipid features. We detected free PUFAs, diPUFA-PLs, and monoPUFA-PLs, all with connections to ferroptosis (Fig. 20D) (see Example 1 ; Klasson et al. 2022; Magtanong et al. 2019; Doll et al. 2017; Kagan et al. 2017; Liang et al. 2022). These data suggest that ferroptosis in Tregs can be induced through ferroptosis-inducing compounds such as RSL3 and by the addition of PUFAs, and that Tregs intrinsically possess a pro-ferroptosis lipid profile.Transcriptional analysis reveals OXPHOS as a metabolic pathway enriched in activated Tregs
[0178] After determining the ferroptosis sensitivity of Tregs and observing that exogenous PUFAs potentiate Treg ferroptosis, we probed pathways related to metabolism upregulated in Tregs that are relevant to ferroptosis. We performed single-cell RNA sequencing (scRNA-seq) of a mixed sample of 50% enriched Tregs and 50% PBMCs to identify pathways enriched in activated Tregs over resting immune cells in the PBMC sample. Processing of the scRNA-seq data using Seurat (Butler et al. 2018; Hao et al. 2021 ; Hao et al. 2023; Satija et al. 2015; Stuart et al. 2019), an established toolkit, revealed distinct clusters that were visualized in a UMAP representation, including monocytes, CD4+conventional T cells (Tconv), CD8+T cells, and B cells, all originating from PBMCs, as well as Tregs. Cell clusters were annotated based on differential gene expression (DGE) analysis (Fig. 15A). We grouped the clusters as originating from PBMCs or enriched Tregs (Fig. 15B).
[0179] We performed gene set enrichment analysis (GSEA), following GSEA guidelines (Mootha et al. 2003; Subramanian et al. 2005), on the DGEs in Tregs versus PBMCs and used the Kyoto Encyclopedia of Genes and Genomes (KEGG)(Kanehisa et al. 2023; Kanehisa and Goto, 2000) to identify metabolic pathways enriched in Tregs. The results revealed that oxidative phosphorylation (OXPHOS) is a top metabolic pathway enriched in the Tregs. Further analysis revealed that genes in mitochondrial complex I in OXPHOS were specifically enriched in Tregs. (Figs. 15C and 15D). Collectively, these results show that OXPHOS is enriched in activated T regs.Inhibition of mitochondrial complex 1 induces ferroptosis in Tregs
[0180] Given that mitochondria have been connected to ferroptosis, we sought to evaluate whether OXPHOS in Tregs regulates their sensitivity to ferroptosis. To investigate whether perturbing OXPHOS in Tregs may induce ferroptosis, we separately inhibited mitochondrial complex I, II, III, or IV with established inhibitors of each complex (Gao et al. 2019), with or without Fer-1 co-treatment (Fig. 16A). We found that inhibition of mitochondrial complex I resulted in notable cell death that was prevented by co-treatment with Fer-1 , suggesting that complex I is most relevant to ferroptosis sensitivity of Tregs versus other mitochondrial OXPHOS complexes.
[0181] We compared sensitivity to rotenone in stimulated Tregs versus unstimulated Tregs or PBMCs, and found that stimulated Tregs were more sensitive (Figs. 22A and 22B). This corroborated the results from scRNA-seq and GSEA, as well as reports that T cells alter their metabolism upon activation and stimulation (Wang et al. 2011).
[0182] To further assess ferroptosis hallmarks after complex I inhibition in Tregs, we evaluated lipid ROS via C11-BODIPY and observed increased lipid ROS upon rotenone treatment and decreased lipid ROS with Fer-1 co-treatment in all donors (Figs. 16B, 20E and 20F). In summary, these results show that ferroptosis is induced upon complex I inhibition in Tregs via rotenone, highlighting a novel opportunity to induce ferroptosis in Tregs by perturbing OXPHOS, and specifically complex I.PC(22:6; 22:6) induces ferroptosis in Tregs and reduces the suppressive capacity of Tregs
[0183] Recently, diPUFA-PLs were reported to induce ferroptosis in cancer models via targeting mitochondrial complex I (see Example 1). Given our observation that inhibiting complex I via rotenone induces ferroptosis in Tregs, and that rotenone is a pesticide with other toxic effects (Varma et al. 2007) that limit itstranslational potential (Wood et al. 2005), we evaluated the effect of diPUFA-PLs in Tregs, as diPUFA PLs have potential translational dietary utility (see Example 1 ; Liang et al. 2022). We treated Tregs with three different diPUFA-PLs, PC(22:6; 22:6), PC(20:4; 20:4), or PC(18:3; 18:3), and observed that Tregs were sensitive to all three diPUFA-PLs; cell death was induced in a dose-dependent manner. We observed complete prevention of cell death when co-treated with Fer-1 , consistent with ferroptosis as the cell death mechanism (Fig. 17A). Moreover, some studies have suggested increased oxidative metabolism in CD4+T cells over CD8+T cells, and increased oxidative metabolism in Tregs compared to Tconv cells (Beier et al. 2015; Cao et al. 2014; Howie et al. 2017). We therefore tested whether there were marked differences in the sensitivities of Tregs, CD8+T cells, and Tconv to the diPUFA-PL PC (22:6; 22:6) and other compounds (Figs. 22C-22F). We observed that in some donors, the Tregs appeared to be more sensitive to PC (22:6; 22:6). Given our Treg-focused system, we decided to continue to probe the diPUFA-PL mechanism in this context as potential ferroptosis-inducing lipids that target mitochondrial complex I in OXPHOS in Tregs.
[0184] Due to concerns about arachidonic-acid(20:4)-induced inflammatory responses (Jang et al. 2020) and that PC(22:6; 22:6) is more potent than PC(18:3; 18:3), we focused on PC(22:6; 22:6) to further probe the ability of diPUFA-PLs to induce ferroptosis in Tregs. We observed that PC(22:6; 22:6) induced lipid ROS in Tregs, noted by the rightward peak shift and that co-treatment with Fer-1 resulted in a leftward peak shift relative to PC(22:6; 22:6) alone (Figs. 17B and 21 A).
[0185] The mechanism by which diPUFA-PLs induce ferroptosis is unclear, beyond interacting with complex I. We hypothesized that diPUFA-PLs might cause complex I disruption, resulting in release of labile iron from iron-sulfur clusters. We thus investigated whether PC(22:6; 22:6) treatment caused an increase in the labile iron pool (LIP). To that end, we used calcein-AM, a probe that is quenched in the presence of labile iron and consequently results in a leftward peak shift (Gederico et al. 2022; Wang et al. 2021), to analyze Tregs after treatment with ferric ammonium citrate (FAC), as a positive control (Fig. 21 C). We observed the expected leftward peak shift under FAC treatment and a rightward peak shift when co-treated with deferoxamine mesylate (DFO), an iron chelator; we subsequently investigated the effect of PC(22:6; 22:6) on the LIP using this method. We observed that PC(22:6; 22:6) treatment indeed resulted in an increase in the LIP based on the leftward peakshift, and that co-treatment with DFO resulted in a rightward peak shift relative to PC(22:6; 22:6) treatment alone (Figs. 17C and 21 B) Thus, PC(22:6; 22:6) likely disrupts complex I to release labile iron, which promotes ferroptosis.
[0186] We found that PC(22:6; 22:6) treatment resulted in the upregulation of Slc7a11 and Chad gene expression, two established pro-ferroptosis markers (Fig. 17D) (Zhang et al. 2019). In addition, we validated that PC(22:6; 22:6) targets complex I in Tregs via a streptavidin-immunoprecipitation experiment and subsequent western blot with complex I antibodies (Fig. 21 D). These results show that in Tregs, the diPUFA-PL PC(22:6; 22:6) induces ferroptosis via binding complex I and causes release of labile iron.
[0187] We then investigated the effect of PC(22:6; 22:6) on the suppressive capacity of Tregs, independent of its effect on viability. We pre-treated Tregs with vehicle control or 20 pM PC(22:6; 22:6) ± Fer-1 for 24 h. This condition was determined based on testing different pre-treatment concentrations over a 24 hour period and using C11-BODIPY as our readout, to determine the optimal concentration that would yield a pro-ferroptosis hallmark with sufficient viable cells. We then performed a suppression assay, co-culturing pre-treated Tregs with Tresps for 72 h, and assessed the suppressive capacity of Tregs, based on the proliferation of Tresps (Fig. 17E). We found that Tresps, including both Tconv and CD8+T cells, proliferated more when co-cultured with Tregs pre-treated with PC(22:6; 22:6) compared to that of Tresps co-cultured with Tregs pre-treated with the vehicle control or with PC(22:6; 22:6) + Fer-1 (Figs. 17E and 21 E). These findings reveal that even before inducing cell death, PC(22:6; 22:6) blocks the suppressive activity of Tregs, highlighting that driving Tregs towards ferroptosis impairs their immunosuppressive activity even before overt cell death occurs.
[0188] Collectively, these results support a model in which PC(22:6; 22:6) induces ferroptosis in Tregs via targeting of mitochondrial complex I, and hinders the suppressive capacity of Tregs. These data highlight the potential therapeutic utility of PC(22:6; 22:6) for targeting Treg metabolism.Investigating Treg OXPHOS signatures in human breast cancers
[0189] We sought to investigate the role of Treg OXPHOS in disease settings to determine whether PC(22:6; 22:6) might have therapeutic potential for eliminating Tregs. We analyzed spatial transcriptomic data from primary estrogen receptor-(ER)-positive breast cancer tissues (He et al. 2024). We computed the OXPHOS signature expression in all spots with more than 10% predicted Tregs upon deconvolution with Starfysh (57), and further computed their distance to the intratumoral region. This analysis revealed elevated expression of OXPHOS signatures in Tregs with proximity to the tumor (Figs. 18A and 18B), suggesting that Treg OXPHOS is enriched in the tumor microenvironment (TME). This result suggests that it may be possible to target Tregs in such breast cancers.
[0190] To further examine the OXPHOS signature in Tregs associated with cancers compared to peripheral circulating Tregs, we analyzed gene expression via RNAseq in Tregs in the TME compared to Tregs from peripheral blood in patients with primary breast cancer (Fig. 18C) (Plitas et al. 2016). DGE analysis revealed upregulation of OXPHOS genes in Tregs from the TME compared to Tregs from the peripheral blood (ATP6V1A, ATP6V1 B2, ATP6V1C1, ATP6V1C2, ATP6V1 D, NDLIFB3, COX7A1 , SDHD). Coupling the results from both the spatial analysis of ER+breast cancer tissues and the DGE analysis between TME-Tregs and Tregs from peripheral blood in primary breast cancer, we find that OXPHOS is specifically enriched in Tregs associated with these breast cancers and therefore that PC(22:6; 22:6) may be beneficial in targeting OXPHOS in tumor-infiltrating Tregs to restore immune tumor surveillance in such breast cancers.Discussion
[0191] The data reported illuminate an opportunity to drive ferroptosis in Tregs by targeting OXPHOS, an enriched metabolic pathway in Tregs and therefore a vulnerability to exploit. Inhibition of mitochondrial complex I in OXPHOS via PC(22:6; 22:6), a diPUFA-PL, induces ferroptosis in Tregs. Moreover, our findings complement the recent mechanistic insights reporting diPUFA-PLs as ferroptosis drivers in cancer cells (see Example 1). Overall, this work highlights an important role of mitochondrial complex I in regulating ferroptosis in Tregs and reveals the therapeutic potential of PC(22:6; 22:6) as a ferroptosis driver in Tregs.
[0192] We observed that Tregs were sensitive to RSL3 in a dose-dependent manner and were rescued by co-treatment with Fer-1 , consistent with a study investigating GPX4 in Tregs (Xu et al. 2021). From scRNA-seq and GSEA, we found OXPHOS as the top metabolic pathway enriched in activated Tregs compared toresting cell types in PBMCs, complementing existing reports suggesting Tregs increase oxidative metabolism upon activation and that OXPHOS is essential for the suppressive function of Tregs (Beier et al. 2015; Howie et al. 2017; Shi et al. 2023). Of all the mitochondrial electron transport chain (ETC) complexes, we found that complex I has the greatest representation in the list of enriched OXPHOS genes in Tregs, suggesting a key role of mitochondrial complex I in Tregs. Moreover, we observed that specifically targeting complex I via rotenone induces ferroptosis in Tregs. This finding is consistent with studies that suggested that mitochondria play an important role in ferroptosis and that mitochondrial ROS produced by complex I leads to ferroptosis (Basit et al. 2017; Gao et al. 2019; Lyamzaev et al. 2023; Mbah and Lyssiotis, 2022; Oh et al. 2022).
[0193] Recently, it was reported that diPUFA-PLs are drivers of ferroptosis via inhibition of mitochondrial complex I (see Example 1). Given the poor translational potential of rotenone (Wood et al. 2005), our finding that PC(22:6; 22:6), a diPUFA- PL, induces ferroptosis in Tregs via inhibition of complex I illuminates a new approach to disrupt Treg metabolism. PC(22:6; 22:6) leads to increased lipid ROS and increases the LIP. The observed increase in the LIP as a result of PC(22:6; 22:6) treatment is likely the consequence of complex I targeting. It has previously been reported that complex I inhibition in dopaminergic neuroblastoma cells results in increased levels of transferrin receptor I (TfR1 ) and the LIP (Urrutia et al. 2017). Moreover, in cancer models, TfR1 has also been associated as a pro-ferroptosis marker (Feng et al. 2020) and diPUFA-PL treatment has been reported to result in the increase in TfR1 expression (see Example 1). Taken together, these studies are consistent with our finding that that PC(22:6; 22:6) inhibits complex I, inducing ferroptosis in Tregs and leading to an increase in the LIP. Additionally, it is known that OXPHOS is essential for Treg immunosuppression (Beier et al. 2015; Howie et al. 2017), strengthening our findings that inhibition of OXPHOS via PC (22:6; 22:6) weakens the immunosuppressive capacity of Tregs. Collectively, our work suggests that PC(22:6; 22:6) reduces Treg viability and function.
[0194] While this model focuses on Tregs isolated from healthy PBMCs, the broader aim is to target Tregs in the TME. One of the hallmarks of many aggressive and drug-resistant cancers is the high infiltration of pro-tumorigenic, immunosuppressive Tregs in the TME (Huang et al. 2021 ; Humphries et al. 2010; Tang et al. 2014; Sayour et al. 2015); thus, targeting Tregs in the TME is of interestto promote tumor surveillance and anti-cancer immune responses. However, the primary concern in Treg-targeted therapeutic approaches is the issue of autoimmunity (Dees et al. 2021 ).
[0195] To that end, several studies identified key differences between tumorinfiltrating Tregs (Tl-Tregs) versus peripheral or splenic Tregs, highlighting opportunities to specifically target Tl-Tregs. In the context of ferroptosis, intratumoral Tregs in mice bearing B16 melanoma show greater expression of GPX4 and elevated levels of lipid peroxides compared to splenic Tregs, which suggests that intratumoral Tregs may possess a more pro-ferroptosis profile (Xu et al. 2021). Tregs in the TME also reprogram their metabolism to support survival in the harsh conditions of the TME. Tl-Tregs increase uptake of glutamate in the TME and have higher lipid content compared to splenic counterparts (Long et al. 2020; Pacella et al. 2018). In mice bearing GL-261 glioblastoma, Tl-Tregs have elevated expression of CD36, a fatty acid transporter, compared to peripheral Tregs (Miska et al. 2019). Moreover, ablation of CD36 in Tregs impairs OXPHOS activity and specifically hinders Tl-T reg-mediated immunosuppression. PD-1 immune checkpoint blockade therapy synergizes with CD36 Treg-specific ablation (Wang et al. 2020). Furthermore, Tl-Tregs reprogram their metabolism via FoxP3 to upregulate OXPHOS, creating a metabolic advantage to survive low-glucose conditions of the TME (Angelin et al. 2017). Our analyses of breast cancer datasets, both spatial and RNAseq, also suggest that Tl-Tregs upregulate OXPHOS (He et al. 2024; Plitas et al. 2016).
[0196] These studies highlight the therapeutic strategy of targeting Tl-T reg metabolism to promote cancer clearance and immunotherapy efficacy, reducing concerns of autoimmunity. Specifically, reports suggesting that OXPHOS is essential for the suppressive function of Tregs (Beier et al. 2015; Howie et al. 2017), and that Tl-Tregs upregulate OXPHOS to survive the harsh TME (Wang et al. 2020; Angelin et al. 2017), further support the therapeutic potential of PC(22:6; 22:6) to preferentially target Tl-Tregs. Moreover, it has been suggested that dietary PLIFAs promote formation of PUFA-containing phospholipids (Liang et al. 2022), suggesting that future studies may explore translational dietary therapeutic approaches of free PUFAs as well as PC(22:6; 22:6). Additionally, exogenous DHA(22:6)-containing PLs have been studied in in vivo contexts of neurodegenerative disease models, cancer models, and in children with ADHD (Zhang et al. 2020), highlighting the lowtoxicity of DHA-PLs and breadth of efficacy studies that already exist. Taken together, these studies support the translational potential of PC(22:6; 22:6). Future studies may also explore PC(22:6; 22:6) in combination with immune checkpoint inhibitors, to improve immunotherapy efficacy in cancers with high Treg infiltration.
[0197] In summary, this study illuminated PC(22:6; 22:6) as means to induce ferroptosis in Tregs via targeting of mitochondrial complex I, highlighting novel applications of diPUFA-PLs, and a new opportunity to modulate Treg metabolism to drive ferroptosis for therapeutic benefit.Example 3Persister cells accumulate diPUFA lipids to drive ferroptosis sensitivity
[0198] Mounting evidence implicates persister cancer cells as the key element of minimal residual disease (MRD) from which cancer relapse occurs (Ramirez et al. 2016; Rambow et al. 2018; Vallette et al. 2019; Hammerlindl and Schaider, 2018; Sanchez-Danes et al. 2018; Maynard et al. 2020). The observation that persisters are differentially and specifically sensitive to ferroptosis, a unique form of metabolically-driven cell death, presents a critical weak point through which identification and targeting of persister cells in MRD may become possible (Hangauer et al. 2017). To identify biomarkers for targetable cells, the drivers of ferroptosis sensitivity in persister cells must be identified. Using three chemotherapeutics and cell lines, we derived persister models across diverse tissues of origin and found that activating transcription factor 4 (ATF4), previously demonstrated as central to lung cancer persister state formation, is differentially expressed in prostate and fibrosarcoma persisters vs parentals, proteins key to ferroptosis are underexpressed in persisters, and revert expression upon persister to parental reversion, the persister lipidome is significantly rewired to drive ferroptosis by accumulating diPUFA phospholipids, upon persister to parental reversion and reacquisition of ferroptosis resistance the lipid signature also reverts back to a parental-like state, and although ATF4 elimination in persisters does not revert ferroptosis sensitivity, mitochondrial elimination in persisters does abrogate ferroptotic sensitivity. Collectively, these findings reveal the mechanism driving persister ferroptosis sensitivity across multiple cancer types, opening up the possibility of leveraging ferroptosis for elimination of minimal residual disease.
[0199] “Persistent” cancer cells were initially identified as a slowly cycling or non-cycling drug-tolerant state achieved by a subpopulation of cells across immortalized cancer lines under pressure of a chemotherapeutic agent (Sharma et al. 2010). Recently, the weight of the evidence highlighting persister state cells as key drivers of MRD maintenance and eventual cancer recurrence has grown (Ramirez et al. 2016; Rambow et al. 2018; Vallette et al. 2019; Hammerlindl and Schaider, 2018; Sanchez-Danes et al. 2018; Maynard et al. 2020), and the ability to identify and target this small but crucial subpopulation of cells holds potential for preventing cancer relapse. However, identification and targeting of persister cells remains challenging.
[0200] Although the persister state has been identified and explored across multiple tissues of origin in immortalized cancer cells (Vinogradova et al. 2016; Raha et al. 2014; Rehman et al. 2021), the mainstay of persister research has been in the non-small cell lung carcinoma (NSCLC) cell line PC9 (Mikubo et al. 2021), in which it was demonstrated that a cascade initiated by mini-mitochondrial outer membrane permeabilization (mini-MOMP) and culminating in upregulation of activating transcription factor 4 (ATF4) drives PC9-derived persister (PSPC9) state formation (Kalkavan et al. 2022). Moreover, it was in a PC9 / PSPC9system that sensitivity of persisters to ferroptosis, a unique lipid peroxidation-driven iron dependent form of non-apoptotic cell death, was discovered (Hangauer et al. 2017; Dixon et al. 2012; Hadian et al. 2023).
[0201] Ferroptosis sensitivity of persister cells and the role of ATF4 in ferroptosis has been established (Dixon et al. 2014), but little is known about how persister ferroptosis sensitivity arises in the first place, how it is maintained during the persister state, and how it is lost when persisters revert to parental-like cells.
[0202] In this Example, we revealed the mechanism driving and maintaining persister cell ferroptosis sensitivity. Utilizing NSCLC, lymph node carcinoma of the prostate (LNCaP), and fibrosarcoma-(HT1080)-derived persisters, we: 1 ) assess key elements of the protein signature of persister cells relevant to ferroptosis, and how those change upon reversion of the persister state, 2) identify crucial transcriptional pathways differentiating persister and parental cells, 3) highlight specific lipid profile changes between persister and parental cells and what happens to the lipid profile upon re-derivation of parental cells, and 4) eliminate upstream and downstreamplayers of the mini-MOMP cascade directly in persister cells, demonstrating how such blockade affects persister ferroptosis sensitivity.METHODSCell Culture and persister derivation
[0203] PC9s and PSPC9. PC9 (Millapore Sigma, #90071810-1 VL) from European Collection of Authenticated Cell Cultures (ECACC) were cultured in RPMI- 1640 medium (ATCC, #30-2001 ) with 10% FBS (Thermo Fisher Scientific, #16140071 ) and 1 % Pen / Strep (Thermo Fisher Scientific, #15140163) in 5% CO2 at 37 °C. To derive PSPC9, PC9 were trypsinized (Invitrogen, #25200-114), counted via VI-CELL analyzer (Beckman Coulter) and replated in 10 cM tissue culture treated dishes (Corning Falcon, #353003) with 15 pM erlotinib (Selleck Chemicals, #S7786) in same media described above for a minimum of 3 days. Media with drug were fully changed every 3 days regardless of culture length. Cycling PSPC9cells are a subset of PSPC9that eventually undergo cell cycle in the presence of erlotinib.
[0204] LNCaPs and PSLNCaP. LNCaPs were cultured in RPMI-1640 medium with 10% FBS and 1 % Pen / Strep in 5% CO2 at 37 °C. To derive psLNCaP, LNCaP were trypsinized, counted via VI-CELL analyzer and replated in 10 cM tissue culture treated dishes with 15 pM enzalutamide (Selleck Chemicals, #S1250) in same media described above for a minimum of 3 days. Media with drug were fully changed every 3 days regardless of culture length. Cycling psLNCaPcells are a subset of psLNCaPthat eventually undergo cell cycle in the presence of enzalutamide.
[0205] HT1080S YFP-Parkin and PSHT108°. HT1080s expressing YFP-Parkin were cultured in Eagle’s Minimum Essential Media (EMEM) (Quality Biological, #12- 018-131 ) with 10% FBS and 1 % Pen / Strep in 5% CO2 at 37 °C. To derive psHT108°, HT1080s were trypsinized, counted via VI-CELL analyzer and replated in 10 cM tissue culture treated dishes with 100 nM doxorubicin (ApexBio, #A3966) in same media described above. Media with drug were fully changed every 3 days regardless of culture length. Unless specified otherwise, all HT1080s and psHT108° were cultured in the presence of Zeocin (Thermo Fisher Scientific, #R25005) at 400 pg / mL to maintain selective pressure for Parkin expression.
[0206] For Mitochondrial elimination, HT1080s of PSHT1080were cultured as described above. After 5 days in culture, psHT108° had 12.5 pM of CCCP (CaymanChemical, #25458) directly added to the 10 cM plates, incubated for an additional 48hrs in conditions described above. Cohorts of HT1080s receiving CCCP were simultaneously trypsinized, counted, replated in 10 cM format, and subject to same CCCP treatment conditions. After 48hrs, cells were trypsinized, counted, and used in follow on experiments in CCCP free media.
[0207] For all cells. Mycoplasma tests (InvivoGen, #rep-mys-50) were routinely performed to ensure cell culture quality and cells were passaged no more than 20 passages. Given differing time scales of experiments, specific length of culture for PS of all tissue variants is specified per experiment (see below). Unless specified otherwise, all 10 cM dishes used to seed and maintain PS of all types were initially seeded at 1x106cells per dish with immediate addition of relevant drug.
[0208] All 10 cM PS cultures were maintained as separate biological replicates, derived from varying parental passage numbers, and often kept in separate incubators when space allowed. To generate sufficient number of PS for any given experiment, the necessary quantity of 10 cM dishes was generated and separately maintained. Separate cultures were then pooled if necessary, counted, and plated into appropriate format (e.g., 24 well, 96 well, etc.) for follow on technical experimental procedure.FACS sorting
[0209] PC9 and PSPC9were cultured as described above. For PSPC9, cells were kept in media with erlotinib for ~6 days. At ~6 days, PSPC9cells and a cohort of PC9 cells were trypsinized, washed with HBSS (Thermo Fisher Scientific, #14025092), counted via VI-CELL, and 2x106cells per condition were blocked with 10% goat serum (Thermo Fisher Scientific, #50062Z) for 30 - 60 minutes, stained with PE conjugated CD24 (BioLegend, #311106), APC conjugated CD133 (BioLegend, #372806), and sytox blue (Thermo Fisher Scientific, #S34857) as per recommended vendor guidelines, then incubated in 5% CO2, 37 °C in the dark. Cells were then re-suspended in HBSS. FACS was performed on a BD Influx cell sorter using BD-FACS™ (version 7.5.1.3.16) for data acquisition. FlowJo software (version 10.9.0) was used for analysis. Gating was conducted on 1x105events per condition (persister vs parental) with FSC vs SSC followed by BV421 to confirm live vs dead cells prior to PE-CD24 vs APC-CD133 analysis.Lipid ROS detection
[0210] Persister cells were derived as described above. On day ~6 (between 5 - 8 days) of persister culture, both persister and a parental cell cohort were trypsinized, counted, and equal numbers were then replated in 10 cM dishes and treated with DMSO, RSL3, and Ferrostatin-1 at concentrations, combinations, and time points indicated in figure at 5% CO2, 37 °C. Cells were then collected, spun down at 300 xg for 5 min, washed with HBSS, and incubated with HBSS containing 2.5 pM C11-BODIPY581'591(Invitrogen D-3861) at 5% CO2, 37 °C for 30 min in the dark. After incubation, cells were once again spun down, washed with HBSS, and resuspended in fresh HBSS for flow cytometry analysis via Beckman CytoFLEX System B4-R0-V0 flow cytometer. Samples were detected with excitation at 488 nm and emission at FITC channel with 525 / 40 nm bandpass filter for oxidized C11- BODIPY. At least 10,000 events after gating were collected for each sample. Flow cytometry data were processed in FlowJo (version 10.9.0). Cells were gated for live cells in SSC-H vs FSC-H plot.Cell viability assays
[0211] CellTiter-Glo luminescence assay. Persisters were derived as described above. At 48hrs prior to CellTiter-Glo (CTG, Promega, G7573) addition, persister cells and a matching parental cohort were trypsinized, washed with HBSS, counted, and replated in either 24 (PerkinElmer, #6005168) or 96 (Thermo Fisher Scientific, #136101 ) well format at 50,000 cells or 10,000 cells per well, respectively. Relevant compounds and controls as specified in each figure were added at concentrations indicated, final volume 1 mL / well and 200 pL / well for 24 and 96 well plates, respectively. After 48hr incubation in 5% CO2, 37 °C, CTG was added directly to all wells at 175 pL / well or 35 pL / well for 24 and 96 well plates, respectively. Plates were then placed on orbital shaker for ~15 minutes on low-speed setting, and luminescence was measured using a Victor X5 plate reader (PerkinElmer). All cell viability data were normalized to the DMSO vehicle condition. DMSO concentration did not exceed .3% for any experiment and always matched greatest % DMSO for any combination drug treatment. GraphPad Prism (version 10) was used for visualization and statistical analysis.
[0212] Vi-cell trypan exclusion dye cell counter. Persisters were derived as described above. At time points indicated in figures, cells were trypsinzed, spun down at 300 xg in a Sorval ST40 centrifuge (Thermo Fisher Scientific) for 5 minutes,resuspended in HBSS, and counted via VI-CELL. GraphPad Prism (version 10) was used for visualization and statistical analysis.
[0213] Geimsa Staining. Persisters were derived as described above. Parental cohort of same cell type was timed to be ready to stain on same day as persister cohort. 3.8 g Giemsa powder (Sigma-Aldrich, #G9641-5G) was added to 250 mL methanol (Honeywell, #34966), heated to 60 °C, and 250 mL glycerol (Sigma-Aldrich, #G5516) was added slowly. Solution was cooled, filtered, and aliqouts for use were dissolved in PBS to final concentration of -10% Giemsa.
[0214] At time of staining, cells were first washed with -3 mL methanol for 5 minutes, the methanol siphoned off, and then incubated with 10% Giemsa for -30 minutes on orbital rotator with low setting. When ready, Giemsa reagent was siphoned off, and 10 cells were either photographed against a white background using smart phone camera or imaged using a ChemiDoc MP (BioRad) on using 590 / 110 nm Coomassie blue setting.Western Blot
[0215] Persisters were derived as described above, along with relevant parental cohorts. Once collected via trypsinization, cells were spun down, resuspended in HBSS and counted. Equal numbers of cells per condition were then aliquoted, washed again with HBSS, pelletized at 300 xg for 5 min, lysed in 80 pL RIPA buffer (Thermo Fisher Scientific, #89901) containing protease inhibitor cocktail (Sigma-Aldrich, #11697498001 ) and incubated on ice for 20 min. Lysate was centrifuged at 17,000 xg for 15 min 4 °C. Supernatant was transferred into a new tube and BSA assay performed, followed by normalization of all conditions for both protein concentration and volume. 4x Laemmli buffer containing 125 pM DTT (Cell Signaling Technology, #7722S) was added to all samples with follow on and incubation at 100 °C for 10 min. An equal amount of protein in the range of 45 - 80 pg was loaded in each lane of the NuPAGE 4-12% Bis-tris gel (Thermo Fisher Scientific, #WG1401) and transferred onto nitrocellulose membranes (Thermo Fisher Scientific, #IB23002) using iBlot2 (Invitrogen) electrophoretic semi-dry western blot transfer system. Membranes were blocked with PBS blocking buffer (LI-COR Biosciences, #927-70001) for 1 hr at room temperature and incubated with primary antibody diluted in 1 :1 PBS-T (PBS with 0.1 % Tween20): blocking buffer at concentration of 1 :250 for protein of interest or 1 :5000 for control, overnight at 4 °C.Primary antibodies used were ATF4 rabbit mAb (Cell Signaling, #11815), GPX4 rabbit mAb (Abeam, #125066), GCH1 rabbit (Bethyl Laboratories, # A305-296A-M, product has since been discontinued), and fi actin mouse mAb (Cell Signaling, #3700T). Membranes were washed three times in PBS-T and then incubated with secondary antibodies IRDye 800CW goat anti-rabbit IgG (LI-CORBiosciences, #926- 32211) and IRDye 680RD donkey anti-mouse IgG (LI-COR Biosciences, #926- 68072) diluted at 1 :5,000 and 1 :20,000 respectively, in 1 :1 PBS-T: blocking buffer for 1 hr at room temperature. Membrane was washed five times in PBS-T and imaged on LI-COR Odyssey infrared imaging system. Images were collected and optimized contrast settings using the Image Studio software. Fiji 2 software (version 2.9.0 / 1.53t) was used for quantification.Bulk RNAseq
[0216] Data collection. Persisters were derived and collected along with parental cohorts. After washing with HBSS, total RNA was extracted from cells using the AHPrep DNA / RNA Isolation Kit (Qiagen, #80204). Total RNA was then quantified using a NanoDrop™ Lite Spectrophotometer (Thermo Fisher Scientific, #ND-LITE- PR).
[0217] Upon RNA quality verification via bioanalyzer, poly-A pull-down was used to enrich mRNAs from total RNA samples, and library construction was performed using Illumina TruSeq chemistry. Libraries are then sequenced using Element AVITI at Columbia Genome Center with multiplex samples in each lane, yielding approximately 40M paired-end 75bp reads for each sample. bases2fastq (version 1.1.0) was used for converting BCL to fastq format, coupled with adaptor trimming. FASTP (version 0.23.3) (Chen et al. 2018) was used for read quality control using default settings and Kallisto (version 0.46.1) (Bray et al. 2016) was used to perform pseudoalignment with bootstrapping to an index created from transcriptomes (Ensembl v96, Human:GRCh38.p13).
[0218] Combining data, batch effect identification and correction. Three sets each of randomly selected parental and persister fastq files were downloaded off GEO (accession GSE189625, SRRs 69,71 ,73,75,77, 115, 117, 119, 127, 129, 131 ) and put through the same software pipeline as data described above. We used Sleuth (version 0.30.0) (Pimentel et al. 2017) for DGE analysis. Briefly, a likely hood ratio test and a Wald test with b statistic modified to be mathematically equivalent toIog2 of the fold change were performed between two models (reduced and full) in transcript and gene mode. Although Sleuth 0.30.0 offers option to aggregate on p- value from transcript differential expression, in order to identify and correct for batch effect but keep a measure of effect size via fold change (specifically, the wald statistic) for follow incorporation into GSEA ranking along with significance, we assessed and corrected for batch effect as described in previous version of Sleuth online tutorial. A batch-naive full vs reduced model was fit, and PCA analysis of top 3 principal components revealed a batch effect in PC1 vs PC2. A second model specifically taking batch as a covariate into account for full model vs reduced model was fit, and the differences between naive vs batch corrected analysis quantified as described in tutorial. All subsequent analysis was performed on batch corrected data.GSEA of combined batch corrected data
[0219] The full list of genes from DGE analysis was then ranked by incorporating p-value and fold change (b statistic of wald test modified to be mathematically equivalent to fold change) using formula: -logio(p.value)*log2(PC). GSEA was performed on the ranked list utilizing KEGG database in FGSEA method (Kanehisa and Goto, 2000; Korotkevich et al. 2021 ) clusterProfiler (version 4.6.2) (Wu et al. 2021 ; Yu et al. 2012) and parameters described in main text.Untargeted lipidomicsLipidomic sample preparation
[0220] Persisters were generated as described above. 15- and 34-day PC9PS -”PC9cohorts were timed to be ready to collect at same time as ~ 6 day persisters, along with cohort of parental cells. All cells were maintained in 10 cM dishes, passaged as necessary to avoid over confluence for 15- and 34-day PC9ps _> PC9. For lipid extraction, cells were scraped in 3 ml_ of ice-cold PBS containing butylated hydroxyl toluene (BHT, 0.001 % w / v in ethanol) and transferred to pre-cold 5-mL tubes. After vortexing, a 300 pL aliquot was taken for protein analysis and the remaining volume (approximately 1.7 mL) was centrifuged at 350 x g for 5 min at 4°C. After centrifugation, the supernatant was aspirated, and the pellet was stored at -80°C. In the next day, samples were mixed with 1 pl of SPLASH lipidomics internal standard mix (Avanti Polar Lipids, Inc.) with a microtip solicitor. After homogenization, samples were transferred to glass vials containing 850 pl of cold methyl-tert-butyl ether (MTBE) and vortex-mixed for 30 s. A 2 h incubation (on ice)was performed to improve the lipid extraction efficiency. Thereafter, 200 pl of ice- cold water were added and the samples were incubated on ice for 20 min. After centrifugation (3,000 r.p.m. for 20 min at 4 °C), the lipid-containing upper phase was collected and dried down under a gentle stream of nitrogen gas. A mixture of 2- propanol / acetonitrile / water (4:3:1 , v / v / v and 0.01 % butylated hydroxytoluene) was used to reconstitute the dried samples before liquid chromatography-mass spectrometry (LC-MS) analysis. A quality control sample was prepared by combining 40 pl of each sample to assess the reproducibility of the features through the runs.
[0221] LC conditions. Lipids were separated using an Acquity LIPLC CSH column (2.1 x 100 mm, 1.7 pm) over a 20-min gradient elution on a Waters Acquity UPLC l-Class system. Mobile phases A [acetonitrile / water (60:40, v / v)] and B [2- propanol / acetonitrile / water (85:10:5, v / v / v)] contained 0.1 % acetic acid and 10 mM ammonium acetate. Following the injections, the gradient was held at 40% mobile phase B for 2 min. At 2.1 min, it reached to 50% B, then increased to 70% B in 12 min, at 12.1 min changed to 70% B and at 18 min increased to 90% B. The eluent composition returned to the initial condition in 1 min, and the column was reequilibrated for an additional 1 min before the next injection was conducted. The oven temperature was set at 55 °C and the flow rate was 400 pl min-1. The flow- through needle mode was used to allow for injections of 6 pl. The quality control sample was injected between the samples and at the beginning and end of the run to monitor the performance and the stability of the MS platform.
[0222] MS conditions. The SYNAPT G2-Si -Q-ToF mass spectrometer was operated in both positive and negative electrospray ionization modes. For the positive mode, a capillary voltage and sampling cone voltage of 2 kV and 32 V were used. The source and desolvation temperatures were kept at 120 and 500 °C, respectively. Nitrogen was used as the desolvation gas with a flow rate of 8001 h-1. For the negative mode, a capillary voltage of 1.5 kV and a cone voltage of 30 V were used. The source temperature was 120 °C and the desolvation gas flow was set to 8001 h-1. Depending on the ionization mode, the protonated molecular ion of leucine encephalin ([M + H]+, mass to charge ratio (mlzy. 556.2771 ) or the deprotonated molecular ion ([M - H]-, m / z: 554.2615) was used as a lock mass for mass accuracy and reproducibility. The data were collected in duplicates in data-independent (MSE) mode over the mass range m / z: 50 to 1 ,200 Da. The quality control sample was alsoacquired in enhanced data-independent ion mobility (HDMSE) in both positive and negative modes for enhancing the structural assignment of lipid species. The electrospray ionization source settings for ion mobility were the same as described above. The travelling wave velocity was set to 650 m s~1and the wave height was 40 V. The helium gas flow in the helium cell region of the ion-mobility spectrometry cell was set to 180 ml min-1. Nitrogen, used as the drift gas, was held at a flow rate of 90 ml min-1in the ion-mobility spectrometry cell. The low collision energy was set to 4 eV and the high collision energy was ramped from 25 to 60 eV in the transfer region of the T-Wave device to induce the fragmentation of mobility-separated precursor ions.
[0223] Untargeted lipidomic data preprocessing and analysis. The structural elucidation and validation of significant features were firstly obtained by searching monoisotopic masses against the available online databases, such as METLIN, Lipid MAPS and HMDB with a mass tolerance of 5 ppm. Fragment ion information obtained by tandem MS (UPLC-HDMSE) was used for the further structural elucidation of significantly changed lipid species. HDMSE data were processed using MSE data viewer (version 1 .3, Waters Corp). Raw data files were processed in Progenesis QI software. Multivariate and univariate statistical analyses were performed using MetaboAnalyst (version 5.0) (Pang et al. 2022) and also a local implementation in an R environment (Pang et al. 2020). Group differences were calculated using one-way ANOVA. P values were corrected for multiple hypothesis testing and an FDR of 0.05 or less was considered significant.
[0224] Targeted Lipidomics. Standards were acquired from Avanti Polar Lipids (PC 18:2_18:2, #850385C; PC 22:6_22:6, #850400C ; PC 20:4_20:4, #850397C) and suspended in the same 4:3:1 mixture as samples described in untargeted section. Standards were run during the prostate carcinoma and fibrosarcoma LC-MS experiment under identical conditions described in untargeted section. Quantification of lipid abundance was performed via TargetLynx within MassLynx (version 4.2) and statistical analysis and visualization performed in GraphPad Prism (version 10). siRNA
[0225] Cells were transfected with Lipofectamine RNAiMAX Transfection Reagent (Thermo Fisher Scientific #13778075) by reverse transfection according to the manufacturer’s protocol. In brief, 80 pmol of siRNA ON-TARGETplus HumanATF4 siRNA SMARTpool (Dharmacon, #L-005125-00-0005) or ON-TARGETplus non-targeting control siRNA, (Dharmacon, #D-001810-01-05) and 15 pL Lipofectamine RNAiMAX (Thermo Fisher Scentific, #13778075) were mixed in 2 mL Opti-MEM reduced serum medium (Life Technologies, #31985) at room temperature for 30 min. Then 1x106cells in 8 mL media were mixed with 2mL transfection reagent and added to 10 cM dish. After 48 hr, cells were collected for follow on assay use.CRISPR / Cas9 ATF4 KO
[0226] Cas9 and ATF4 sgRNA expressing plasmid (ABM, #126101110595) was heat shock transformed into DH5a competent e. coli cells (Thermo Fisher Scientific, #18258012), with follow on selection and expansion via ampicillin (IBI Scientific, #IB02040) as per manufacturer recommendations. Bacteria were then Mira prepped (Pronobis et al. 2016) using Qiagen spin mini prep kit (Qiagen, #27104) reagents, and plasmid quantified on nanodrop spectrophotometer (Thermo Fisher Scientific). ATF4 / Cas9 containing virus was then generated using HEK293T: briefly, HEK293T cells (ATCC, #CRL-3216) cultured in DMEM (Cytiva, #SH30243) and 10% FBS were reverse transfected via siRNA protocol described above, but using plasmid concentrations of 5 pg ATF4, 5 pg Gag-Pol (Addgene, # 12260), and 1 pg VSV-G (Addgene, #8454) for every 15 pL Lipofectamine. After 24 hr incubation in 5% CO2 at 37 °C, media was changed to 100% HEK293T media and cells relocated to 5% CO2 at 32 °C. Virus media was collected every 24 hrs for 2 days and pooled. Lenti-X (Takara Bio, # 631231) concentrator was then used as per manufacturer protocol to increase virus concentration to x25, and cells were infected with and maintained in virus containing media for 36 hrs. Upon removal of viral media, cells were maintained in selection agent puromycin (Santa Cruz Biotechnology, #sc-108071A) for duration of experiment time point up to collection and counting for viability assay.Statistics
[0227] Statistical analyses performed using GraphPad Prism 10, Sleuth 0.30.0, clusterProfiler 4.6.2, and Metaboanlayst 5.0 (which software used to analyze which experiment specified in relevant methods section). For each experiment, the particular statistical analysis is detailed in the respective figure legend. Unpaired student’s T-test, one-way ANOVA, or two-way ANOVA withappropriate post-hoc testing was performed on approximately normally distributed data. All statistical testing was two-tailed.Data availability
[0228] The data supporting the findings of this study are available within the paper and its supplementary information. RNA-seq data are available in the NCBI’s GEO database under the accession code (to be put in). Lipidomics data are available in MetaboLights under study number (to be put in).RESULTSPC9 and PSPC9match established literature hallmarks and profiles
[0229] We set out to demonstrate a NSCLC parental / persister system is consistent with established literature hallmarks of PC9 and PSPC9cells. PSPC9are CD24 and CD133 positive over PC9 cells by FACS (Fig. 23A), PSPC9are resistant to erlotinib, but differentially sensitive to ferroptosis over PC9 (Figs. 23B-23C), and PC9 cells rederived from PSPC9upon erlotinib removal (PC9PS _> PC9) re-acquire erlotinib sensitivity, resume accelerated cell cycle over PSPC9, and re-acquire ferroptosis resistance (Figs. 23D-23F).
[0230] These data indicate that this PC9 / PSPC9system is consistent with established literature hallmarks of PC9 and PSPC9cells.PSPC9have overexpressed ATF4 and underexpressed GPX4 and GCH1 vs PC9, and the protein signature reverts upon PSPC9to PC9 reversion
[0231] Given the role of ATF4 in PSPC9state formation and the pivotal function of GPX4 in lipid ROS buildup mitigation and ferroptosis suppression, we measured ATF4 and GPX4 by western blot in PC9 vs PSPC9cells. ATF4 is overexpressed in PSPC9vs PC9, while GPX4 is underexpressed (Figs. 28A-28B). Additionally, GTP Cyclohydrolase 1 (GCH1 ), a protein central to a complementary axis of lipid ROS mitigation recently discovered in the context of ferroptosis (Kraft et al. 2019), was also underexpressed in PSPC9(Fig. 28C).
[0232] Since PC9PS PC9regain their ferroptosis resistance upon erlotinib removal and subsequent passaging, we decided to test if the ATF4, GPX4, and GCH1 protein signature of PC9PS _> PC9reverts as well. ATF4, GPX4, and GCH1 signature reverted in PC9PS PC9cells (Fig. 28D). Moreover, in a direct comparison of PC9, RSPC9, cycling PSPC9(PSPC9cells kept in the presence of chemotherapeutic that have resumed cell cycle), and PC9PS _> PC9, ATF4 was overexpressed in thepersister state regardless of cell cycle rate, but underexpressed in PC9PS PC9back down to levels comparable with erlotinib naive PC9 (Fig. 28E).
[0233] In summary, these data demonstrate that mitigators of ferroptotic cell death are downregulated in PSPC9cells, but regain expression upon PC9PS _> PC9conversion, while simultaneously, upregulated drivers of the PSPC9state revert back down to a treatment naive profile upon erlotinib PC9ps -> PC9conversion.PSPC9viability results and protein signatures generalize to LNCaP-derived persisters (PSLNCaP)
[0234] After treatment with the cytostatic androgen receptor (AR) antagonist enzalutamide, LNCaPs acquire a persister-like growth arrested, ferroptosis sensitive state (PSLNCaP), and the typical rapid-cycling psLNCaPpopulations that become prevalent in culture several weeks later still maintain their ferroptosis sensitivity as well (Fig. 29A). Moreover, lipid-ROS is generated in both LNCaP and psLNCaPupon GPX4 inhibition, prevented by Fer-1 (Fig. 29B), and ATF4 is overexpressed and GPX4 underexpressed in psLNCaPvs LNCaP cells (Fig. 29C). Additionally, upon removal of enzalutamide and passaging in normal media, psLNCaPcells re-enter the cell cycle (Fig. 29D), and upon re-addition of enzalutamide, LNCaPps LNCaPonce again succumb to cell cycle arrest (Fig. 29E) and are sensitive to ferroptosis (Fig.29F)
[0235] Thus, many of the viability and protein signature findings from our PC9 / PSPC9system generalize to LNCaP vs. psLNCaPcells.Transcriptomic analysis of combined persister data reveals metabolism pathways as key differential in PC9 / PSPC9system
[0236] To identify pathways that might underly the ferroptosis sensitivity differential between persister and parental cells, we performed bulk RNAseq on PC9 vs PSPC9. For robustness, we downloaded PC9 and PSPc9fastqs onto Gene Expression Omnibus (GEO), and ran both sets of fastq data through the same analysis pipeline. After identifying and correcting for batch effects (Fig. 30A, Table 2), we performed differential gene expression (DGE) analysis followed by gene set enrichment analysis (GSEA) on the combined data (Figs. 24A-24B). Samples clustered along biological replicates for all significant genes regardless of institution (Figs. 30B-30C), and the top 20 are highlighted in Fig. 24A.
[0237] GSEA (Subramanian et al. 2005; Mootha et al. 2003) website guidelines recommend a false discovery rate (FDR) < 0.25 for exploratory analysis ofa relatively smaller number of gene sets being analyzed using standard parameter settings (phenotype permutation, min to max set size boundaries of ~ 15 to 500, respectively, etc.). Using Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa and Goto, 2000; Kanehisa et al. 2023) and boundaries of 20 to 500, we observed 26 out of ~ 355 human pathways (hsa pathways) enriched in the joint data set (data not shown but available). Additionally, we noticed that regardless of number of re-runs, the majority of these pathways were consistently tied at around FDR ~ 0.13 or lower, including pathways previously identified as differential between persisters and parentals (Kalkavan et al. 2022; Oren et al. 2021), in the same direction as previously observed (e.g., NF-Kappa signaling, cytokine-cytokine receptor interaction, DNA replication). Moreover, we noticed multiple negatively enriched metabolic pathway in PSPC9over PC9, including fructose and mannose, pentose and glucoronate interconversion, galactose, biosynthesis of unsaturated fatty acids, fatty acid metabolism, and cholesterol (Fig. 24B).
[0238] Collectively, these data are both consistent with previous observations and suggest a novel, prominent differential signature in lipid and sugar metabolism between parental and persister cells.Table 2. Comparison of pre and post batch corrected DEG by significance ranking. Targetjd is the ensemble gene identifier. Rank_naive is the rank of the gene by significance pre-batch effect correction, after model fitting; rank_corrected is the rank of the gene by significance post-batch effect correction, after model fitting. Relative difference in position shift calculated as absolute_value(rank_naive - rank_corrected) I (rank_naive + rank_corrected). Showing first page of total of 330 rank shifted genes with initial naive q_val < .05. Sample statistics same as Figs. 24A-24BPSPC9have a ferroptosis-sensitive lipid profile
[0239] Guided by transcriptomics results, we directly interrogated lipid profiles of PC9 vs PSPC9cells via untargeted lipidomics. Globally, with no filtering or statistical significance testing applied, PC9 vs PSPC9samples clustered along biological condition boundaries and displayed stark contrast lipid profile (Fig. 31A). Upon filtering and significance testing, we observed that although PSPC9do contain an abundance of canonical mixed-acyl phospholipids with a single polyunsaturated fatty acyl tail (monoPUFA PLs) relative to PC9, PSPC9are also enriched for a minor class of phospholipids with diacyl polyunsaturated fatty acid tails (diPUFA PLs) (Fig.25A) recently characterized as initiators of ferroptosis execution (Qiu et al., under review). Conversely, PC9 were enriched for phospholipids with mono or completely saturated fatty acid tails. Additionally, we observed an abundance of free PUFAs in PSPC9over PC9, but vice versa for mono and fully saturated free fatty acids (FFA) (Fig. 25B).
[0240] PSPC9thus have a lipidomic profile rich in lipids known to be particularly susceptible to peroxidation and that act as triggers for ferroptosis execution in mammalian cells, whereas PC9 do not.15- and 34-day untargeted lipidomic analysis of PC9, PSPC9, and PC9ps -> PC9reveals ferroptosis favorable lipidome reverts to unfavorable upon reacquisition of ferroptosis resistance.
[0241] To establish whether the lipid profile differential of PSPC9and PC9 is correlated with ferroptosis sensitivity, we conducted a multi time point untargeted lipidomic analysis between PC9, PSPC9, and PC9ps _> PC9at 15 and 34 days: cycling but not yet ferroptosis resistant (Fig. 26E) and cycling and ferroptosis resistant (Fig. 26C), respectively. Untargeted lipidomics reveals PSPC9as distinct from PC9 and both 15- and 34-day PC9PS -> PC9,which cluster together (Fig. 31 B).
[0242] Moreover, nearly all of the PUFA-PLs and FFA observed in figure 3 were again significant and differentially abundant, with a similar lipid signature profile between PSPC9and all other conditions (i.e., PSPC9have elevated diPUFA PLs and free PUFAs relative to PC9s, as well as both 15- and 34-day PC9ps -> PC9(Figs. 26A- 26B). Notably, 15-day PC9PS -> PC9were stj|| sensitive to RSL3 induced ferroptosis, but did not have an elevated diPUFA PLs profile of the species identified here. These findings indicate that in acquiring a ferroptosis sensitive persister state, PSPC9cells undergo a substantial shift in lipid architecture, resulting in a profile particularly susceptible to ferroptosis, and upon exiting the persister state and re-acquiring ferroptosis resistance, PC9PS _> PC9ultimately regain a lipid architecture less favorable to ferroptosis and more similar to treatment naive PC9.
[0243] However, to identify what factors could be driving the ferroptosis sensitivity of 15 day PC9PS _> PC9other than presence of diPUFA PLs, we 1 ) identified significant differentially abundant lipid species between the two ferroptosis sensitive and resistant cell states (PSPC9and 15 day PC9ps -> PC9vs PC9 and 34 day PC9ps ->PC9) (Fig. 26F), highlighting an abundance of ether linked PUFA PLs in ferroptosis resistant cells and depletion in ferroptosis sensitive, and 2) given recent workdemonstrating diPUFA PLs initiate ferroptosis execution through the mitochondria (Qiu et al., under review), sought to assess what factors other than direct lipid composition could also be involved in PC9, PSPC9, and PC9PS _> PC9ferroptosis sensitivity (subsequent section).Mitochondrial elimination in HT1080 derived persisters (PSHT108°) partially reverts ferroptosis sensitivity, and psHT108° and psLNCaPhave elevated diPUFA PLs relative to parental
[0244] Although ATF4 is central to lung and prostate cancer persister state formation and is upregulated in both PSPC9and psLNCaPcells, we found that neither short term siRNA KD nor long term CRISPR / Cas9 KO of ATF4 in PSPC9abrogated PSPC9ferroptosis sensitivity (Figs. 32A-32D). We then decided to explore aspects of persister formation upstream of ATF4 that could also be driving ferroptosis sensitivity. Using Parkin-expressing HT-1080 cells and doxorubicin to induce a ferroptosis-sensitized, non-cycling / barely-cycling persister state (Figs. 33A-33B), we eliminated mitochondria using carbonyl cyanide m-chlorophenyl hydrazone (CCCP) (Figs. 33D-33E), reverted ferroptosis sensitivity from -23% to -54% viability between the two separate assays (Figs. 33B-33C).
[0245] We therefore decided to perform a head-to-head viability assay between PSHT1080and PSHT108° without mitochondria. Upon mitochondrial elimination (Fig. 27A) we observed a near identical abrogation of ferroptosis sensitivity: from -16% to 43% viability (Fig. 27C). Moreover, independent repetition of the experiment in reduced serum media (2.5% FBS vs. previous 10%) sensitized cells to ferroptosis, resulted in similar viability rescue (21 % to 61 %) for psHT1080Mito_cells, did not affect PSHTio80doxorubicin induced death, regardless of mitochondrial presence, and in contract to normal 10% FBS media, did rescue doxorubicin induced cell death in HT1080 Mito- (Fig. 27D and Figs. 34A-34B). Additionally, we assessed ATF4 expression levels, and found ATF4 signature to be opposite of what was observed in the lung and prostate persister systems (Fig. 27B), i.e. , ATF4 was overexpressed in parental cells but underexpressed in persisters.
[0246] Finally, we assessed whether our lipidomics findings were reflected in the HT1080 and LNCaP persister systems. Globally, cells clustered by tissue of origin (Fig. 31C). We simultaneously ran diPUFA PL standards shown to drive ferroptosis (e.g., PC 20:4_20:4) and other diPUFA PLs during LCMS to confirm M / Z values and retention times (RT) in a targeted approach, and observed that 1 ) PC20:4_20:4 was significantly and with a large effect size overabundant in psHT1080vs HT1080, but not for psLNCaPvs LNCaP, 2) PC 18:2_18:2 was significantly and with a large effect size overabundant in psHT108° vs HT1080, but was reversed in abundance for psLNCaPvs LNCaP (albeit with a reduced effect size) and 3) PC 22:6_22:6, though more abundant in fibrosarcoma than prostate carcinoma, was not differentially abundant in either tissue between PS vs parental.
[0247] Together, these data suggest a critical role for mitochondria in at least the maintenance of ferroptosis sensitivity within psHT108°, and raise the intriguing possibility that ATF4 / persister state formation relationship could be modulated differentially across varying cancer types. Moreover, the multi tissue lipidomics analysis collectively highlights the importance of looking at different persister systems through the same analytical lens, and coupled with the mitochondrial data and the work as described in Example 1 , imply an intricate relationship between diPUFA PL abundance, mitochondrial presence, and ferroptosis sensitivity in the persister state.Discussion
[0248] This work illuminates previously unknown aspects of persister ferroptosis sensitivity, both in terms of acquisition and maintenance. Our evidence supports presence of mitochondria (or elements attached to / within) as inextricable factors for maintenance of ferroptosis sensitivity once persister state is achieved. We also found that the persister lipid profile is distinctly primed to undergo ferroptosis via enrichment of diPUFA PLs, as well as free PUFAs. Thus, in compliment with our recent work demonstrating that exogenous addition of diPUFA PLs triggers ferroptosis execution via accumulation in mitochondria (see Example 1 ), our findings here strongly implicate mitochondria (or elements within) as architects of ferroptosis sensitivity within persister cells.
[0249] This position is further strengthened by our observation that neither short term nor long term ATF4 inhibition / elimination in PSPC9- previously shown to be a critical PCPC9formation element downstream of mitochondria - modulated PSPC9ferroptosis sensitivity, but upon re-derivation of parental cells from persister state and re-acquisition of ferroptosis resistance, pc9ps-> PC9lipid profile did revert to a parental like architecture. Taken together, these findings suggest that mitochondria drive lipid profile remodeling during persister state formation and maintain persisterlipid profile while cells are in a persister state, which in turn induces persister ferroptosis sensitivity.
[0250] However, it is clear that not all ferroptosis sensitivity is abrogated upon mitochondrial elimination, and we do not know if elimination of persister mitochondria followed by subsequent reversion of persister to parental cell state would result in inhibition of lipid profile reversion and maintenance of ferroptosis sensitivity, i.e., would mitochondrial elimination inhibit lipid architecture remodeling in PC9PS -> PC9.
[0251] We also observed that 15-day PC9PS -> PC9jidnOf have anjjpuFA PL enrichment, but were still sensitive to ferroptosis. Moreover, diPUFA PL signatures in targeted analysis for fibrosarcoma and prostate carcinoma models showed a varied profile - some were significantly and with wide area of effect abundant in PS vs parental, others show an opposite signature, and some were not differential between PS and parental at all.
[0252] On the one hand this could be a result of direct lipid species abundance, and varies depending on tissue of origin. We observed that several of the significant ether linked PUFA PL lipid species were depleted in ferroptosis sensitive PSPC9and 15-day PC9ps _> PC9, but abundant in ferroptosis resistant PC9 and 34-day PC9PS’> PC9. Moreover, the saturated or MUFA PL ether linked species did not have this pattern. The importance of ether linked phospholipids to mitochondrial ROS production and mitigation capacity was recently highlighted by Chen et al. (Chen et al. 2023) in non-explicitly persister cancer models, and it could be that several select ether PUFA phospholipids are critical aspects of ferroptosis sensitivity in persister vs parental cells.
[0253] On the other hand, ferroptosis sensitivity is of course a constellation of elements, and we directly observed mitigation of ferroptosis sensitivity by mitochondrial elimination. Given the work of Chen et al. and Qiu et al., it seems more likely that there is an interplay between lipid architecture, mitochondrial presence, and ferroptosis sensitivity during the acquisition of the PS state and reversion back to parental, and our efforts here have acquired several still frame snapshots along this motion picture process.
[0254] Zhang et al. recently demonstrated that GPX4 is overexpressed in two colorectal cancer (CRC) cell line 5-fluorouracil induced persisters (Zhang et al. 2022). Moreover, in our own fibrosarcoma persister model we observed ATF4 expression levels in opposite to the expression signature observed in lung and, moremarginally, prostate cancer models. It seems reasonable that different tissues of origin would have the same key players in persister state formation and maintenance, but these elements may be modulated differently depending on other factors inside the particular cancer cell model.
[0255] Additionally, while not explicitly performed in a persister system, the recent findings of Liang and colleagues that MBOAT2 suppression leads to phospholipid profile remodeling and ferroptosis sensitization is both consistent with and complimentary to our findings in persister cells (Liang et al. 2023). It would be valuable to explore what aspects of ferroptosis sensitization, if any, are specific to LNCaP and HT1080s (the two cell lines used in both our and Liang et al. study) vs pgLNCaPanc| P§HTI O8Oanc| h0Wthese aspects might manifest through time in the attainment and maintenance of the persister state.
[0256] It is encouraging that all PS cells used in this study, regardless of tissue type and chemotherapeutic, exhibited identical phenotypes of ferroptosis sensitivity and near arrest / full arrest of cell cycle - this suggests a unifying importance of ferroptosis susceptibility to maintenance of the persister state, and invites further investigation of the relationship between chemotherapeutic resistance and ferroptosis susceptibility. In compliment, the differences across PS tissue types (protein expression, lipid abundance, etc.) we observed underlying the unifying feature of ferroptosis sensitivity are especially intriguing, as they emphasize the importance of studying multiple persister models to understand what mechanisms could be underlying a feature that, on its surface, appears identical across a broad swath of tissue types. This becomes especially important in a clinical setting, where individualized approaches to ferroptosis induction (or prevention) may become necessary depending on the cancer tissue of origin, disease state, etc. Thus, the mechanistic aspects we have identified could be leveraged as a tool against MRD across multiple cancer types, potentially complimenting and enhancing other treatments in the prevention of cancer recurrence.CITED DOCUEMNTS1. Dai, Y., Tang, H., and Pang, S. (2021 ). The crucial roles of phospholipids in aging and lifespan regulation. Front Physiol 12, 775648.10.3389 / fphys.2021 .775648.2. Wang, B., and Tontonoz, P. (2019). Phospholipid remodeling in physiology and disease. Annu. Rev. Physiol. 81, 165-188. 10.1146 / annurev-physiol- 020518-114444.3. Chilton, F.H., Fonteh, A. N., Surette, M. E., Triggiani, M., Winkler, J. D. (1996). Control of arachidonate levels within inflammatory cells. BBA-Lipid Lipid Met 1299, 1-15. 10.1016 / 0005-2760(95)00169-7.4. Siegel, M.I., McConnell, R. T., Brent, D. A., Chandrasurin, P. I. S. A. L., Macfarlane, R. D., McNeal, C. J. (1982). The formation of diarachidonyl diglyceride by rat neutrophils. Mol. Pharmacol. 21, 688-693.5. Blank, M.L., Cress, E.A., Robinson, M. and Snyder, F. (1985). Metabolism of unique diarachidonoyl and linoleoylarachidonoyl species of ethanolamine and choline phosphoglycerides in rat testes. BBA-Lipid Lipid Met 833, 366-371. 10.1016 / 0005-2760(85)90092-X.6. Chilton, F.H., and Murphy, R.C. (1987). Stimulated production and natural occurrence of 1 ,2-diarachidonoylglycerophosphocholine in human neutrophils. Biochem. Biophys. Res. Commun. 145, 1126-1133. 10.1016 / 0006- 291X(87)91554-3.7. Werlein, A., Peters, A., Ngoune, R., Winkler, K., and Putz, G. (2015).Interference of phosphatidylcholines with in-vitro cell proliferation - no flock without black sheep. Biochim Biophys Acta 1848, 1599-1608.10.1016 / j.bbamem.2015.04.010.8. Yuan, H., Li, X., Zhang, X., Kang, R., and Tang, D. (2016). Identification of ACSL4 as a biomarker and contributor of ferroptosis. Biochem Biophys Res Commun 478, 1338-1343. 10.1016 / j.bbrc.2016.08.124.9. Shan, K., Feng, N., Zhu, D., Qu, H., Fu, G., Li, J., Cui, J., Chen, H., Wang, R., Qi, Y., and Chen, Y.Q. (2022). Free docosahexaenoic acid promotes ferroptotic cell death via lipoxygenase dependent and independent pathways in cancer cells. Eur J Nutr 61, 4059-4075. 10.1007 / s00394-022-02940-w.Liang, D., Minikes, A.M., and Jiang, X. (2022). Ferroptosis at the intersection of lipid metabolism and cellular signaling. Mol Cell 82, 2215-2227. 10.1016 / j.molcel.2022.03.022. agtanong, L., Ko, P.J., To, M., Cao, J.Y., Forcina, G.C., Tarangelo, A., Ward, C.C., Cho, K., Patti, G.J., Nomura, D.K., et al. (2019). Exogenous monounsaturated fatty acids promote a ferroptosis-resistant cell state. Cell Chem Biol 26, 420-432. 10.1016 / j.chembiol.2018.11 .016. Dixon, S.J., Winter, G.E., Musavi, L.S., Lee, E.D., Snijder, B., Rebsamen, M., Superti-Furga, G., and Stockwell, B.R. (2015). Human haploid cell genetics reveals roles for lipid metabolismgenes in nonapoptotic cell death. ACS Chem Biol 10, 1604-1609. 10.1021 / acschembio.5b00245. Doll, S., Proneth, B., Tyurina, Y.Y., Panzilius, E., Kobayashi, S., Ingold, I., Irmler, M., Beckers, J., Aichler, M., Walch, A., et al. (2017). ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol 13, 91-98. 10.1038 / nchembio.2239. Kagan, V.E., Mao, G., Qu, F., Angeli, J.P., Doll, S., Croix, C.S., Dar, H.H., Liu, B., Tyurin, V.A., Ritov, V.B., et al. (2017). Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis. Nat Chem Biol 13, 81-90. 10.1038 / nchembio.2238. Stockwell, B.R. (2022). Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell 185, 2401-2421. 10.1016 / j.cell.2022.06.003. Kraft, V.A.N., Bezjian, C.T., Pfeiffer, S., Ringelstetter, L., Muller, C., Zandkarimi, F., Merl-Pham, J., Bao, X., Anastasov, N., Kossl, J., et al. (2020). GTP cyclohydrolase 1 / tetrahydrobiopterin counteract ferroptosis through lipid remodeling. ACS Cent Sci 6, 41-53. 10.1021 / acscentsci.9b01063. von Krusenstiern, A.N., Robson, R.N., Qian, N., Qiu, B., Hu, F., Reznik, E., Smith, N., Zandkarimi, F., Estes, V.M., Dupont, M., et al. (2023). Identification of essential sites of lipid peroxidation in ferroptosis. Nat Chem Biol. 10.1038 / S41589-022-01249-3. Li, Y., Wang, X., Huang, Z., Zhou, Y., Xia, J., Hu, W., Wang, X., Du, J., Tong, X., and Wang, Y. (2021). CISD3 inhibition drives cystine-deprivation induced ferroptosis. Cell Death Dis 12, 839. 10.1038 / s41419-021 -04128-2.Li, Y., Xia, J., Shao, F., Zhou, Y., Yu, J., Wu, H., Du, J., and Ren, X. (2021). Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis. Biochem Biophys Res Commun 534, 877-884. 10.1016 / j.bbrc.2020.10.083. Gaschler, M.M., Hu, F., Feng, H., Linkermann, A., Min, W., and Stockwell, B.R. (2018). Determination of the subcellular localization and mechanism of action of ferrostatins in suppressing ferroptosis. ACS Chem Biol 13, 1013- 1020. 10.1021 / acschembio.8b00199. Chen, X., Kang, R., Kroemer, G., and Tang, D. (2021). Organelle-specific regulation of ferroptosis. Cell Death Differ 28, 2843-2856. 10.1038 / s41418- 021-00859-z. ao, M., Yi, J., Zhu, J., Minikes, A.M., Monian, P., Thompson, C.B., and Jiang, X. (2019). Role of mitochondria in ferroptosis. Mol Cell 73, 354-363 e353. 10.1016 / j.molcel.2018.10.042. Mbah, N.E., and Lyssiotis, C.A. (2022). Metabolic regulation of ferroptosis in the tumor microenvironment. J Biol Chem 298, 101617.10.1016 / j.jbc.2022.101617. Oh, S.J., Ikeda, M., Ide, T., Hur, K.Y., and Lee, M.S. (2022). Mitochondrial event as an ultimate step in ferroptosis. Cell Death Discov 8, 414. 10.1038 / S41420-022-01199-8. Lyamzaev, K.G., Panteleeva, A.A., Simonyan, R.A., Avetisyan, A.V., and Chernyak, B.V. (2023). Mitochondrial lipid peroxidation is responsible for ferroptosis. Cells 12, 611. 10.3390 / cellsl 2040611 . Feng, H., Schorpp, K., Jin, J., Yozwiak, C.E., Hoffstrom, B.G., Decker, A.M., Rajbhandari, P., Stokes, M.E., Bender, H.G., Csuka, J.M., et al. (2020). Transferrin receptor is a specific ferroptosis marker. Cell Rep 30, 3411-3423. 10.1016 / j.celrep.2020.02.049. Gaschler, M.M., Andia, A.A., Liu, H., Csuka, J.M., Hurlocker, B., Vaiana, C.A., Heindel, D.W., Zuckerman, D.S., Bos, P.H., Reznik, E., et al. (2018). FINO(2) initiates ferroptosis through GPX4 inactivation and iron oxidation. Nat Chem Biol 14, 507-515. 10.1038 / s41589-018-0031 -6. Ding, J., Ji, J., Rabow, Z., Shen, T., Folz, J., Brydges, C.R., Fan, S., Lu, X., Mehta, S., Showalter, M.R., et al. (2021). A metabolome atlas of the aging mouse brain. Nat Commun 12, 6021. 10.1038 / S41467-021 -26310-y.Chen, D., Chu, B., Yang, X., Liu, Z., Jin, Y., Kon, N., Rabadan, R., Jiang, X., Stockwell, B.R., and Gu, W. (2021). iPLA2beta-mediated lipid detoxification controls p53-driven ferroptosis independent of GPX4. Nat Commun 72, 3644. 10.1038 / S41467-021 -23902-6. Stockwell, B.R., Friedmann Angeli, J.P., Bayir, H., Bush, A.I., Conrad, M., Dixon, S.J., Fulda, S., Gascon, S., Hatzios, S.K., Kagan, V.E., et al. (2017). Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell 777, 273-285. 10.1016 / j.cell.2O17.09.021. Jakaria, M., Belaidi, A.A., Bush, A. I., and Ayton, S. (2021). Ferroptosis as a mechanism of neurodegeneration in Alzheimer's disease. J Neurochem 159, 804-825. 10.1111 / jnc.15519. Dong, L., Zhou, S., Bai, X., and He, X. (2023). Construction of a prognostic model for HCC based on ferroptosis-related IncRNAs expression and its potential to predict the response and irAEs of immunotherapy. Front Pharmacol 14, 1090895. 10.3389 / fphar.2023.1090895. Sassano, M.L., Felipe-Abrio, B., and Agostinis, P. (2022). ER-mitochondria contact sites; a multifaceted factory for Ca(2+) signaling and lipid transport. Front Cell Dev Biol 70, 988014. 10.3389 / fcell.2022.988014. Niu, B., Lei, X., Xu, Q., Ju, Y., Xu, D., Mao, L., Li, J., Zheng, Y„ Sun, N., Zhang, X., et al. (2022). Protecting mitochondria via inhibiting VDAC1 oligomerization alleviates ferroptosis in acetaminophen-induced acute liver injury. Cell Biol Toxicol 38, 505-530. 10.1007 / s10565-021 -09624-x. Wiernicki, B., Dubois, H., Tyurina, Y.Y., Hassannia, B., Bayir, H., Kagan, V.E., Vandenabeele, P., Wullaert, A., and Vanden Berghe, T. (2020). Excessive phospholipid peroxidation distinguishes ferroptosis from other cell death modes including pyroptosis. Cell Death Dis 77, 922. 10.1038 / s41419-020- 03118-0. Wenzel, S.E., Tyurina, Y.Y., Zhao, J., St Croix, C.M., Dar, H.H., Mao, G., Tyurin, V.A., Anthonymuthu, T.S., Kapralov, A.A., Amoscato, A.A., et al. (2017). PEBP1 wardens ferroptosis by enabling lipoxygenase generation of lipid death signals. Cell 171, 628-641. 10.1016Zj.cell.2017.09.044. Zhao, J., O'Donnell, V.B., Balzar, S., St Croix, C.M., Trudeau, J.B., and Wenzel, S.E. (2011). 15-Lipoxygenase 1 interacts with phosphatidylethanolamine-binding protein to regulate MARK signaling inhuman airway epithelial cells. Proc Natl Acad Sci 108, 14246-14251. 10.1073 / pnas.1018075108. Defries, D., Curtis, K., Petkau, J.C., Shariati-levari, S., Blewett, H., and Aliani, M. (2022). Patterns of alpha-linolenic acid incorporation into phospholipids in H4IIE cells. J Nutr Biochem 106, 109014. 10.1016 / j.jnutbio.2022.109014. Cui, W., Liu, D., Gu, W., and Chu, B. (2021). Peroxisome-driven ether-linked phospholipids biosynthesis is essential for ferroptosis. Cell Death Differ 28, 2536-2551. 10.1038 / s41418-021-00769-0. Lee, H., Zhuang, L., and Gan, B. (2021). Ether phospholipids govern ferroptosis. J Genet Genomics 48, 517-519. 10.1016 / j.jgg.2O21.05.003. Sun, W.Y., Tyurin, V.A., Mikulska-Ruminska, K., Shrivastava, I.H., Anthonymuthu, T.S., Zhai, Y.J., Pan, M.H., Gong, H.B., Lu, D.H., Sun, J., et al. (2021 ). Phospholipase iPLA(2)beta averts ferroptosis by eliminating a redox lipid death signal. Nat Chem Biol 17, 465-476. 10.1038 / s41589-020-00734-x. Lu, B., Chen, X.B., Hong, Y.C., Zhu, H., He, Q.J., Yang, B., Ying, M.D., and Cao, J. (2019). Identification of PRDX6 as a regulator of ferroptosis. Acta Pharmacol Sin 40, 1334-1342. 10.1038 / s41401 -019-0233-9. Bartolacci, C., Andreani, C., Vale, G., Berto, S., Melegari, M., Crouch, A.C., Baluya, D.L., Kemble, G., Hodges, K., Starrett, J., et al. (2022). Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer. Nat Commun 13, 4327. 10.1038 / s41467-022-31963-4. Levental, K.R., Malmberg, E., Symons, J.L., Fan, Y.Y., Chapkin, R.S., Ernst, R., and Levental, I. (2020). Lipidomic and biophysical homeostasis of mammalian membranes counteracts dietary lipid perturbations to maintain cellular fitness. Nat Commun 11, 1339. 10.1038 / S41467-020-15203-1. Irvine, R.F., Dawson, R. M. (1979). Transfer of arachidonic acid between phospholipids in rat liver microsomes. Biochem. Biophys. Res. Commun. 91, 1399-1405. 10.1016 / 0006-291 X(79)91222-1 . Renne, M.F., Bao, X., Hokken, M.W., Bierhuizen, A.S., Hermansson, M., Sprenger, R.R., Ewing, T.A., Ma, X., Cox, R.C., Brouwers, J.F., et al. (2022). Molecular species selectivity of lipid transport creates a mitochondrial sink for di-unsaturated phospholipids. EMBO J 41, e106837. 10.15252 / embj.2020106837.Sullivan, E.M., Pennington, E.R., Green, W.D., Beck, M.A., Brown, D.A., and Shaikh, S.R. (2018). Mechanisms by which dietary fatty acids regulate mitochondrial structure-function in health and disease. Adv Nutr 9, 247-262. 10.1093 / advances / nmy007. Herbst, E.A., Paglialunga, S., Gerling, C., Whitfield, J., Mukai, K., Chabowski, A., Heigenhauser, G.J., Spriet, L.L., and Holloway, G.P. (2014). Omega-3 supplementation alters mitochondrial membrane composition and respiration kinetics in human skeletal muscle. J Physiol 592, 1341-1352. 10.1113 / jphysiol .2013.267336. Malis, C.D., Weber, P.C., Leaf, A., and Bonventre, J.V. (1990). Incorporation of marine lipids into mitochondrial membranes increases susceptibility to damage by calcium and reactive oxygen species: Evidence for enhanced activation of phospholipase A2 in mitochondria enriched with n-3 fatty acids. Proc Natl Acad Sci USA 87, 8845-8849. Basit, F., van Oppen, L.M., Schockel, L., Bossenbroek, H.M., van Emst-de Vries, S.E., Hermeling, J.C., Grefte, S., Kopitz, C., Heroult, M., Hgm Willems, P., and Koopman, W.J. (2017). Mitochondrial complex I inhibition triggers a mitophagy-dependent ROS increase leading to necroptosis and ferroptosis in melanoma cells. Cell Death Dis 8, e2716. 10.1038 / cddis.2017.133. Simoes, I.C.M., Morciano, G., Lebiedzinska-Arciszewska, M., Aguiari, G., Pinton, P., Potes, Y., and Wieckowski, M.R. (2020). The mystery of mitochondria-ER contact sites in physiology and pathology: A cancer perspective. Biochim Biophys Acta Mol Basis Dis 1866, 165834. 10.1016 / j.bbadis.2020.165834. Vecellio Reane, D., Rizzuto, R., and Raffaello, A. (2020). The ER- mitochondria tether at the hub of Ca2+ signaling. Curr. Opin. Physiol. 17, 261- 268. 10.1016 / j. cophys.2020.08.013. Yang, W.S., SriRamaratnam, R., Welsch, M.E., Shimada, K., Skouta, R., Viswanathan, V.S., Cheah, J.H., Clemons, P.A., Shamji, A.F., Clish, C.B., et al. (2014). Regulation of ferroptotic cancer cell death by GPX4. Cell 156, 317- 331. 10.1016 / j. cell.2013.12.010. hang, Y., Tan, H., Daniels, J.D., Zandkarimi, F., Liu, H., Brown, L.M., Uchida, K., O'Connor, O.A., and Stockwell, B.R. (2019). Imidazole Ketone ErastinInduces Ferroptosis and Slows Tumor Growth in a Mouse Lymphoma Model. Cell Chem Biol 26, 623-633 e629. 10.1016 / j.chembiol.2019.01.008. Huang da, W., Sherman, B.T., and Lempicki, R.A. (2009). Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4, 44-57. 10.1038 / nprot.2008.211 . herman, B.T., Hao, M., Qiu, J., Jiao, X., Baseler, M.W., Lane, H.C., Imamichi, T., and Chang, W. (2022). DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res 50, W216-221. 10.1093 / nar / gkac194. Wu, T., Hu, E., Xu, S., Chen, M., Guo, P., Dai, Z., Feng, T., Zhou, L., Tang,W., Zhan, L., et al. (2021 ). clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. The Innovation 2, 100141.10.1016 / j.xinn.2021.100141. Yu, G., Wang, L.G., Han, Y., and He, Q.Y. (2012). clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS 16, 284-287. 10.1089 / omi.2011.0118. Kanehisa, M., and Goto, S. (2000). KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 28, 27-30. 10.1093 / nar / 28.1.27. Korotkevich, G., Sukhov, V., Budin, N., Shpak, B., Artyomov, M.N., and Sergushichev, A. (2021). Fast gene set enrichment analysis. BioRxiv. 10.1101 / 060012. L. Huang et al., Targeting regulatory T cells for immunotherapy in melanoma. Mol Biomed 2, 11 (2021). W. Humphries, J. Wei, J. H. Sampson, A. B. Heimberger, The role of tregs in glioma-mediated immunosuppression: potential target for intervention. Neurosurg Clin N Am 21 , 125-137 (2010). R. Saleh, E. Elkord, FoxP3(+) T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets. Cancer Lett 490, 174-185 (2020). Y. Tang et al., An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma. PLoS One 9, e91551 (2014). Y. Togashi, K. Shitara, H. Nishikawa, Regulatory T cells in cancer immunosuppression - implications for anticancer therapy. Nat Rev Clin Oncol 16, 356-371 (2019).S. Dees, R. Ganesan, S. Singh, I. S. Grewal, Regulatory T cell targeting in cancer: Emerging strategies in immunotherapy. Eur J Immunol 51, 280-291 (2021 ). E. J. Sayour et al., Increased proportion of FoxP3+ regulatory T cells in tumor infiltrating lymphocytes is associated with tumor recurrence and reduced survival in patients with glioblastoma. Cancer Immunol Immunother 64, 419- 427 (2015). B. R. McRitchie, B. Akkaya, Exhaust the exhausters: Targeting regulatory T cells in the tumor microenvironment. Front Immunol 3, 940052 (2022). J. Miska et al., HIF-1a Is a Metabolic Switch between Glycolytic-Driven Migration and Oxidative Phosphorylation-Driven Immunosuppression of Tregs in Glioblastoma. Cell Reports 27 , 226-237.e224 (2019). D. Rao et al., Metabolic profiles of regulatory T cells in the tumour microenvironment. Cancer Immunol Immunother70, 2417-2427 (2021). V. Sasidharan Nair, R. Saleh, S. M. Toor, F. S. Cyprian, E. Elkord, Metabolic reprogramming of T regulatory cells in the hypoxic tumor microenvironment. Cancer Immunol Immunother70, 2103-2121 (2021). H. Wang et al., CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nature Immunology 21 , 298-308 (2020). Y. Yan et al., Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity. J Hematol Oncol 15, 104 (2022). S. J. Dixon et al., Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 149, 1060-1072 (2012). B. R. Stockwell, Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell 185, 2401-2421 (2022). M. A. Badgley et al., Cysteine depletion induces pancreatic tumor ferroptosis in mice. Science 368, 85-89 (2020). L. Ferrada, M. J. Barahona, M. Vera, B. R. Stockwell, F. Nualart, Dehydroascorbic acid sensitizes cancer cells to system x(c)(-) inhibition- induced ferroptosis by promoting lipid droplet peroxidation. Cell Death Dis 14, 637 (2023).P. S. Upadhyayula et al., Dietary restriction of cysteine and methionine sensitizes gliomas to ferroptosis and induces alterations in energetic metabolism. Nat Commun 14, 1187 (2023). C. Zhang, X. Liu, S. Jin, Y. Chen, R. Guo, Ferroptosis in cancer therapy: a novel approach to reversing drug resistance. Mol Cancer 21 , 47 (2022). Z. Hui et al., Single-Cell Sequencing Reveals the Transcriptome and TCR Characteristics of pTregs and in vitro Expanded iTregs. Front Immunol 12, 619932 (2021). T. Maj et al., Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1 -blockade resistance in tumor. Nat Immunol 18, 1332-1341 (2017). F. Zuo et al., Study on the preparation and function of regulatory T cells from human peripheral blood. Ann Transl Med 9, 1521 (2021). A. F. Dos Santos, G. Fazeli, T. N. Xavier da Silva, J. P. Friedmann Angeli, Ferroptosis: mechanisms and implications for cancer development and therapy response. Trends Cell Biol 33, 1062-1076 (2023). W. S. Yang, B. R. Stockwell, Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS- harboring cancer cells. Chem Biol 15, 234-245 (2008). T. D. Klasson et al., ACSL3 regulates lipid droplet biogenesis and ferroptosis sensitivity in clear cell renal cell carcinoma. Cancer Metab 10, 14 (2022). A. Butler, P. Hoffman, P. Smibert, E. Papalexi, R. Satija, Integrating single-cell transcriptomic data across different conditions, technologies, and species. Nat Biotech nol 36, 411-420 (2018). Y. Hao et al., Integrated analysis of multimodal single-cell data. Cell 184, 3573-3587 e3529 (2021 ). Y. Hao et al., Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat Biotechnol, (2023). R. Satija, J. A. Farrell, D. Gennert, A. F. Schier, A. Regev, Spatial reconstruction of single-cell gene expression data. Nat Biotechnol 33, 495- 502 (2015). T. Stuart et al., Comprehensive Integration of Single-Cell Data. Cell 177, 1888-1902. e1821 (2019).V. K. Mootha et al., PGC-1a-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nature Genetics 34, 267-273 (2003). A. Subramanian et al., Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences 102, 15545-15550 (2005). M. Kanehisa, M. Furumichi, Y. Sato, M. Kawashima, M. Ishiguro-Watanabe, KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res 51 , D587-D592 (2023). R. Wang et al., The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 35, 871-882 (2011). H. Varma, R. Cheng, C. Voisine, A. C. Hart, B. R. Stockwell, Inhibitors of metabolism rescue cell death in Huntington's disease models. Proc Natl Acad Sci U S A 104, 14525-14530 (2007). D. M. Wood, H. Alsahaf, P. Streete, P. I. Dargan, A. L. Jones, Fatality after deliberate ingestion of the pesticide rotenone: a case report. Crit Care 9, R280-284 (2005). II. H. Beier et al., Essential role of mitochondrial energy metabolism in Foxp3(+) T-regulatory cell function and allograft survival. FASEB J 29, 2315- 2326 (2015). Y. Cao, J. C. Rathmell, A. N. Macintyre, Metabolic reprogramming towards aerobic glycolysis correlates with greater proliferative ability and resistance to metabolic inhibition in CD8 versus CD4 T cells. PLoS One 9, e104104 (2014). D. Howie et al., Foxp3 drives oxidative phosphorylation and protection from lipotoxicity. JCI Insight 2, e89160 (2017). Y. Jang, M. Kim, S. W. Hwang, Molecular mechanisms underlying the actions of arachidonic acid-derived prostaglandins on peripheral nociception. Journal of Neuroinflammation 17, 30 (2020). G. Federico et al., NCOA4 links iron bioavailability to DNA metabolism. Cell Rep 40, 111207 (2022). L. Wang, S. Ouyang, B. Li, H. Wu, F. Wang, GSK-3beta manipulates ferroptosis sensitivity by dominating iron homeostasis. Cell Death Discov 7, 334 (2021 ).S. He et al., Starfysh integrates spatial transcriptomic and histologic data to reveal heterogeneous tumor-immune hubs. Nature Biotechnology, (2024). G. Plitas et al., Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer. Immunity 45, 1122-1134 (2016). C. Xu et al., The glutathione peroxidase Gpx4 prevents lipid peroxidation and ferroptosis to sustain Treg cell activation and suppression of antitumor immunity. Cell Rep 35, 109235 (2021). L. Shi, J. Y. Lim, L. C. Kam, Substrate stiffness enhances human regulatory T cell induction and metabolism. Biomate als 292, 121928 (2023). P. J. Urrutia et al., Cell death induced by mitochondrial complex I inhibition is mediated by Iron Regulatory Protein 1. Biochim Biophys Acta Mol Basis Dis 1863, 2202-2209 (2017). Y. Long et al., Dysregulation of Glutamate Transport Enhances Treg Function That Promotes VEGF Blockade Resistance in Glioblastoma. Cancer Research 80, 499-509 (2020). I. Pacella et al., Fatty acid metabolism complements glycolysis in the selective regulatory T cell expansion during tumor growth. Proceedings of the National Academy of Sciences 115, E6546-E6555 (2018). A. Angelin et al., Foxp3 Reprograms T Cell Metabolism to Function in Low- Glucose, High-Lactate Environments. Cell Metabolism 25, 1282-1293. e1287 (2017). Y. Zhang et al., Advances in exogenous docosahexaenoic acid-containing phospholipids: Sources, positional isomerism, biological activities, and advantages. Comprehensive Reviews in Food Science and Food Safety 19, 1420-1448 (2020). L. Wang et al., Standardization of cryopreserved peripheral blood mononuclear cells through a resting process for clinical immunomonitoring- Development of an algorithm. Cytometry A 89, 246-258 (2016). H. Tian et al., Multi-modal mass spectrometry imaging reveals single-cell metabolic states in mammalian liver. bioRxiv, 2022.2009.2026.508878 (2022). M. J. Conroy et al., LIPID MAPS: update to databases and tools for the lipidomics community. Nucleic Acids Research 52, D1677-D1682 (2023). A. Liberzon et al., The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst , 417-425 (2015).Ramirez, M. et al. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nature communications 7, 10690 (2016). Rambow, F. et al. Toward minimal residual disease-directed therapy in melanoma. Cell 174, 843-855. e819 (2018). Vallette, F. M. et al. Dormant, quiescent, tolerant and persister cells: Four synonyms for the same target in cancer. Biochemical pharmacology 162, 169- 176 (2019). Hammerlindl, H. & Schaider, H. Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance. Journal of cell communication and signaling 12, 133-141 (2018). Sanchez-Danes, A. et al. A slow-cycling LGR5 tumour population mediates basal cell carcinoma relapse after therapy. Nature 562, 434-438 (2018). Maynard, A. et al. Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing. Cell 182, 1232-1251. e1222 (2020). Hangauer, M. J. et al. Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition. Nature 551 , 247-250 (2017). Sharma, S. V. et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141 , 69-80, doi: 10.1016 / j. cell.2010.02.027 (2010). Vinogradova, M. et al. An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. Nature chemical biology 12, 531-538 (2016). Raha, D. et al. The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. Cancer research 74, 3579-3590 (2014). Rehman, S. K. et al. Colorectal cancer cells enter a diapause-like DTP state to survive chemotherapy. Cell 184, 226-242. e221 (2021). Mikubo, M., Inoue, Y., Liu, G. & Tsao, M.-S. Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy. Journal of Thoracic Oncology 16, 1798-1809 (2021). Kalkavan, H. et al. Sublethal cytochrome c release generates drug-tolerant persister cells. Cell 185, 3356-3374 e3322, doi: 10.1016 / j.cell.2O22.07.025 (2022).129. Hadian, K. & Stockwell, B. R. The therapeutic potential of targeting regulated non-apoptotic cell death. Nat Rev Drug Discov, doi:10.1038 / s41573-023- 00749-8 (2023).130. Dixon, S. J. et al. Pharmacological inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. elife 3, e02523 (2014).131. Oren, Y. et al. Cycling cancer persister cells arise from lineages with distinct programs. Nature 596, 576-582, doi:10.1038 / s41586-021-03796-6 (2021 ).132. Chen, Z. et al. Ether phospholipids are required for mitochondrial reactive oxygen species homeostasis. Nature communications 14, 2194 (2023).133. Zhang, X. et al. Glutathione peroxidase 4 as a therapeutic target for anti- colorectal cancer drug-tolerant persister cells. Frontiers in Oncology 12, 913669 (2022).134. Liang, D. et al. Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones. Cell (2023).135. Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884-i890 (2018).136. Bray, N. L, Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nature biotechnology 34, 525-527 (2016).137. Pimentel, H., Bray, N. L., Puente, S., Melsted, P. & Pachter, L. Differential analysis of RNA-seq incorporating quantification uncertainty. Nature methods 14, 687-690 (2017).138. Pang, Z. et al. Using MetaboAnalyst 5.0 for LC-HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics data. Nature protocols 17, 1735-1761 (2022).139. Pang, Z., Chong, J., Li, S. & Xia, J. MetaboAnalystR 3.0: toward an optimized workflow for global metabolomics. Metabolites 10, 186 (2020).140. Pronobis, M. I., Deuitch, N. & Peifer, M. The Miraprep: A protocol that uses a Miniprep kit and provides Maxiprep yields. PLoS One 11 , e0160509 (2016).
[0257] All documents cited in this application are hereby incorporated by reference as if recited in full herein. In the event of a conflict between the teachings of this application and those of the incorporated documents, the teachings of this application control.
[0258] Although illustrative embodiments of the present disclosure have been described herein, it should be understood that the disclosure is not limited to those described, and that various other changes or modifications may be made by one skilled in the art without departing from the scope or spirit of the disclosure.
Claims
WHAT IS CLAIMED IS:
1. A composition for inhibiting mitochondrial complex I in a cell, comprising an effective amount of a phospholipid with two polyunsaturated fatty acyl tails (PL-PUFA2).
2. The composition of claim 1 , wherein the cell is selected from a neural cell, a cancer cell, a persister state cancer cell, a pro-tumorigenic regulatory T cell (Treg), and combinations thereof.
3. The composition of claim 2, wherein the cancer is selected from the group consisting of hepatocellular carcinoma, sarcoma, glioma, fibrosarcoma, renal cell carcinoma, ovarian cancer, prostate cancer, breast cancer, pancreatic cancer, melanoma, colon cancer, diffuse large B cell lymphoma, leukemia, multiple myeloma, lung cancer, clear-cell carcinoma, and non-small cell lung carcinoma.
4. The composition of claim 1 , wherein the phospholipid is selected from a phosphatidylethanolamine (PE), a phosphatidylcholine (PC), a phosphatidylserine (PS), a phosphatidylinositol (PI), a phosphatidic acid (PA), or combinations thereof.
5. The composition of claim 1 , wherein the PL-PUFA2 is a phosphatidylcholine with two polyunsaturated fatty acyl tails (PC-PUFA2).
6. The composition of claim 5, wherein the PC-PUFA2 is PC(22:6; 22:6), which is a phosphatidylcholine containing two docosahexaenoic acid (DHA) tails.
7. A method for inhibiting mitochondrial complex I in a cell, comprising contacting the cell with an effective amount of the composition according to any one of claims 1-6.
8. A method for treating or ameliorating the effects of a disease in a subject in need thereof, comprising administering to the subject an effective amount of the composition according to any one of claims 1-6.
9. The method of claim 8, wherein the subject is a mammal.
10. The method of claim 9, wherein the mammal is selected from the group consisting of humans, veterinary animals, and agricultural animals.11 . The method of claim 8, wherein the subject is a human.
12. The method of claim 8, wherein the disease is a glutathione peroxidase 4 (GPX4)-associated disease.
13. The method of claim 8, wherein the disease is selected from the group consisting of a cancer, a neurotic disorder, a neurodegenerative disorder, spondylometaphyseal dysplasia, mixed cerebral palsy, pontocerebellar hypoplasia, and male infertility.
14. The method of claim 8, wherein the disease is a cancer.
15. The method of claim 15, wherein the cancer is selected from the group consisting of hepatocellular carcinoma, sarcoma, glioma, fibrosarcoma, renal cell carcinoma, ovarian cancer, prostate cancer, breast cancer, pancreatic cancer, melanoma, colon cancer, diffuse large B cell lymphoma, leukemia, multiple myeloma, lung cancer, clear-cell carcinoma, and non-small cell lung carcinoma.
16. The method of claim 14, the cancer is hypersensitive to ferroptosis.
17. The method of claim 14, wherein the cancer is refractory to standard cancer treatment.
18. The method of claim 17, wherein the standard cancer treatment comprises chemotherapy, radiation therapy, targeted therapy, immunotherapy, and combinations thereof.
19. The method of claim 8, wherein the disease is a minimal residual disease (MRD).
20. The method of claim 19, wherein the subject has persister state cancer cells.
21. The method of claim 8, wherein the subject has pro-tumorigenic regulatory T cells (Tregs) in the tumor microenviroment (TME).
22. The method of any one of claims 8-21 , further comprising administering to the subject an effective amount of a second agent that induces ferroptosis.
23. The method of claim 22, wherein the second agent is selected from the group consisting of erastin, imidazole ketone erastin (IKE), piperazine erastin (PE), sulfasalazine, sorafenib, RSL3, ferroptosis inducer 56 (FIN56), caspaseindependent lethal 56 (CIL56), deplete GPX4 protein, mevalonate-derived coenzyme Q10, ferroptosis inducer endoperoxide (FINO2), and combinations thereof.
24. A method for inducing ferroptosis in a cell, comprising contacting the cell with an effective amount of a phospholipid with two polyunsaturated fatty acyl tails (PL-PUFA2).
25. The method of claim 22, wherein the cell is a persister state cancer cell.
26. The method of claim 22, wherein the cell is a pro-tumorigenic regulatory T cell (Treg).
27. The method of claim 22, wherein the PL-PUFA2 is PC(22:6; 22:6), which is a phosphatidylcholine containing two docosahexaenoic acid (DHA) tails.
28. The method of any one of claims 24-27, further comprising contacting the cell with an effective amount of a second agent that induces ferroptosis.
29. The method of claim 28, wherein the second agent is selected from the group consisting of erastin, imidazole ketone erastin (IKE), piperazine erastin (PE), sulfasalazine, sorafenib, RSL3, ferroptosis inducer 56 (FIN56), caspaseindependent lethal 56 (CIL56), deplete GPX4 protein, mevalonate-derived coenzyme Q10, ferroptosis inducer endoperoxide (FINO2), and combinations thereof.
30. A method for treating or ameliorating the effects of a disease in a subject in need thereof, comprising(a) obtaining a biological sample from the subject;(b) measuring the level of a phospholipid with two polyunsaturated fatty acyl tails (PL-PUFA2) in the sample and comparing it to a predetermined reference;(c) identifying the subject as sensitive to an agent that induces ferroptosis, if the level of the PL-PUFA2 measured in step (b) is higher than the predetermined reference; and(d) administering to the sensitive subject an effective amount of the agent.
31. The method of claim 30, wherein the disease is a glutathione peroxidase 4 (GPX4)-associated disease.
32. The method of claim 30, wherein the disease is selected from the group consisting of a cancer, a neurotic disorder, a neurodegenerative disorder, spondylometaphyseal dysplasia, mixed cerebral palsy, pontocerebellar hypoplasia, and male infertility.
33. The method of claim 30, wherein the disease is a cancer.
34. The method of claim 33, wherein the cancer is selected from the group consisting of hepatocellular carcinoma, sarcoma, glioma, fibrosarcoma, renal cell carcinoma, ovarian cancer, prostate cancer, breast cancer, pancreatic cancer, melanoma, colon cancer, diffuse large B cell lymphoma, leukemia,multiple myeloma, lung cancer, clear-cell carcinoma, and non-small cell lung carcinoma.
35. The method of claim 33, the cancer is hypersensitive to ferroptosis.
36. The method of claim 33, wherein the cancer is refractory to standard cancer treatment.
37. The method of claim 36, wherein the standard cancer treatment comprises chemotherapy, radiation therapy, targeted therapy, immunotherapy, and combinations thereof.
38. The method of claim 30, wherein the subject is a mammal.
39. The method of claim 38, wherein the mammal is selected from the group consisting of humans, veterinary animals, and agricultural animals.
40. The method of claim 30, wherein the subject is a human.41 . The method of claim 30, wherein the biological sample is a biopsy sample.
42. The method of claim 33, wherein the biological sample is a blood smaple that contains circulating cancer cells.
43. The method of claim 30, wherein the phospholipid is selected from a phosphatidylethanolamine (PE), a phosphatidylcholine (PC), a phosphatidylserine (PS), a phosphatidylinositol (PI), a phosphatidic acid (PA), or combinations thereof.
44. The method of claim 30, wherein the PL-PUFA2 is a phosphatidylcholine with two polyunsaturated fatty acyl tails (PC-PUFA2).
45. The method of claim 30, wherein the level of the PL-PUFA2 is measured by mass spectrum.
46. The method of claim 30, wherein the level of the PL-PUFA2 is measured by antibodies or other binding agents, using ELISA.
47. The method of claim 30, wherein the agent that induces ferroptosis is selected from the group consisting of erastin, imidazole ketone erastin (IKE), piperazine erastin (PE), sulfasalazine, sorafenib, RSL3, ferroptosis inducer 56 (FIN56), caspase-independent lethal 56 (CIL56), deplete GPX4 protein, mevalonate-derived coenzyme Q10, ferroptosis inducer endoperoxide (FINO2), and combinations thereof.
48. A method for treating or ameliorating the effects of a cancer in a subject in need thereof, comprising:(a) obtaining a biological sample from the subject;(b) measuring the level of a phosphatidylcholine with two polyunsaturated fatty acyl tails (PC-PUFA2) in the sample and comparing it to a predetermined reference;(c) identifying the subject as sensitive to an agent that induces ferroptosis, if the level of the PC-PUFA2 measured in step (b) is higher than the predetermined reference; and(d) administering to the sensitive subject an effective amount of the agent.
49. A dietary supplement for a subject having a cancer, comprising an effective amount of a phospholipid with two polyunsaturated fatty acyl tails (PL-PUFA2).
50. The dietary supplement of claim 49, wherein the PL-PUFA2 is PC(22:6; 22:6), which is a phosphatidylcholine containing two docosahexaenoic acid (DHA) tails.
Citation Information
Patent Citations
Method for producing long-chain polyunsaturated fatty acid-containing phospholipid using Schizochytrium microorganism
JP4344827B2
Compounds useful for the treatment and / or care of the skin, hair, nails and / or mucous membranes
US20200214960A1
GPX4 compounds and compositions and methods of treatment using same
WO2021183908A1
